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Numerous cellular processes and therapeutic interventions rely on vesicular-
mediated endocytosis to gain entry into cells and sub-cellular compartments, as well as for 
transcellular transport across biological barriers such as found at the blood-brain interface. 
Yet, endocytic behavior can be altered in disease, representing an additional hurdle in the 
design of effective therapeutic strategies. Lysosomal storage disorders (LSDs), 
characterized by lysosomal accumulation of undigested substrates as a result of deficient 
enzymatic activity, illustrate this paradigm. Currently, intravenous infusion of recombinant 
lysosomal enzymes to replace those deficient is the standard clinical approach for these 
disorders. However, clathrin-mediated endocytosis utilized by replacement enzymes for 
cellular uptake and lysosomal trafficking is altered, thereby impacting treatment efficacy 
  
as recently demonstrated in acid sphingomyelinase-deficient type A Niemann-Pick disease 
(NPD). Therefore, alternative means to bypass defunct routes is warranted. Therapeutic 
delivery via polymer nanocarriers targeting intercellular adhesion molecule-1 (anti-ICAM 
NCs), a cell-surface molecule overexpressed in endothelial and subjacent tissue cells 
during inflammation, such as in LSDs, represents a viable option since it permits uptake, 
intra- and transcellular transport via a unique endocytic route called the cell adhesion 
molecule (CAM) pathway. In this dissertation, cell culture and animal models were used 
to examine the (1) endocytic activity of the CAM pathway and other clathrin-independent 
routes in type A NPD, (2) role of targeting valency (i.e., density of ICAM-1-targeting 
molecules on the NC surface) in regulating the CAM pathway, and (3) effects induced via 
engagement of ICAM-1 on cells by anti-ICAM NCs. The results herein demonstrate the 
CAM pathway is more active in diseased cells compared to other classical endocytic 
pathways, making it the most amenable route for therapeutic enzyme replacement. Further, 
modulating targeting valency of NCs optimized this strategy for enhanced enzyme delivery 
to the brain, a target organ for type A NPD. Lastly, anti-ICAM NCs attenuated endothelial 
release of soluble ICAM-1, an inflammatory regulator, representing a secondary benefit of 
this system. Overall, this work validates utility of anti-ICAM NCs for enzyme replacement 
to treat NPD and likely other LSDs, and provides insight into biological processes and 
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Chapter 1: Introduction and Overview 
1.1. Motivation and Goals 
Lysosomal storage disorders (LSDs) are a rare class of approximately 60 genetic 
diseases most commonly caused by dysfunctional acid hydrolases found within the 
lysosomal lumen [1]. As a result of this defect, undigested metabolites accumulate within 
lysosomes and, secondarily, within compartments of the endo-lysosomal and autophagic 
pathways [1-4]. Due to the role of functional lysosomal activity in maintaining cellular 
homeostasis [1, 5-8], such aberrant storage leads to pathology in peripheral organs, and 
often times the central nervous system (CNS) as well [1, 4, 9-13].  
A number of therapies currently exist for LSDs, each having benefits and 
disadvantages depending on the particular LSD and its associated symptoms [9, 11, 12, 14-
20]. Intravenous infusion of wild-type recombinant lysosomal enzymes to replace those 
deficient, known as enzyme replacement therapy (ERT), is the current clinical standard 
[11, 12, 16, 18-36]. In this approach, the replacement enzymes bind to mannose-6-
phosphate (M6P) receptors on the surface of cells, followed by clathrin-mediated 
endocytosis and subsequent trafficking to lysosomes to degrade the storage material [9, 11, 
16, 37]. While ERT has been successful for treatment of peripheral organs, this approach 
is still significantly hindered by rapid clearance from the circulation, potential for 
immunogenicity, inactivation by proteases, and the inability of these enzymes to cross the 
blood-brain barrier (BBB) [9, 12-16, 19, 25, 38-40]. Hence, neurological disorders that 
associate with at least half of all LSDs remain untreated with conventional ERT [9, 13, 15].  
In order to circumvent the BBB, recombinant enzymes have been fused to affinity 




mediated transport across this barrier, such as the insulin receptor, transferrin (Tf) receptor, 
low-density lipoprotein, and others [27, 41-44]. However, such approaches do not provide 
protection against enzyme degradation or offer control over delivery in the context of 
cellular uptake, lysosomal trafficking, enzyme release in lysosomes, transcytosis, etc. As 
an alternative strategy, nano-scale drug carriers (NCs) have tunable physiochemical 
properties and can be additionally functionalized with stealth polymers and/or biological 
agents to overcome these challenges [45-50]. Most commonly, NCs are targeted to cell-
surface receptors involved in vesicular-mediated endocytic uptake, which is often 
accompanied by lysosomal trafficking, and in certain cases, transcytosis across cellular 
barriers [47, 51-56]. Consequently, lysosomal enzyme delivery via NCs has shown promise 
for treatment of LSDs [9, 16, 19].  
Depending on the receptor targeted, endocytosis can occur via classical routes (e.g., 
clathrin- or caveolae-mediated), or independent pathways that are currently less understood 
[47, 51, 53, 54]. However, recent work by our laboratory has shown altered clathrin-
mediated endocytosis of acid sphingomyelinase (ASM) deficient in type A Niemann-Pick 
disease (NPD), resulting in diminished therapeutic efficacy [57]. Therefore, better 
understanding of the status of such vesicular-mediated pathways in LSDs is imperative to 
improve delivery of lysosomal enzymes or other therapeutics that rely on these routes for 
entry into and across cells.  
Targeting enzyme-loaded NCs to intercellular adhesion molecule-1 (ICAM-1), a 
transmembrane glycoprotein expressed on the vascular endothelium and other cell types, 
is a particularly attractive strategy for LSD treatment [58-65]. Due to role of ICAM-1 in 




is upregulated during pathological states (e.g., in LSDs) [66, 67], making it amenable for 
enhanced enzyme delivery to peripheral organs and the CNS. Importantly, multivalent NCs 
targeted to ICAM-1 (anti-ICAM NCs) induce cellular uptake via the cell adhesion 
molecule (CAM) pathway [68], a unique endocytic route that enables enzyme trafficking 
to lysosomes with enhanced degradation of the stored substrate [60-64, 69], as well as 
delivery across cellular barriers (e.g., BBB) in cell culture and animal models [58-61, 65, 
70-72]. Hence, utilization of the CAM pathway represents a viable treatment option for 
LSDs, especially those characterized by neurological defects. Interestingly, the CAM 
pathway is even functional when classical pathways are inhibited [57]. In fact, delivery of 
recombinant ASM via anti-ICAM NCs markedly increased enzyme uptake in type A NPD 
cells compared to free ASM, resulting in significant reduction of lysosomal storage and, 
consequently, restoration of the clathrin pathway [57, 62, 63].  Therefore, anti-ICAM NCs 
may provide an alternative route for therapeutic delivery in LSDs that associate with 
dysfunctional endocytic behavior.  
In light of this information, the overall goal of this dissertation is to enhance our 
understanding of vesicular-mediated transport in LSDs and apply this knowledge to 
improve the design and efficacy of therapeutic strategies for these disorders. These goals 
are addressed in the following three specific aims: 
Aim 1: Probe the status of vesicular-mediated transport in type A NPD.  
Aim 2: Elucidate regulation of the CAM pathway in order to optimize therapeutic 
enzyme delivery via anti-ICAM NCs for type A NPD.  
Aim 3: Examine potential effects of anti-ICAM NCs that may exacerbate inflammation 




 First in Chapter 3, we build off our laboratory’s recent finding of impaired 
clathrin-mediated endocytosis in type A NPD by examining potential alterations in 
caveolae-mediated endocytosis, macropinocytosis, and non-classical CAM-mediated 
endocytosis, followed by exploration of aberrancies in transcytosis via the clathrin, 
caveolar, and CAM pathways in this disease.  
Based on the preliminary evidence described above, it appears exploiting the CAM 
pathway for enzyme delivery via anti-ICAM NCs is an advantageous strategy over 
conventional clathrin-mediated ERT. While we have learned much regarding the CAM 
pathway over the last decade, better understanding of its regulation is still needed in order 
to further optimize the design of anti-ICAM NCs for therapeutic applications. As such, in 
Chapter 4 we focus on how anti-ICAM targeting valency (i.e., number of targeting 
molecules per carrier) influences the CAM pathway, including anti-ICAM NC binding and 
associated cell-signaling, endocytic uptake, lysosomal trafficking, and transendothelial 
transcytosis, along with examination of the implications of targeting valency on therapeutic 
ASM delivery to the brain in cell culture and mice. In this work, we also paid particular 
attention to understanding the relationship between lysosomal trafficking and transcytosis, 
as well as how NCs dissociate from their bound receptor on the basolateral cell-surface 
after transcytosis, a phenomenon poorly studied for any given targeted drug carrier.  
Lastly, an important consideration in the design of any drug carrier is the potential 
for effects that may hinder treatment efficacy or further exacerbate disease. Since ICAM-
1 is a critical player in inflammation [73, 74], a condition found in many pathologies 
including LSDs [66], effects of blocking this receptor via anti-ICAM NCs warrants 




explores the effect of ICAM-1 engagement by anti-ICAM NCs on the release of an 
inflammatory regulator, soluble ICAM-1 (sICAM-1) [75, 76].  
 
1.2. Significance and Novelty 
Through completion of the aforementioned aims, this dissertation renders 
knowledge on vesicular-mediated transport in LSDs, NC design parameters, and cellular 
mechanisms regulating transport of anti-ICAM NCs via the CAM pathway, as well as 
potential side effects of utilizing anti-ICAM NCs for LSD therapy, which altogether will 
aid in guiding translational drug delivery for improved treatment of these disorders.  
Given the reliance of many therapeutics on vesicular-mediated transport, 
understanding potential alterations in the pathways regulating these processes is paramount 
for rationale therapeutic design. Currently, clathrin-mediated endocytosis is known to be 
impacted in type A NPD [21, 57]. However, potential aberrancies in other routes that could 
be exploited for therapeutic delivery have not been investigated. Hence, the work presented 
herein along with present literature will help define the most amenable pathways for 
treatment of LSDs.   
Delivery of recombinant lysosomal enzymes via anti-ICAM NCs has shown to be 
a viable and promising alternative to current ERT strategies [58-65, 69-72]. As mentioned 
in the prior section, the widespread distribution and overexpression of ICAM-1 in LSDs 
permits enhanced enzyme delivery to all peripheral organs affected [58, 60, 61]. Moreover, 
no treatment currently exists for neurological LSDs due to the tight barrier at the blood-
brain interface [9]. Yet, our laboratory has demonstrated in several works that anti-ICAM 




following intravenous administration [59-61, 65, 71, 72], offering for the first time a means 
to treat these particular LSDs, and perhaps other neurological disorders (e.g., Alzheimer’s, 
Parkinson’s, Huntington’s, etc.). In contrast to the classical clathrin and caveolar routes, 
the CAM pathway also permits uptake and intracellular trafficking of carriers with various 
sizes and geometries [62, 77-79], which offers flexibility in the design of enzyme carriers 
and represents a novel strategy in the field of drug delivery. As well, after anti-ICAM NC 
uptake, ~ 50% of the internalized ICAM-1 receptor recycles back to the plasma membrane 
within 1 h [80], permitting binding of anti-ICAM NCs left in the circulation or binding by 
a subsequent dose. Of great therapeutic potential, anti-ICAM NCs may also provide a 
means to circumvent defunct pathways in LSDs, such as recently found in the case of 
altered clathrin-mediated endocytosis in type A NPD [57].  
To better understand regulation of the CAM pathway, we chose to study modulation 
of valency since it is an important design parameter of drug carriers that influences their 
targeting and overall avidity [47]. However, the effects of valency on associated cell-
signaling and uptake, and more specifically lysosomal trafficking and transcytosis have not 
been extensively explored; yet, both are critical processes for successful treatment of LSDs, 
especially those associated with neurological impairments. Therefore, this work is 
significant because investigation into the effects of targeting valency will enable 
optimization of anti-ICAM NCs that permit sufficient binding and cellular uptake, while 
also providing maximum transport across the BBB for enhanced lysosomal enzyme 
delivery to the brain.  
Another particularly interesting aspect of this work is our examination of the 




particularly whether they are independent pathways or sequential events, which is currently 
not well-known for any targeted drug carriers. Therefore, understanding these mechanisms 
is critical for development of carriers that can be tailored for intracellular accumulation 
and/or transcellular delivery to subjacent tissues, which are both desirable for treatment of 
LSDs, and may need to be differentially tuned for other applications.  
Due to the multivalent nature of anti-ICAM NCs, they strongly bind to ICAM-1 
receptors expressed on the surface of cells [81]. Yet, how these ligand-receptor complexes 
dissociate from their bound receptor on the basolateral cell-surface after transcytosis is 
another poorly understood process. In this dissertation, we provide preliminary work 
demonstrating a mechanism for basolateral detachment of transcytosed anti-ICAM NCs, 
while also shedding light on how targeting valency impacts this process. Altogether, this 
work will provide better understanding of ICAM-1 biology and the cellular events 
regulating transport, associated with ICAM-1 engagement of not only drug carriers but 
natural ligands (i.e., leukocytes) as well, which holds great significance to the fields of 
vascular biology and drug delivery.  
Lastly, little information is currently available regarding how carrier binding to 
their target receptor affects the receptor’s physiological function. We explore this concept 
by examining the release of sICAM-1 in the absence and presence of anti-ICAM NCs. In 
doing so, this work will provide insight into the development of novel approaches using 
ligand-targeted drug carriers to exploit or modulate the function of a receptor in order to 






Chapter 2: Background1 
2.1. Lysosomes and Lysosomal Storage Disorders 
Constituting approximately 5% of the intracellular volume of mammalian cells, 
lysosomes are acidic, membrane-bound organelles that play a crucial role in a number of 
cellular processes required to maintain homeostasis [6]. Therefore, any lysosomal 
aberration could potentially lead to disease. The most well-known class of diseases caused 
by dysfunctional lysosomes are the lysosomal storage disorders (LSDs), a group of 
approximately 60 different diseases characterized by lysosomal accumulation of non-
degraded metabolites [1]. Although each particular LSD is relatively rare, the combined 
prevalence of these diseases is estimated to be 1 in every 2,000 live births, while the 
prevalence of some LSDs is much higher in certain populations, such as the case of 
Gaucher disease in the Ashkenazi Jewish population (1 in 855 births) [82].   
 
2.1.1. Lysosome Structure and Function  
Lysosomes are heterogeneous in size and morphology, and contain more than 50 
acid hydrolases that function at a pH between 4.5-5.0 maintained by vacuolar H+-ATPases 
[1, 6, 83, 84]. Along with activator molecules, these hydrolases are responsible for the 
degradation of different substrates (e.g., proteins, lipids, sugars, nucleic acids) taken up 
                                                 
1Chapter 2 contains text, tables, and figures reproduced in part with permission from: (1) Manthe, R.L. and 
Muro. S., Lysosomes and nanotherapeutics: diseases, treatments, and side effects., in Handbook of 
Nanobiomedical Research, V. Torchilin, Editor. 2014, World Scientific Publishing Co.: Singapore. Vol. 2, 
Chapter 8: p. 261-305; © 2014 World Scientific Publishing Co. (2) Rappaport, J., Manthe, R.L., et al., 
Altered clathrin-independent endocytosis in type A Niemann-Pick disease cells and rescue by ICAM-1-
targeted enzyme delivery. Mol Pharm, 2015. 12(5): p. 1366-76; © 2015 American Chemical Society. (3) 
Manthe, R.L.* and Rappaport, J.*, et al., A comparative study on the alterations of endocytic pathways in 





from the extracellular environment via endocytosis [8]. Lysosomes also offer protection 
against foreign substances and pathogens that invade the cell, and contribute to the disposal 
of intracellular components that are no longer needed through a process called autophagy, 
where degradation of intracellular macromolecular assemblies render monomeric units that 
may be returned to the cytosol and recycled as new building blocks [1, 6, 8]. In addition, 
lysosomes play an important role in removing plasmalemma lipids and proteins, and 
repairing this structure after injury (e.g., due to mechanical stress in muscle cells) [5, 7]. 
Plasmalemma disruption leads to increased intracellular calcium, which triggers targeted 
fusion of lysosomes to the plasmalemma for addition of a new phospholipid membrane to 
repair the damaged area [5, 7].  
With regard to lysosomal hydrolases, these enzymes enter the rough endoplasmic 
reticulum (ER) during their synthesis [6, 16]. Oligosaccharides containing mannose 
residues are then added to these enzymes, followed by transport to the Golgi apparatus 
where phosphorylation of the mannose residues yields enzymes tagged with M6P [85, 86]. 
Binding of M6P residues to their respective receptors in the trans-Golgi network (TGN) 
mediates intracellular trafficking of these enzymes to lysosomes, where they dissociate 
from M6P receptors due to the acidic luminal pH in this compartment [85, 86]. Delivery 
occurs via multiple fusion and fission cycles with late endosomes, with M6P receptors 
being recycled back to the TGN [6]. In addition, a fraction of the lysosomal enzymes are 
secreted to the extracellular milieu via exocytosis [86, 87]. Secreted enzymes that contain 
M6P bind to M6P receptors on the surface of nearby cells, inducing clathrin-mediated 
endocytosis that results in transport to lysosomes [86, 87]. Some secreted enzymes contain 




macrophages [87]. Lastly, lysosomes also contain highly glycosylated integral proteins in 
their membrane, including LAMP-1, LAMP-2, tetraspanin CD63 or LAMP-3, LIMP-2, 
etc. [8, 88]. These proteins assist in maintaining lysosome stability and integrity, transport 
of soluble metabolites out of lysosomes, and chaperone-mediated autophagy and 
macroautophagy [1, 88]. LIMP-2 also acts as a receptor for sorting several lysosomal 
proteins in an M6P-independent manner [6].  
 
2.1.2. Lysosomal Storage Disorders 
LSDs consist of about 60 different diseases affecting humans and several animal 
species [1]. Most of these disorders are caused by dysfunctional lysosomal enzymes, 
resulting in lysosomal accumulation of unmetabolized substrates, including lipids, 
glycoproteins, and glycosaminoglycans [1] (Figure 1). However, several LSDs are caused 
by defective integral membrane proteins, such as LAMP-2A in Danon disease and NPC1 
in type C Niemann-Pick disease (NPC) [1]. Also in a number of LSDs, the primary defects 
affect proteins in the ER, Golgi, and endosomal pathways involved in the synthesis, 
modification, and trafficking of lysosomal proteins [1, 12, 89]. This is the case in 
mucolipidosis (ML) type II (I Cell disease) and ML type III (pseudo-Hurler 
polydystrophy), which cause lysosomal enzymes to be secreted from the cell [1]. Certain 
LSDs also associate with a more neutral lysosomal pH [90, 91] that affects hydrolase and 
vesicle maturation, intracellular trafficking, recycling of M6P receptors back to the Golgi, 





Figure 1. Overview of some aberrations identified in LSDs. Genetic mutations associated with 
LSDs cause dysfunctions in upstream compartments, lysosomal membrane components, and 
lysosomal enzymes, all of which affect lysosome function. Defects include incorrect folding of 
lysosomal enzymes in the ER, dysfunctional trafficking due to defective recognition or defective 
glycosylation, insufficient lysosomal acidification, and dysfunctional integral membrane proteins 
of the lysosome. Consequently, LSDs are characterized by aberrant accumulation of undigested 
substrates in the lysosome. Figure reproduced from [19]. 
 
All LSDs are monogenic diseases inherited as autosomal recessive traits, with the 
exception of Fabry disease, mucopolysaccharidosis (MPS) type II (Hunter disease), and 
Danon disease [12, 94]. In some cases, although only one gene is defective, the enzyme it 
encodes may modify the activity of several other enzymes [1], leading to multiple enzyme 
deficiencies such as in the case of multiple sulphatase deficiency (MSD) [95]. Depending 
on the age when clinical symptoms begin to develop, LSDs are classified as infantile, 
juvenile, or adult forms [1]. Since lysosomes are essential components of almost all cell 
types, the primary and secondary affects associated with LSDs manifest into a wide range 
of phenotypic symptoms in multiple tissues and organs [1]. Infantile forms are the most 




newborns though, as late onset of LSDs characterized by neurological symptoms are also 
seen in juvenile and adult forms [1, 96]. Overall, at least half of all LSDs associate with 
severe CNS disorders (e.g., seizures, dementia, ataxia, brainstem dysfunction, vision loss, 
movement disorders, etc.) that result in early death [1, 9]. Less severe LSDs manifest in 
infancy and progress slowly into adulthood, mainly causing peripheral disease, including 
damage to the liver, spleen, striated muscle, kidneys, lungs, bone, immune system, etc. [1, 
9, 82]. Regardless, inflammation caused by oxidative stress and leukocyte activation from 
biochemical and metabolic stresses often causes the initial pathology to further spread and 
increase in severity [9, 20]. Moreover, multiple epigenetic and environmental factors 
contribute further to the phenotypic variability of LSDs [1, 82]. 
The prevalence and location of gene mutations frequently differ in patients with the 
same LSD and can lead to varying degrees of severity in patients [1]. For example, both 
types A and B Niemann-Pick disease (NPD) are caused by deficiency of acid 
sphingomyelinase (ASM), a lysosomal enzyme responsible for hydrolysis of 
sphingomyelin to ceramide, which results in aberrant sphingomyelin storage [97]. Despite 
both disorders being caused by ASM deficiency, patients with type A NPD suffer from 
severe neurodegeneration and have additional complications associated with visceral 
organs such as the lungs, liver, and spleen [97]. Consequently, most patients with type A 
NPD often do not survive past the age of three years old [97]. In contrast, type B NPD is 
less severe than type A and these patients have minimal or no neurological impairments; 
instead, they develop problems associated with visceral organs in early childhood, 
particularly hepatosplenomegaly and pulmonary dysfunction [97]. Deficiency of ASM 




SMPD1 gene that encodes this enzyme [97]. However, development of either type A or B 
NPD often depends on the particular genetic mutation and the level of remaining ASM 
activity in cells, which along with patho-physiological examination is used for diagnosis 
of either type of NPD [97-99]. Type A NPD associates with lower residual ASM activity 
and specific mutations (e.g., R496L) have been linked to this disorder [97, 100-102]. In 
contrast, type B NPD associates with greater (yet still inadequate) ASM activity and 
common mutations (e.g., deltaR608) causing this disorder have been identified as well [97, 
100, 103, 104]. Epigenetic factors also seem to influence the correlation between genotype 
and phenotype for types A and B NPD [97, 103-105]. For example, just three mutations 
are known to account for nearly 90% of type A NPD in the Ashkenazi Jewish population 
[97], and a single mutation has been linked to more than 90% of patients with type B NPD 
in Chile [104]. As such, the relationship between genotype and phenotype are beginning to 
be made, as well as genetic screening for these disorders [97, 106]. Overall, in this work 
we particularly focused on type A NPD since this disorder is a good model to study both 
disease and therapies relative to CNS and peripheral LSDs.  
Lastly, lysosomal substrate accumulation in LSDs also causes secondary 
accumulation in compartments of the endo-lysosomal and autophagic pathways [1-4]. For 
example, lysosomal storage can delay the rate at which autophagic vacuoles are processed 
or affect autophagosome-lysosome fusion, resulting in retention of materials in 
autophagosomes, as shown in Pompe disease, ML type IV, MPS type IIA, and MSD [2, 3, 
107]. In cell culture models of MPS type IIIA and MSD, this effect associates with 




membrane, which locks the SNAREs in place and inhibits their capacity to assist in 
autophagosome-lysosome fusion [108].  
Some of these systems, particularly autophagy components, are also impaired in 
non-LSD diseases, including neurodegenerative disorders, inflammatory diseases, and a 
variety of cancers [3, 109-113]. In the case of neurodegenerative diseases such as 
Alzheimer’s, Huntington’s, and Parkinson’s diseases, patients progressively lose cognitive 
and motor abilities due to neuronal death resulting from protein accumulation in autophagic 
vacuoles, which is similar to the neurological effects of LSDs described above [110-112, 
114]. In Alzheimer’s disease, as an interesting example, dysfunction of the autophagic 
pathway, resulting in amyloid plaques, is caused by defective lysosomal proteolysis [114], 
leading to the accumulation of undigested substrates in lysosomes and autophagic vacuoles 
within dystrophic axons and dendrites [111]. The cause of this dysfunction is mutated 
presenilin-1 (PS1), which affects proper glycosylation and transport of vacuolar H+-
ATPases, resulting in poor lysosome acidification and, hence, poor activation of lysosomal 
hydrolases (see Figure 1) [111].   
Apart from the autophagic pathway, several groups including our laboratory have 
also observed alterations in the behavior of endocytic receptors and their associated 
pathways in LSDs [21, 57, 115-121]. Consequently, these alterations impact intracellular 
delivery and effects of therapeutic lysosomal enzymes [21, 57, 121], such as the case of 
ASM required for NPD treatment [21, 57]. Alterations in vesicular-mediated transport are 





2.1.3. Clinical and Experimental Treatments for LSDs 
A number of strategies have been proposed to treat LSDs and are summarized in 
Table 1 [9, 11, 12, 14-20]. Organ or cell transplantation has been clinically implemented 
to alleviate phenotypic symptoms in several LSDs, such as Gaucher, Pompe, and Krabbe 
diseases, among others [16, 20]. Organ transplantation, commonly of the liver and kidneys, 
is performed in severe cases of organ failure [1]. Alternatively, cell therapy involves 
transplantation of healthy bone marrow or mesenchymal stem cells [122], which can then 
secrete normal or wild-type lysosomal enzymes and be endocytosed with transport to 
lysosomes in neighboring diseased cells for repair of the defective enzyme activity (cross 
correction effect) [16, 37]. These options alleviate LSD symptoms in organs of the 
reticuloendothelial system (RES), but are limited in scope due to lack of suitable donors 















Table 1. Examples of different treatment modalities for LSDs. 
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Gene therapy is a treatment option with great promise in terms of therapeutic 
efficacy [20, 123, 124]. Various viral vectors (e.g., adenovirus, adeno-associated virus, 
retrovirus, and lentivirus) have been utilized for delivery of wild-type cDNA sequences 
into diseased cells to restore functional enzymes and tested in clinical trials for several 
LSDs [20, 123-126]. The efficacy of this approach is greater in peripheral organs, 
especially those of the RES, while CNS treatment remains elusive and, hence, intracerebral 
administration and alternative approaches are being explored [9, 124, 127-132]. The 
overall safety of gene therapy (e.g., immunogenicity, random insertion in the host genome) 
is also being investigated [9, 124].   
Small molecule therapies have also been explored, including substrate reduction, 
chemical chaperones, and cytosolic molecules [9]. In substrate reduction therapy, 
inhibitory molecules reduce the biosynthesis of accumulating substrates, such as N-
butyldeoxynojirimycin (Miglustat or Zavesca®), which has been tested for Fabry and Tay-
Sachs [133, 134], and is clinically approved for Gaucher disease [135]. Cysteamine is 
another substrate inhibitor successfully used to treat Cystinosis [136, 137], and genistein 
is currently in clinical trials for treatment of MPS [135]. However, lack of complete 
specificity and long-term effects of impairing anabolic routes need to be fully investigated. 
Certain accumulated metabolites can be removed using small molecules such as 
cyclodextrins, which have been shown to remove excess cholesterol and 
glycosphingolipids in a mouse model of NPC disease [138] and are currently in clinical 
trials for treatment of this disorder [139, 140]. In addition, some of these inhibitors act as 
chemical chaperones that assist in lysosomal protein folding and are being explored in 




helpful in the case of mutations that cause incorrect enzyme folding (not affecting the 
catalytic site) and facilitates transport into lysosomes since misfolded enzymes often 
accumulate in upstream compartments [143].  
Other approaches have focused on lysosomal-associated transport. When substrate 
accumulation is due to defective lysosomal transport, storage can be reduced by increasing 
intracellular levels of the molecules controlling intracellular vesicle trafficking [9]. This is 
the case of Rab9 overexpression, which reduces cholesterol and sphingolipid storage in 
NPC disease [144]. However, increasing intracellular levels of cytosolic molecules 
requires gene therapy or protein transduction and, therefore, is bound to the limitations of 
these methods. Alternatively, inducing lysosome exocytosis helps release non-degraded 
metabolites extracellularly, which can be achieved through use of cyclodextrins, δ-
tocopherol, or by overexpression of transcription factor EB (TFEB) [145-149].  
Lastly, ERT is the most widely used clinical therapy for LSDs with several products 
currently FDA-approved or in different phases of clinical trials for treatment of Gaucher, 
Fabry, Pompe, several types of MPS, and a few other LSDs [18, 30-36]. In this approach, 
wild-type recombinant lysosomal enzymes are intravenously infused in patients to replace 
those absent in the disease [16]. Glycosylation motifs on these enzymes bind to cell-surface 
M6P receptors, or the enzymes can be modified to target other clathrin-associated receptors 
[9, 11]. In principle, cells then take up the enzymes via clathrin-mediated endocytosis and 
deliver them to lysosomes to clear stored substrates [9, 11]. ERT relies on the cross 
correction effect and the fact that relatively low amounts of the ‘correcting enzyme’ (≤ 10-
20% of endogenous levels) are needed for therapeutic effects [37]. Although this therapy 




reduce its efficacy, including rapid clearance from the circulation, inactivation by 
proteases, immunogenicity with production of antibodies against recombinant enzymes, 
and the inability of recombinant lysosomal enzymes to cross the blood-brain barrier (BBB) 
[9, 12-16, 19, 25, 38-40]. Several approaches have focused on overcoming these caveats, 
including optimization of enzyme glycosylation, modification of said residues, or 
enhancement of mannose or M6P receptor expression to improve enzyme targeting [21, 
22, 29, 87].    
ERT via glycosylation-independent mechanisms is another option achieved by 
designing fusion proteins that contain the enzyme fused to an affinity peptide for 
recognition by cell-surface receptors [16]. Examples of this strategy have been shown to 
improve delivery of several LSD enzymes through use of insulin-like growth factor II (ILF-
II) peptides to target M6P receptors, receptor-associated protein that binds to low-density 
lipoprotein receptors, or others, all of which result in clathrin-dependent endocytosis and 
lysosomal transport [9, 23, 27, 41-44]. Chimeras containing protein transduction domains 
(e.g., HIV Tat) have also been used to improve charge-mediated binding to the plasma 
membrane, followed by passive endocytic uptake and/or penetration through the 
plasmalemma [24, 26, 28].   
Although certainly valuable, most these approaches are suboptimal, which has 
resulted in a limited number of clinically-approved ERT for peripheral organ treatment in 
a small fraction of LSDs [11, 13, 150]. As such, ERT is advantageous for type B NPD and, 
in fact, a recombinant form of ASM (Olipudase Alfa®) is currently in phase II/III of 
clinical trials for this disease after phase Ib studies showed minimal adverse reactions and 




and liver, and improved patient quality of life [151]. However, there are currently no 
treatments approved nor under investigation in clinical trials for the majority of LSDs that 
are characterized by neurological dysfunctions, such as in the case of type A NPD [9, 13, 
15, 97]. Hence, there is a compelling need for more effective approaches for enzyme 
replacement to adequately address these diseases. 
 
2.2. Nanocarriers for Drug Delivery 
Nanotechnology has had a profound impact on the medical field, including delivery 
of therapeutic agents such as small chemicals, and protein- and nucleic acid-based 
therapeutics [45, 50]. Nano-scale (< 1 μm) drug delivery systems (nanocarriers; NCs) can 
be fabricated from a wide array of materials including synthetic, semi-synthetic, and 
biological products to form structures with unique compositions and architectures [45, 50]. 
To improve the efficacy of therapeutic agents, NCs must be able to overcome the barriers 
that limit the efficacy of drugs in solution, such as issues with poor drug solubility and 
stability, rapid degradation and/or clearance from the circulation, systemic toxicity, poor 
accumulation in disease target sites, difficulty in maintaining drug concentrations within 
therapeutic windows, and subcellular transport to the molecular targets requiring 
therapeutic intervention [47, 48] (Figure 2). These factors can be controlled by the 
physicochemical properties of the NC, which can be modified by additional 







Figure 2. Structure and function of drug delivery systems. Various types of drug delivery 
systems currently exist and provide enhanced therapeutic efficacy compared to drugs in solution 
due to their ability to prolong circulation, bind to specific sites, and gain access to therapeutic 
targets of interest through enhanced transcellular, intracellular, and cytosolic transport, while also 
providing control over cargo release. Figure reproduced from [19]. 
 
 
2.2.1. Nanocarrier Types and Properties 
Liposomes are the oldest and probably most investigated drug delivery system 
[152]. Based on natural phospholipids found in cellular membranes, liposomes self-
assemble in aqueous solution into bilayered spherical vesicles with a diameter ranging from 
50 nm to several μm [153, 154]. Their main advantage derives from the amphiphilic nature 
of phospholipids, allowing for hydrophilic molecules to be entrapped in the liposome inner 
aqueous lumen or onto its surface, while hydrophobic molecules partition into the bilayer 




circulation time and to provide site-specific targeting [49, 153]. They have modest drug-
loading capacity and can tolerate a low degree of the aforementioned modifications, which 
affects their stability and clearance [155, 156].   
Closely related to liposomes are polymersomes and polymeric micelles. 
Polymersomes are analogous to liposomes, but are composed of amphiphilic block 
copolymers as opposed to phospholipids [153, 157]. They also form bilayered vesicles of 
a comparable size range and can be loaded with hydrophilic and hydrophobic agents [153]. 
While polymersomes are more rigid and less permeable to drugs than liposomes [153], 
they allow for a higher degree of functionalization, chemical stability, and structural 
control [153, 157]. Amphiphilic block copolymers can also self-assemble into micelles (a 
few nm in diameter), which possess only an inner hydrophobic core and an outer 
hydrophilic layer [48, 153]. They can be functionalized for targeting, have low toxicity and 
high loading capacity for water-insoluble drugs, and offer advantages including simplicity 
of preparation, controlled release profile, and prolonged blood circulation time [48, 153].   
NCs fabricated from biodegradable polymers (synthetic, natural, or hybrid) have 
become one of the most popular drug delivery systems due to their versatility as therapeutic 
carriers [48, 158, 159]. They can exist in a variety of shapes and sizes (10-1,000 nm) as 
hollow or solid structures with varying degrees of porosity [153, 160]. The therapeutic 
agent can be encapsulated, adsorbed onto the carrier surface, or dispersed throughout the 
polymer matrix [46, 48]. Control of drug release can be achieved via diffusion, surface 
erosion, or bulk degradation of the NC over a period of time [153, 160].  
With regard to materials, some of the most commonly used biocompatible synthetic 




polyglycolides, poly(lactide-co-glycolides), poly(methyl methacrylate), poly(acrylic acid), 
poly(vinyl alcohol), and poly(ethylene glycol), which is commonly referred to as PEG 
[161, 162]. Poly(lactic-co-glycolic acid) (PLGA) is one of the most widely investigated 
polymers for NCs because of its FDA-approval (owing to its good biocompatibility) [163] 
and controllable rate of degradation (hence, controlled drug release) via modification of 
particle size and the ratio of lactic to glycolic acid [160]. PEG is also widely used in drug 
delivery systems because of its ability to solubilize hydrophobic drugs and its relatively 
low interaction with components of the immune system, thereby allowing for prolonged 
blood circulation [160, 164]. Since some synthetic polymers have somewhat poor batch-
to-batch variability and residual chemicals from their fabrication may pose safety concerns 
[153], natural polymers such as chitosan, gelatin, albumin, natural gum, and sodium 
alginate are also utilized [162]. A number of polymers are also sensitive to biologically-
relevant stimuli such as changes in pH, which results in swelling of the drug delivery 
system with concomitant drug release [165, 166]. These polymers include chitosan, 
polyethylenimine, poly(acrylic acid), poly(L-lysine), and others [165, 166].  
Other nano-scale systems are based on inorganic materials, such as silica NCs, 
metal NCs, quantum dots, and carbon nanotubes [48]. While often used in diagnostic 
applications, these carriers are also advantageous for drug delivery due to their small size 
(< 50 nm) and ease of functionalization with targeting moieties, drugs, etc. [48]. However, 
they are still under investigation in regard to their safety. Some of these systems also 
possess inherent imaging capability, allowing for real-time monitoring of biodistribution 
and treatment efficacy [167-169]. One relevant example is that of 10-100 nm 




delivery applications because they are relatively biocompatible, biodegradable, can serve 
as an MRI contrast agent [48, 167], and their distribution can be manipulated by applying 
an external magnetic field over the desired area of accumulation [167].  
 
2.2.2. Targeting Strategies 
Regardless if therapeutic intervention is required at one localized site or at multiple 
sites throughout various organ systems in the body, targeting can enhance the efficacy of 
drug delivery systems by maximizing their bioadhesion [45, 47]. This can be achieved in 
a non-specific manner by targeting common elements (e.g., negative charge of the cell-
surface, affinity to ubiquitous macromolecules) or more specifically by taking advantage 
of physiological features unique to the diseased tissue, including increased vascular 
permeability (passive targeting) and specific cell/tissue markers that are overexpressed 
during the pathological state (active targeting) [47, 170]. Specific targeting helps maintain 
therapeutic levels of a drug at the diseased site(s) while minimizing potential side effects 
in healthy tissues [45, 47].   
The most common passive targeting strategy is the enhanced permeability and 
retention (EPR) effect exploited in cancer therapy, which takes advantage of the leaky 
vasculature of tumor areas to enhance NC accumulation within the cancerous tissue [171].  
NCs that rely on the EPR effect are approved clinically for the treatment of several cancers 
[48]. A representative example is Doxil, a PEGylated liposome that encapsulates the 
chemotherapeutic agent doxorubicin, used in the treatment of ovarian cancer, breast cancer, 
and Kaposi’s sarcoma [48]. The EPR phenomenon also occurs in other diseases where 




endothelium, such as in infection, infarction, rheumatoid arthritis, etc. [48, 164]. Similar to 
the EPR effect, NCs also accumulate within organs characterized by discontinuous blood 
vessels that do not present a barrier to diffusion of compounds, such as the liver and spleen 
[47]. By the first pass phenomenon, NCs can also be passively targeted to organs directly 
downstream of the administration site via normal blood flow [47].   
In some disorders where multiple organ systems are affected, non-specific active 
targeting can enhance ubiquitous delivery of NCs throughout the body [9, 14]. This can be 
achieved by relying on non-specific interactions of NCs toward general biological features, 
such as in the case of positively-charged moieties in HIV Tat peptide, RGD counterparts, 
and other sequences that can provide affinity to the negatively-charged plasmalemma of 
cells [47, 172]. Coating NCs with cationic polymers, such as chitosan, serves a similar 
purpose [165].  
Specific active targeting is typically employed when localized treatment is required 
[47]. This is achieved by addressing NCs to specific markers of diseased sites (including 
extracellular or cell-surface determinants) using affinity moieties such as proteins and 
peptides, antibodies and their fragments, sugars, and aptamers [47, 173, 174]. Targeting 
moieties can be coupled to NCs via hydrophobic or electrostatic interactions, chemical 
conjugation, etc. [47]. This approach can also be designed to target specific cell-surface 
receptors involved in vesicular-mediated endocytic transport into or across cells as 
discussed below [47, 175]. As well, the number of targeting moieties per carrier (i.e., 
valency) influences their avidity, binding, uptake, intracellular trafficking, transcytosis, 





2.2.3. Transport into Cells and across Cellular Barriers 
In most cases, the targets for therapeutic action are intracellular; hence, once drug 
carriers reach the diseased tissues they must gain access to particular intracellular 
compartments to act on the molecular component(s) responsible for a given pathology [45, 
47, 52, 174]. Most commonly, this requires drug delivery to the cell cytosol for action in 
this location or in order to gain access to other organelles [45, 47]. Physical mechanisms 
such as ultrasound or electroporation can be used to temporarily increase the permeability 
of the plasma membrane for entry into the cytosol, although these techniques are only 
applicable locally and/or are relatively toxic [47, 181]. Alternatively, some toxins or 
positively-charged cell-penetrating peptides that achieve cell-surface binding via forming 
pores or by electrostatic interactions, respectively, can facilitate translocation through the 
phospholipid bilayer [172, 182]. This route is typically restricted to molecular conjugates 
rather than larger NCs and also lacks site-specificity since it mainly exploits general 
plasmalemma features [47]. In order to improve these aspects, endocytosis is often used 
[47, 183].  
Through endocytosis, cells internalize plasma membrane components, extracellular 
materials, and objects bound to the cell-surface in membrane-bound vesicles that pinch off 
into the cytosol [53]. This process occurs via distinct pathways, each having a different 
biological role and relevance to drug delivery [53, 54, 184]. The most common pathways 
are those that internalize fluid and dissolved solutes, termed pinocytosis, some of which 
also concentrate cell-surface receptors with affinity for specific extracellular ligands [53, 
54, 184]. The most ubiquitous pinocytic pathway is clathrin-mediated endocytosis, which 




lipoprotein, M6P, Tf, etc., as mentioned previously [185]. This route has been widely 
targeted for delivery of therapeutics, drug conjugates, and carriers bearing clathrin-
associated ligands [51, 53, 185]. Another common pinocytic pathway is caveolae-mediated 
endocytosis, characterized by caveolin-1-rich vesicles that form in lipid raft domains of the 
plasma membrane [186]. Therapeutics bearing albumin, cholera toxin B (CTB), or 
antibodies to aminopeptidase P, PV1, GM1, and other caveolae components have been 
shown to internalize within caveolar vesicles [47, 51, 187]. Given the small size of 
endocytic vesicles resulting from these two pathways, commonly within 50-200 nm in 
diameter, pinocytosis via the clathrin- and caveolae-mediated routes is also referred to as 
micropinocytosis [51, 54]. Conversely, in the third classical pinocytic mechanism, 
macropinocytosis, vesicles do not concentrate specific receptors but instead internalize 
large volumes of fluid (vesicle diameter > 500 nm) to promote cell growth, sample 
antigens, etc. [188]. Hence, macropinocytosis is amenable for uptake of drug delivery 
systems with a variety of sizes and shapes [47, 175]. Although especially active in 
macrophages and dendritic cells, this pathway can be transiently induced by epidermal 
growth factor (EGF) in other cell types, therefore also playing a key role in biology and 
drug uptake [56, 188]. In addition to these classical pinocytic pathways, less common 
routes have been observed in association with certain cell-surface receptors, including 
CAM-mediated endocytosis induced by binding to ICAM-1 [68], as well as that of GPI-
anchored proteins, IL-2β receptor, and bound growth factors  [189]. 
Intracellular trafficking and the final destination of internalized material is often 
determined by the endocytic route targeted [47]. In some instances, clathrin- or CAM-




[80, 190, 191]. Instead, the caveolar pathway may lead to retrograde transport to the Golgi 
apparatus or the ER [47]. Most commonly though, materials internalized by endocytosis, 
including drugs and drug carriers, traffic to lysosomal compartments [47]. This can be an 
obstacle to therapy when drugs and/or their carriers get trapped and degraded in lysosomes, 
or an advantage when lysosomal features (enzymes, pH, etc.) can be exploited to control 
drug release or trigger escape to the cytosol [19, 54, 184]. In addition, endo-lysosomal 
trafficking is required in diseases where the therapeutic target is the lysosome itself, such 
as in LSDs [9, 19, 184].  
Targeting of pathways associated with transport across cellular barriers is also 
necessary for NC accumulation in tissues and can be achieved by endocytosis in certain 
instances [9]. Prominent examples of such cellular barriers are the endothelial lining of the 
BBB and the epithelial lining of the gastrointestinal tract, where tight junctions between 
neighboring cells prevent free transport of substances between the blood and tissue [192, 
193]. To overcome these permeability barriers, paracellular and transcellular pathways are 
utilized [9]. The paracellular route involves transport between neighboring cells via 
transient disruption of tight junctions, which can be induced by certain NCs (e.g., small 
dendrimers) or by application of hyperosmotic solutions, vasoactive agents, ultrasound, 
solvents, or stabilizers [194-197]. Since this route is often associated with leakage of 
substances between the compartments separated by the barrier, the transcellular route is 
used as an alternative [9]. This involves NC binding to specific receptors located on the 
apical surface of cells that constitute the barrier, followed by endocytosis, trafficking across 




called transcytosis and can be induced by targeting certain receptors associated with 
clathrin-, caveolae-, or CAM-mediated endocytosis [70, 71, 175, 198-200].   
 
2.3. Lysosomal Delivery of Nanocarriers 
To overcome the limitations posed by current LSD therapies, NC systems are being 
explored. During the 1970s and early 1980s, liposomes were utilized to improve ERT [201-
206]. However, with the development of a greater variety of drug delivery systems in recent 
years [45, 50], new opportunities exist for the treatment of LSDs. 
 
2.3.1. Nanocarriers for ERT 
As discussed in Section 2.1.3, ERT is a promising treatment option for patients 
with LSDs and are clinically available for a small number of these diseases. However, 
delivery of ‘naked’ recombinant enzymes poses several limitations, including limited 
circulation, lack of protection from premature degradation, immunogenicity with 
production of antibodies, suboptimal targeting, lack of transport across cellular barriers 
such as the BBB, limited regulation over the subjacent endocytic uptake and lysosomal 
transport mechanism, and lack of control over enzyme release rate in lysosomes [9]. 
Unfortunately, the use of fusion proteins improves only aspects related to targeting and 
uptake [16]. Overall, these drawbacks make ERT a limited and expensive treatment 
averaging several hundred-thousand dollars per patient each year [36, 207-210].  
To overcome these obstacles, recombinant lysosomal enzymes can be coupled to 
drug delivery carriers [9] (Table 2). Enzyme encapsulation can protect from degradation 




the NC surface can help protect against degradation by proteases, immunological 
responses, and prolong systemic circulation [211, 212]. As well, targeting can be improved 
by coating NCs with multiple copies of affinity moieties, which enhances their overall 
avidity due to multivalency [81], thereby allowing selection over the mechanism of 
transport across cellular barriers and into cells [9]. Enzyme-carrying systems can also be 
co-loaded with small cell-permeable compounds so that lysosomal degradation of NCs 
releases these cargoes within the cell for combined therapeutic interventions (e.g., using 
recombinant enzymes and small molecule treatments) [9].  
 
Table 2. Advantages of using NCs in ERT for LSDs. 
Challenges of ERT for LSDs How NCs Overcome Challenges 
Rapid clearance from the circulation  
PEG or other stealth strategies; modification of NC 
physicochemical properties 
Loss of enzyme activity by proteases 
or generation of blocking antibodies 
NCs provide protection by encapsulation or by 
posing steric hindrance to proteases and the immune 
system 
Glycosylation defects of lysosomal 
enzymes 
Use of glycosylation-independent mechanisms for 
enzyme targeting 
Preferential accumulation in the RES Carrier functionalization for active targeting 
Inadequate transport across tissue and 
cellular barriers 
Carrier functionalization to enhance transport 
Gaining cell entry 
Targeting cell-surface receptors involved in various 
forms of endocytosis 
Need frequent administrations due to 
inefficient delivery and lack of 
sustained release 
NCs provide controlled release of cargo by 
modulation of NC composition 
Table adapted from [19]. 
 
Liposomes were the first drug delivery systems investigated in the context of LSD 
treatments. Initial studies conducted during the 1970s and early 1980s tested the potential 
of liposomes for enzyme delivery of β-fructofuranosidase, α-mannosidase, β-




formulation depends heavily on the physicochemical properties of the liposome, which can 
be influenced by the phospholipid composition, entrapped lysosomal enzyme, preparation 
method, etc. [202-204, 206]. For example, liposomal formulations showed enhanced 
uptake of β-glucuronidase (MPS type VII) in the liver, whereas negatively-charged 
liposomes accumulated in lysosomes more efficiently and positively-charged liposomes 
showed longer enzyme activity (11 versus 2 days) [204]. The addition of PEG to liposomal 
formulations also enhanced both enzyme delivery and prolonged activity in lysosomes 
[213]. In cases where lysosomal delivery is required to treat immune cells (e.g., Batten 
disease) [214, 215], liposomes can be coated with autologous heat-aggregated IgG or 
apolipoprotein E to enhance accumulation in lysosomes of polymorphonucleocytes [214]. 
In a similar technique, phagocytes were targeted by liposomes coated with heat-aggregated 
isologous IgM [215]. More recently, liposomes modified with lysosomotropic agents (e.g., 
octadecyl-rhodamine B (Rh)) and loaded with velaglucerase alfa (VPRIV™) for ERT of 
Gaucher disease type I were shown to improve uptake by monocytes and fibroblasts in 
culture, accumulation in lysosomes, and enzymatic activity [216-218]. As well, addition of 
RGD peptides to liposomes significantly enhanced the delivery of recombinant α-
galactosidase, resulting in reduced lysosomal storage in a cell model of Fabry disease 
[219].    
Apart from liposomes, limited work has been published on the use of other drug 
delivery systems for LSD enzyme replacement. At the micro-scale, calcium alginate 
microspheres loaded with glucocerebrosidase have been tested in cell culture to mimic 
local implantation in Gaucher disease type I [220]. This would achieve prolonged enzyme 




by intravenous administration is suboptimal at alleviating bone pathologies characteristic 
of this disease [220]. Immobilization of lysosomal enzymes on magnetic microparticles 
has also been reported [221].  
At the sub-micrometer scale, several NC modalities have been used for endocytic 
uptake in cells other than those of the immune system. With regard to inorganic particles, 
quantum dots with surface-immobilized enzymes resulted in lysosomal transport with 
sufficient enzyme delivery to restore normal substrate levels in a cell culture model [222]. 
Gold NCs (13 nm) coated with cell-penetrating peptides (penetratin and Tat) and lysosomal 
sorting proteins (L1 and L2) showed targeted localization into lysosomes in cell cultures 
and have been proposed to be applicable for delivery of lysosomal enzymes [223]. As per 
polymer-based carriers, polyelectrolyte-based complexes (< 200 nm) of trimethyl chitosan 
displayed pH-dependent dissociation of α-galactosidase with enzyme release within the 
lysosomal compartment in a cell culture model [224]. Moreover, biodegradable PLGA NCs 
modified with a small glycopeptide appear promising for therapeutic enzyme delivery 
across the BBB in mouse models of MPS type I and II [225]. Lastly, delivery of α-
galactosidase (deficient in Fabry disease) via NCs comprised of human serum albumin and 
silk worm-derived 30Kc19 protein have also recently been shown to have enhanced 
cellular uptake, stability, and degradation of the accumulated lysosomal substrate in patient 
fibroblasts [226]. 
Overall, these approaches have shown enhanced enzyme circulation and 
accumulation in the CNS and RES organs in vivo, or improved enzyme stability with 





2.3.2. ICAM-1-Mediated ERT  
Long after the liposomal studies of the 1970s and 1980s, the first strategy that 
attempted delivery of recombinant lysosomal enzymes using NCs was published in 2004 
and focused on targeting ICAM-1 using model polymer NCs (~200-250 nm) coated with 
anti-ICAM antibodies (anti-ICAM NCs) [63]. ICAM-1 is a transmembrane, 
immunoglobulin-like glycoprotein involved in inflammation [66, 67] and was selected for 
targeting because of several reasons. ICAM-1 is expressed on most cell types in the body, 
which is amenable for targeting both peripheral organs and the CNS via different modes of 
administration (e.g., intravascular, intrathecal, and others) [66]. It is particularly 
overexpressed during pathology, including inflammation associated with LSDs, which can 
provide preferential targeting to most affected sites [66]. ICAM-1 is abundant on 
endothelial cells lining the vasculature, in direct contact with lysosomal enzymes injected 
into the circulation, and is uniquely involved in mediating transcellular extravasation of 
leukocytes from the bloodstream to tissues without opening of the cell junctions, which 
may facilitate transport across cellular barriers [66, 67].  
In addition, ICAM-1 has been found to mediate endocytosis with transport to 
lysosomes via CAM-mediated endocytosis [68] (Figure 3). This is a unique mechanism 
different from classical macropinocytosis, phagocytosis, and clathrin- or caveolae-
mediated endocytosis, and has been shown in all cell types tested to date, including 
endothelial, epithelial, mesothelial, fibroblasts, skeletal muscle, neurons, cells of the RES, 
etc. [66, 68, 227]. Further, the CAM pathway provides uptake of drug carriers within an 
ample range of sizes (100 nm to a few μm) in non-immune cells [62, 77-79]. This is 




protein NHE1 and the sphingomyelin/ceramide pathway, which regulate the 
physicochemical properties of the cell-surface and reorganization of the cytoskeleton into 
actin stress fibers, facilitating engulfment and endocytosis of micron-sized objects targeted 
to ICAM-1 [68, 78, 227].  
 
Figure 3. Mechanism of CAM-mediated endocytosis and transcytosis. The cartoon shows the 
regulatory elements subjacent to CAM-mediated endocytosis (induced upon ICAM-1 engagement 
by anti-ICAM NCs) and the associated subcellular (lysosomal or transcytotic) trafficking. Figure 
reproduced from [19] (Figure originally modified from [78, 191] with permission). 
 
 
Several studies used model polystyrene NCs or biocompatible PLGA counterparts 
to improve delivery of recombinant lysosomal enzymes by targeting ICAM-1, including 




61, 70], and α-glucosidase deficient in Pompe disease [60]. This strategy reduced the 
circulation time of lysosomal enzymes (preferable to avoid immunogenicity and other side 
effects), while providing enhanced enzyme accumulation in most LSD target organs after 
intravenous administration in mouse models, as compared to free enzyme [58-61, 65, 72]. 
For instance, anti-ICAM NCs enhanced enzyme accumulation by ~200-fold in the lungs 
and ~15-fold in the liver, which are target organs in type B NPD [58]. As well, there were 
~5-fold and ~1.5-fold increases in the heart and kidneys that are primarily affected in Fabry 
disease [61], and in Pompe, enzyme accumulation was enhanced by ~10-fold in the heart 
and ~6-fold in the skeletal muscle, both of which are major targets in this disease [60].  
Importantly, it has recently been found that anti-ICAM NCs can also undergo 
transcytosis across transwell models of the BBB [71] and gastrointestinal epithelium [70], 
as well as transport lysosomal enzymes across the BBB in mice [59-61, 65, 72]. As a result, 
this strategy markedly enhanced accumulation of lysosomal enzymes compared to free 
counterparts in the brains of mice after a single intravenous injection: ~7-fold increase for 
ASM, ~4-fold increase for α-galactosidase, and ~6-fold increase for α-glucosidase [60, 61].  
Similar to clathrin-mediated transport via the Tf receptor and low-density 
lipoprotein receptor [51, 175, 199, 200], targeting ICAM-1 permits not only transcellular 
delivery, but lysosomal trafficking as well [9, 16]. Specifically, anti-ICAM NCs tested in 
cell cultures improved uptake, lysosomal transport, and lysosomal degradation of the 
intended substrate compared to free enzymes [60-64, 69]. As well, recent work 
demonstrated ASM delivery via anti-ICAM NCs can restore altered clathrin-mediated 
endocytosis in type A NPD by attenuating lysosomal storage, suggesting this pathway can 




lysosomal transport can also be controlled by modulation of several design parameters, 
such as carrier size and shape [62, 79], targeting valency [79], the molecular epitope to 
which carriers bind [228], and pharmacological agents that impact the cell machinery 
involved in regulation of endocytic transport [227, 229].  
Overall, targeting ICAM-1 permits rapid and enhanced enzyme accumulation 
throughout multiple tissues and organs, which is preferable to avoid immunogenicity and 
other unintended side effects associated with prolonged enzyme circulation and the need 
for frequent dosing. Although several studies suggest that no acute toxicity associates with 
this strategy [61, 230-235], given the importance and complexity of ICAM-1 signaling and 
function [66, 75], additional examination into potential side effects is necessary to clearly 




Chapter 3: Status of Vesicular-Mediated Transport in Type A 
NPD2 
 
3.1. Introduction  
Vesicular-mediated endocytic uptake, intracellular trafficking, and transcellular 
delivery of therapeutics are critical processes that impact the success of many treatment 
modalities, such as in the case of ERT for LSDs discussed in Chapter 2. However, it has 
become increasingly apparent that these processes are altered in disease, including LSDs 
[21, 57, 115-120]. Specifically, lysosomal accumulation of non-degraded substrates in 
LSD cells affects not only metabolic flux, but also causes intracellular “traffic jams” that 
interfere with fusion of pre-lysosomal compartments (e.g., autophagosomes and 
endosomes), biosynthetic and secretory activity, cytoskeletal rearrangement, compartment 
transport, and other homeostatic processes) [1, 10, 21, 108, 236-238]. Consequently, 
therapeutic delivery may be impaired in these diseases, representing an important question 
of great fundamental and translational interest.  
In particular, lysosomal accumulation of lipids in certain LSDs has been linked with 
aberrant trafficking of plasma membrane components and ligands associated with clathrin 
and caveolar pathways [21, 108, 118, 119, 238]. This is the case for cells from patients 
with type A NPD, which is characterized by ASM deficiency leading to sphingomyelin 
and, secondarily, cholesterol storage [239]. As a consequence of this storage, patients 
                                                 
2Chapter 3 contains text and figures reproduced in part with permission from: (1) Rappaport, J., Manthe, 
R.L., et al., Altered clathrin-independent endocytosis in type A Niemann-Pick disease cells and rescue by 
ICAM-1-targeted enzyme delivery. Mol Pharm, 2015. 12(5): p. 1366-76; © 2015 American Chemical 
Society. (2) Manthe, R.L.* and Rappaport, J.*, et al., A comparative study on the alterations of endocytic 





suffer severe neurological defects that often result in death at a young age [97]. In type A 
NPD cells, our laboratory recently demonstrated a link between lysosomal storage and 
altered clathrin-mediated endocytosis [57]. Compared to healthy wild-type cells, type A 
NPD cells exhibited reduced uptake of Tf [57], a model ligand known to undergo clathrin-
mediated endocytosis [51]. Further supporting this finding, there was a reduction in the 
formation of clathrin-coated pits in these cells, as well as abnormal distribution of 
intracellular clathrin heavy chain and recruitment to sites of Tf binding [57]. Similarly, 
dextran uptake via bulk fluid-phase pinocytosis was also reduced in this disease [57]. As a 
direct result of altered clathrin-mediated endocytosis in these cells, our laboratory also 
observed diminished uptake of therapeutic ASM [57], which again targets the clathrin route 
via the M6P receptor [21, 239]. This finding was supported by prior work demonstrating 
reduced ASM uptake by alveolar macrophages from a mouse model of NPD [21]. 
As an alternative to clathrin-mediated endocytosis, other pathways could be 
exploited for therapeutic delivery, including caveolae-mediated endocytosis, 
macropinocytosis, and CAM-mediated endocytosis as described in Section 2.2.3. As a 
brief reminder, caveolae-mediated endocytosis occurs in most cell types [53, 56, 240] and 
is characterized by caveolin-1-rich invaginations of ~50-100 nm that form in lipid raft 
regions of the plasmalemma [186, 240]. Uptake via this route has been achieved by 
exploiting caveolar ligands, such as CTB, simian virus 40, albumin, or antibodies to 
caveolar markers such as GM1 [47, 51, 56, 187, 241, 242]. Alternatively, macropinocytosis 
is characterized by constitutive uptake of fluids in large vesicles (> 500 nm in diameter) 
and can be transiently induced in non-hematopoietic cells by EGF [56, 188]. Lastly, the 




enhance ASM delivery by coupling the enzyme to ICAM-1-targeted NCs, resulting in 
greater degradation of the associated lysosomal storage compared to free ASM and 
restoration of the clathrin pathway [57]. 
However, potential aberrancies in each of these routes have not been investigated. 
Hence, the goal of this chapter was to provide a thorough investigation into alterations in 
endocytic uptake and trafficking via these three pathways. As well, additional analysis was 
performed to further probe abnormalities associated with the clathrin pathway that were 
not previously examined. Since targeting certain receptors of the clathrin, caveolar, and 
CAM pathways can also induce transcytosis across biological barriers [70, 71, 175, 198-
200], the chapter concludes with examination of altered transcytosis via these routes, which 
is required to transport therapeutic ASM across the BBB. Together, these results will aid 
rationale design of therapeutics by providing insight into strategies to bypass or restore 
defunct pathways for enhanced efficacy.  
 
3.2. Materials and Methods 
3.2.1. Antibodies and Reagents 
 Alexa Fluor 488-, Alexa Fluor 594-, and fluorescein-labeled Tf or CTB, fluorescent 
secondary antibodies, and Texas Red-labeled dextran (10,000 MW) were from Invitrogen 
(Carlsbad, CA). Non-fluorescent human Tf and CTB were from Sigma-Aldrich (St. Louis, 
MO). Antibodies to Tf and CTB were from Calbiochem (La Jolla, CA), and those against 
markers of early endosomes (EEA-1) and lysosomes (LAMP-1) were from Calbiochem 
(La Jolla, CA) or Santa Cruz Biotechnology (Dallas, TX), respectively. Antibody to 




by the NICHD of the NIH and maintained by The University of Iowa, Department of 
Biology (Iowa City, IA). Mouse monoclonal anti-human ICAM-1 (clone R6.5) [243] was 
from American Type Culture Collection (Manassas, VA). Green Fluoresbrite® 100 nm 
diameter polystyrene beads were from Polysciences (Warrington, PA). Cell culture 
reagents were from Gibco-BRL (Grand Island, NY) or Cellgro (Manassas, VA). Porous 
transwell inserts (1.0 µm-pore) were from Thermo Fisher Scientific (Waltham, MA). 
Iodine-125 (125I) and Iodogen pre-coated tubes were from Perkin Elmer (Waltham, MA) 
and Thermo Fisher Scientific (Waltham, MA), respectively. Unless otherwise noted, all 
other reagents were from Sigma-Aldrich (St. Louis, MO).  
 
3.2.2. Cell Cultures 
Primary skin fibroblasts obtained from wild-type and type A NPD patients 
(homozygous for the R496L mutation) were kindly provided by Dr. Edward Schuchman 
(Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New 
York, NY). Cells were seeded on glass coverslips and incubated at 37°C, 5% CO2, and 
95% relative humidity in Dulbecco’s Modified Eagle Medium supplemented with 10% 
fetal bovine serum (FBS), 2 mM glutamine, 100 U/mL penicillin, and 100 μg/mL 
streptomycin. Alternatively, human brain microvascular endothelial cells (HBMECs) from 
Applied Cell Biology Research Institute (Kirkland, WA) were cultured in RPMI 1640 basal 
medium supplemented with 20% FBS, 2 mM L-glutamine, 30 µg/mL endothelial cell 
growth supplement (ECGS), 100 µg/mL heparin, 100 U/mL penicillin, and 100 µg/mL 
streptomycin. HBMECs were grown to confluence at 37°C, 5% CO2, and 95% relative 




inserts, both in 24-well plates. To mimic intracellular lipid storage that is characteristic of 
type A NPD, HBMECs were incubated for 48 h prior to assay with 20 µM imipramine, 
which degrades endogenous ASM and renders it inactive [244]; hence, creating ASM 
deficiency and intracellular lipid storage characteristic of this disease [57]. Where 
indicated, cells were incubated overnight with 10 ng/mL tumor necrosis factor alpha 
(TNFα) to mimic inflammatory activation typical of NPD and other LSDs [9, 239].  
 
3.2.3. Ligand Uptake by Caveoli  
Wild-type and type A NPD fibroblasts were incubated in medium containing 33.3 
µg/mL red Alexa Fluor-594 CTB for varying periods of time (15 min to 5 h) at 37°C to 
measure the kinetics of uptake by caveolar endocytosis. Cells were then washed, fixed with 
2% paraformaldehyde, and incubated with goat anti-CTB followed by green FITC-labeled 
rat anti-goat IgG. This protocol renders CTB bound to the cell-surface double stained in 
red and green (red + green = yellow) versus internalized CTB, which appears only red, as 
previously described [68]. To verify that CTB uptake was mainly contributed by caveolae- 
relative to clathrin-mediated endocytosis, similar experiments were conducted in the 
presence of 1 μg/mL filipin (inhibits caveolar uptake [245]), 50 μM monodansylcadaverine 
(MDC; inhibits the clathrin pathway [246]), or a mixture of both inhibitors. All samples 
were washed, mounted on slides, and analyzed by fluorescence microscopy. This was done 
using an Olympus IX81 microscope with a UPlanApo 60x objective (Olympus, Inc.; 
Center Valley, PA) and filters optimized for red, green, and blue fluorescence (Semrock, 
Inc.; Rochester, NY). Images were taken with an ORCA-ER camera (Hamamatsu; 




CO), and analyzed using Image-Pro 6.3 (Media Cybernetics, Inc.; Rockville, MD). To 
facilitate analysis using a customized algorithm that detects both fluorescent pixels and 
endosomal-sized vesicles, both surpassing a background threshold fluorescence [57, 247], 
CTB was pseudocolored green and the additional stains were pseudocolored red. 
Therefore, surface CTB appears yellow relative to green internalized counterparts. The 
percentage of internalized green fluorescent pixels over the total cell-associated 
fluorescence and the absolute number of green fluorescent vesicles were quantified. Where 
indicated, these parameters were expressed per cell area (in mm2), which was obtained 
from observation of the cell borders by phase-contrast microscopy. Regression analysis 
was performed with SigmaPlot 11.0 (Systat Software Inc.; San Jose, CA). 
 
3.2.4. Fluid-Phase Uptake and Validation via Selected Pathways 
To quantify bulk fluid-phase pinocytosis, wild-type and type A NPD fibroblasts 
were incubated at 37°C for varying periods of time (30 min to 8 h) with 1 mg/mL Texas 
Red-labeled dextran (10,000 MW), a fluid-phase marker for endocytosis. Cells were 
washed, fixed with 2% paraformaldehyde, and the number of fluorescent dextran-filled 
compartments was quantified by fluorescence microscopy using the customized algorithm 
described in Section 3.2.3. Where indicated, this parameter was expressed per cell area (in 
mm2). 
To validate dextran uptake via selected pathways, wild-type fibroblasts were 
incubated for 30 min at 37°C with Texas Red-labeled dextran in the presence of 200 µg/mL 
Tf or 33.3 µg/mL of CTB, ligands of clathrin- or caveolae-mediated endocytosis, 




fixed with 2% paraformaldehyde. Alternatively, cells incubated with Texas Red-labeled 
dextran alone were washed, fixed, and permeabilized for 5 min with 0.2% Triton X-100 
followed by immunostaining of ganglioside GM1 detected using a green Alexa Fluor 488-
labeled secondary antibody. Cell samples were examined by fluorescence microscopy 
using the algorithm previously described. In merged-channel images, uptake of red dextran 
within green Tf-, CTB-, or ganglioside GM1-containing vesicles was visualized as 
colocalization of these colors (yellow), indicating co-uptake via clathrin- or caveolae-
mediated endocytosis. The percentage of colocalization was calculated for each cell using 
the total fluorescence area occupied by each label and the total number of endosome-size 
vesicles occupied by each label.  
Additionally, macropinocytosis was evaluated by incubating wild-type or type A 
NPD cells for varying periods of time  (15 min to 8 h) at 37°C with 1 mg/mL Texas Red-
labeled dextran in medium containing 100 ng/mL EGF, which stimulates formation of 
membrane ruffles and macropinocytosis [188]. Cell samples were washed, fixed with 2% 
paraformaldehyde, and the number of fluorescent dextran-filled compartments was 
quantified and expressed per cell area (in mm2) as described above.  
Specific inhibition of macropinocytosis was also verified by incubating wild-type 
fibroblasts at 37°C for 30 min with 200 µg/mL red Alexa Fluor 594-conjugated Tf (clathrin 
route), 1 h with 33.3 µg/mL red Alexa Fluor 594-conjugated CTB (caveolar route), or co-
incubation for 30 min with 1 mg/mL Texas Red-labeled dextran and 100 ng/mL EGF 
(macropinocytosis) in the absence (control condition) versus presence of 3 mM amiloride, 
which is known to inhibit macropinocytosis [248, 249]. Cells were washed, fixed with 2% 




using antibodies conjugated to green FITC. All samples were analyzed by fluorescence 
microscopy using the customized algorithm described earlier, which required Tf or CTB 
to be pseudocolored green, while the additional cell-surface stains were pseudocolored in 
red. Therefore, in merged-channel images, surface Tf or CTB appear yellow versus 
internalized counterparts that appear green. The percentage of internalized green 
fluorescent pixels over the total cell-associated fluorescence was quantified and compared 
between control and amiloride conditions. Similarly, the total number of endocytic vesicles 
occupied by dextran was quantified and compared between the two conditions.  
Regression analysis for bulk fluid-phase uptake and macropinocytosis was 
performed with SigmaPlot 11.0. 
 
3.2.5. Intracellular Trafficking of Ligands 
 Wild-type and type A NPD fibroblasts were incubated for 30 min at 37°C with 200 
µg/mL of Tf or 33.3 µg/mL of CTB, both conjugated to red Alexa Fluor 594. Samples were 
then washed, fixed, and permeabilized as described in Section 3.2.4. Early endosomal 
compartments were then labeled using anti-EEA-1 followed by a secondary antibody 
conjugated to green Alexa Fluor 488. Alternatively, lysosomes were labeled using green 
Alexa Fluor 488-conjugated anti-LAMP-1. Cells were visualized by fluorescence 
microscopy, where colocalization of red-labeled ligands (Tf or CTB) with green-labeled 
compartment markers appear yellow in merged-channel images, and were analyzed using 
the algorithm described. This colocalization was expressed as a percentage of the total 





3.2.6. Preparation and Characterization of Anti-ICAM NCs  
 Model polymer NCs were prepared by adsorbing R6.5 antibody (anti-ICAM) onto 
the surface of 100 nm, green fluorescent polystyrene beads [57, 64]. Briefly, ~5 µM total 
antibody was incubated with ~1013 NCs/mL for 1 h at room temperature, followed by 
washing and centrifugation at 12,000 rpm for 3 min to remove non-bound antibody. NCs 
were resuspended at a final concentration of ~7 x 1011 NCs/mL in phosphate buffered saline 
containing 1% bovine serum albumin, followed by sonication at low power to mitigate 
aggregates. The diameter of the resulting anti-ICAM NCs was 258 ± 7 nm with a 
polydispersity index (PDI) of  0.15 ± 0.03, as measured by dynamic light scattering 
(Zetasizer Nano-S90, Malvern Instruments; Westborough, MA). Although not intended for 
clinical use, these prototype carriers have been demonstrated to render coating efficacy, in 
vivo targeting, and intracellular transport comparable to anti-ICAM NCs made of 
biodegradable PLGA [58, 81], and are therefore a valid model.  
 
3.2.7. Anti-ICAM NC Uptake via the CAM Pathway 
TNFα-activated healthy (control) and imipramine-treated (diseased) HBMECs 
were exposed for 1 h at 37°C to green fluorescent anti-ICAM NCs, then washed and fixed 
with 2% paraformaldehyde. Samples were incubated with a secondary antibody labeled 
with Texas Red, which is only accessible to anti-ICAM on the coat of cell-surface located 
NCs (not internalized ones), as demonstrated [247]. This allows differential staining of 
cell-surface bound (green + red = yellow) and internalized (green alone) NCs. The absolute 




cell-associated (surface-bound + internalized) NCs were quantified by fluorescence 
microscopy, as described [247].   
 
3.2.8. Transcytosis of Model Ligands  
Healthy (control) and imipramine-treated (diseased) HBMECs were cultured on 1.0 
µm-pore transwell inserts. For assessment of the CAM pathway, both healthy and diseased 
cells were activated overnight with TNFα. 125I-labeled Tf (clathrin pathway), CTB 
(caveolar pathway), or free anti-ICAM (CAM pathway) were then added to the apical 
chamber of transwell inserts (2-3 µg) and incubated for 30 min at 37°C to allow binding to 
cells. Afterwards, the non-bound fraction or ligand that leaked across the cell monolayer 
was removed by washing both the apical and basolateral chambers. The bound cargo was 
then further incubated with cells in fresh medium at 37°C for additional time up to 24 h to 
permit transcytosis across the monolayer. At select time points, the 125I content in the 
basolateral chamber was measured using a gamma counter (2470 Wizard2, Perkin Elmer; 
Waltham, MA), and the amount of Tf, CTB, or anti-ICAM transcytosed was calculated 
based on their respective specific activities (CPM/mass).  
 
3.2.9. Statistics 
Fluorescence experiments involved two or three independent assays and 
microscopy analysis involved random selection of 8-15 regions located throughout the 
sample for image acquisition. Individual analysis of each cell contained in such images 
was pursued, where all vesicles contained per cell were included in the analysis (this 




experiments, data were n ≥ 3. Data were calculated as the mean ± standard error of the 
mean (SEM), where statistical significance was determined as p < 0.05 by Student’s t-test.  
 
3.3. Results 
3.3.1. Endocytosis of Caveolar Ligands 
To build upon our laboratory’s recent study demonstrating altered clathrin-
mediated endocytosis in type A NPD fibroblasts [57], here we focused on clathrin-
independent routes. First, we examined uptake of fluorescent CTB, a molecule that 
associates with ganglioside GM1 on the plasmalemma and internalizes largely by caveolae-
mediated endocytosis [250]. Over the course of 1 h, total CTB associated with wild-type 
(herein referred to as healthy) cells to a significantly greater extent than type A NPD (herein 
referred to as diseased) cells, and also localized to the perinuclear region versus an 
endosomal-punctate-like appearance as observed in the disease case (Figure 4A). Hence, 
CTB distribution in healthy cells was consistent with Golgi and ER trafficking, as expected 
for caveolar uptake of this toxin [240, 250]. Verifying this route (since clathrin-mediated 
endocytosis could also contribute to CTB uptake [251]), only treatment with filipin, a 
cholesterol-binding agent that inhibits caveolar endocytosis [245], but not MDC, an 
inhibitor of clathrin-coated pits [246], significantly diminished CTB endocytosis in healthy 
cells: 47% versus 81% of control, respectively (Figure 4B). Further, CTB uptake in the 
presence of both filipin and MDC did not differ from filipin alone (51% of control; Figure 
4B). Importantly, total association of CTB with diseased cells was only 64% that of healthy 
cells (Figure 4A), indicating a defect in the caveolar route. In fact, filipin inhibition of 




80% of control, respectively; Figure 4B) and no effect was found for diseased cells treated 
with MDC alone (111% of control), which is expected because these cells have impaired 
clathrin-mediated uptake [57].  
 
Figure 4. Binding and internalization of CTB in type A NPD fibroblasts. (A) Fluorescence 
microscopy of wild-type (Wt) and NPD fibroblasts incubated with fluorescent CTB (pseudocolored 
green) for 1 h at 37°C. Non-bound CTB was washed off, cells were fixed, and surface-bound CTB 
was immunostained (red + green = yellow, arrowheads) to distinguish it from internalized CTB 
(green, arrows). Dotted lines mark the cell borders, as observed by phase-contrast microscopy. 
Scale bar = 10 µm. Total, internal, and surface CTB (fluorescent objects over background) were 
quantified. (B) Uptake of CTB by Wt and NPD fibroblasts was assessed after 1 h as described in 
(A). Incubations were conducted in the presence of filipin (inhibits caveolae-mediated 
endocytosis), MDC (inhibits clathrin-mediated endocytosis), or a mixture of both inhibitors. The 
number of internalized vesicles containing CTB was quantified as in (A) and expressed as a 
percentage of the uptake found for their respective controls (absence of inhibitors; indicated by the 
solid horizontal line). Data are the mean ± SEM. (A) *Comparison to Wt cells. (B) *Comparison of 
inhibitor-treated cells versus control; #comparison of MDC or filipin + MDC mixture versus filipin 




 The endocytic differences observed between healthy and diseased cells mostly 
applied to the internalized fraction of CTB (47% that of healthy cells), whereas the amount 
of CTB bound to the cell-surface was similar in both cell types (Figure 4A), suggesting 
that the defect may lie in the uptake process. Examination of the kinetics of CTB uptake 
suggested this event was slower in diseased versus healthy cells: the half-time for maximal 
uptake was 26 and 12 min, respectively, when comparing the percentage of CTB that was 
internalized from the total cell-associated fraction (Figure 5A). With time, this parameter 
reached a similar saturation (95% uptake for healthy cells and 94% uptake for diseased 
cells; Figure 5A). When quantifying the number of internalized vesicles containing CTB, 
the uptake kinetics were even more affected (half-time of 20 min for healthy cells versus 
134 min for diseased cells; Figure 5B), and when the number of internalized vesicles 
containing CTB was normalized to the cell-surface area (because different cell sizes would 
render different numbers of invaginating vesicles even if the rate of uptake was the same), 
a similar, yet more acute pattern was observed (Figure 5C). Overall, reduced CTB uptake 










Figure 5. Kinetics of CTB uptake in type A NPD fibroblasts. Kinetics of CTB uptake in Wt 
versus NPD fibroblasts, examined as described in Figure 4. The graphs show the (A) percentage 
of internalized CTB from the total cell-associated CTB, (B) total number of CTB-positive vesicles 
internalized per cell, and (C) number of internalized vesicles normalized per cell area, to account 
for the difference in Wt and NPD cell sizes. Solid lines depict regression curves, with R2 ≥ 0.94 for 
all curves. Data are the mean ± SEM. *Comparison to Wt cells (p < 0.05 by Student’s t-test). Figure 
adapted from [252]. 
 
3.3.2. Fluid-Phase Uptake in Bulk and via Clathrin or Caveolar Pathways  
 Next, we evaluated bulk fluid-phase uptake of fluorescent dextran. Diseased cells 
exhibited reduced dextran uptake at 60-70% compared to healthy cells (see 1 h time point 




altered uptake of CTB, diseased cells showed slower dextran uptake kinetics compared to 
that of healthy cells (half-time for maximal internalization was 67 versus 29 min, 
respectively), yet maximal uptake per cell was not diminished (Figure 6A). However, 
when the number of dextran-containing vesicles was normalized to cell size, maximal 
uptake at saturation seemed reduced for diseased cells (Figure 6B).  
 
 
Figure 6. Kinetics of bulk pinocytosis in type A NPD fibroblasts. (A) Microscopy images and 
quantification of the number of dextran-filled vesicles (fluorescent objects over background) 
associated with Wt or NPD fibroblasts incubated for varying periods of time at 37°C with medium 
containing fluorescent dextran (microscopy images show 1 h as an example). Dotted lines mark the 
cell borders, as observed by phase-contrast microscopy. Scale bar = 10 µm. (B) The number of 
dextran-filled vesicles per cell area. Solid lines depict regression curves, with R2 ≥ 0.95 for all 
curves. Data are the mean ± SEM. *Comparison to Wt cells (p < 0.05 by Student’s t-test). Figure 




The observed decrease in dextran uptake may be attributed to alteration in one or a 
combination of the pathways that contribute to bulk pinocytosis: clathrin-, caveolae-, and 
macropinocytic endocytosis [53]. For most cells, clathrin-coated pits and caveoli are the 
most likely uptake mechanisms since macropinocytosis is largely restricted to immune 
cells and cells transiently stimulated by growth factors [188]. To confirm this, fluorescent 
dextran internalized by healthy cells significantly colocalized with ligands that associate 
with the clathrin route [185] (41-48% colocalization with Tf) or the caveolar route [250, 
252]  (48-53% colocalization with CTB) (Figure 7A). As well, since a fraction of CTB 
may enter certain cells via the clathrin pathway [251], we further confirmed dextran uptake 
via caveoli in healthy cells by colocalization with a lipid raft domain constituent: the CTB 
target, ganglioside GM1 (40-55% colocalization; Figure 7B). The contribution of clathrin 
and caveolar pathways to endocytosis has been shown to differ between different cell types 
and culture conditions [253-256]. Yet in this case, the validation described above indicates 
that these two routes contributed similarly to dextran uptake in these cells, which parallels 
previous data [57, 252]. 
 
 
Figure 7. Fluid-phase uptake via clathrin- or caveolae-mediated endocytosis. (A) 
Quantification of the percent colocalization of red fluorescent dextran-filled vesicles internalized 
by Wt fibroblasts (30 min at 37°C) along with green fluorescent Tf or CTB. (B) Quantification of 
the percent colocalization of red fluorescent dextran-filled vesicles internalized by Wt fibroblasts 
(30 min at 37°C) with green fluorescent-immunostained ganglioside GM1. Colocalization area and 




3.3.3. Fluid-Phase Uptake via Macropinocytosis 
 Since macropinocytosis is known to contribute to non-specific uptake of 
extracellular fluid, we also evaluated this route. Specifically, we examined dextran uptake 
in healthy and diseased cells under induction with EGF, a treatment that results in the 
formation of membrane ruffles on the cell-surface in non-immune cells and, hence, 
transiently induces macropinocytosis [188]. To first verify this premise, amiloride (an 
inhibitor of macropinocytosis [248, 249]) was found to inhibit dextran uptake in healthy 
cells, while it did not affect uptake of Tf (clathrin pathway) or CTB (caveolar pathway) 
(Figure 8).  
 
 
Figure 8. Specific inhibition of macropinocytosis. (A) Wt fibroblasts were incubated for 30 min 
at 37°C with fluorescent Tf  (clathrin route), 1 h with fluorescent CTB (caveolar route), or co-
incubated for 30 min with fluorescent dextran and EGF (macropinocytosis). Incubations were 
performed in the absence (control) versus presence of amiloride, an inhibitor of macropinocytosis. 
Uptake of Tf, CTB, and dextran were assessed and quantified as described previously. Data were 
normalized to control cells (absence of inhibitor), which is indicated by the solid horizontal line. 
Data are the mean ± SEM. *Comparison to control cells (p < 0.05 by Student’s t-test). Figure 
reproduced from [257]. 
 
With this verification in place, we found diseased cells internalized only 72% as 
much dextran as healthy cells after 1 h (Figures 9A-B), demonstrating deficient 
macropinocytic activity. Both the kinetics associated with this endocytic route and the 




in diseased cells relative to 17 min in healthy cells, with diseased cells reaching only 86% 
of the maximal uptake observed in healthy samples (Figure 9B). Further, a more altered 
result was found when the number of internalized vesicles was normalized to the cell size: 
maximal uptake per mm2 in disease was 67% of healthy cells (Figure 9C).  
 
 
Figure 9. Macropinocytosis in type A NPD fibroblasts. (A) Microscopy images of Wt and NPD 
fibroblasts incubated for 1 h at 37°C in medium containing 100 ng/mL EGF (to stimulate 
macropinocytosis) and fluorescent dextran. Dotted lines mark the cell borders, as observed by 
phase-contrast microscopy. Scale bar = 10 µm. (B, C) Kinetics of EGF-induced uptake of dextran 
in Wt and NPD cells was assessed at the indicated times, as described in Figure 6. Panel (B) shows 
the number of dextran-filled vesicles per cell and (C) shows the number of dextran-filled vesicles 
per cell area. Lines depict regression curves, with R2 ≥ 0.98 for all curves. Data are the mean ± 




3.3.4. Intracellular Trafficking of Clathrin and Caveolar Ligands  
 With alterations being observed in diseased cells for both the clathrin pathway [57] 
and caveolar pathway (demonstrated herein), we next evaluated potential changes in the 
intracellular trafficking of ligands internalized via clathrin- or caveolae-mediated routes. 
For this purpose, we examined the colocalization of Tf or CTB with markers of early 
endosomes (EEA-1) or lysosomes (LAMP-1). Fluorescence microscopy visualization 
(Figures 10A-B) and quantification (Figure 10C) showed an enhanced number of both 
early endosomes and lysosomes in diseased cells compared to healthy cells (149% and 
152% of healthy levels, respectively), which is expected in LSDs [1, 19]. Most importantly, 
a smaller fraction of Tf and CTB colocalized with endosomal compartments (67% and 78% 
of the healthy level; Figures 10A and 10D), and this was also the case for colocalization 
of these ligands with lysosomes (23% and 70% of the healthy level; Figures 10B and 10E). 
Therefore, intracellular trafficking subsequent to clathrin- and caveolae-mediated uptake 














Figure 10. Intracellular trafficking of ligands in type A NPD fibroblasts. Wt or NPD fibroblasts 
were incubated for 30 min at 37°C with fluorescent Tf or CTB (pseudocolored green), followed by 
immunostaining of (A) early endosomes or (B) lysosomes using antibodies against EEA-1 or 
LAMP-1, respectively (pseudocolored red). Cell nuclei were stained blue with DAPI. 
Colocalization of Tf or CTB with EEA-1 or LAMP-1 appears yellow (red + green; arrowheads), 
while Tf or CTB localized in other areas are visualized as green (arrows). Dashed lines mark the 
cell borders, as observed by phase-contrast microscopy. Scale bar = 10 µm. (C) Quantification of 
the number of EEA-1- or LAMP-1-positive vesicles. (D) Colocalization of Tf or CTB with EEA-
1, or (E) with LAMP-1, expressed as the percentage of the total Tf or CTB associated with cells. 
Data are the mean ± SEM. *Comparison to Wt cells (p < 0.05 by Student’s t-test). Figure adapted 
from [257]. 
 
3.3.5. Anti-ICAM NC Uptake via the CAM Pathway  
Since uptake via bulk fluid-phase, receptor-mediated pathways (clathrin or 
caveolar), and macropinocytosis is impaired in type A NPD as  shown herein and in other 




improve therapeutic efficacy. As described previously, utilizing the CAM pathway for 
enzyme delivery via their coupling to anti-ICAM NCs represents an attractive and viable 
approach for enzyme replacement in LSDs. In fact, the specificity of anti-ICAM NCs to 
enhance binding, uptake, lysosomal enzyme delivery and activity, storage reduction in cell 
culture, and biodistribution in mouse models, relative to naked ASM or control IgG NCs 
has already been documented in several prior publications [57, 58, 60, 61, 68, 81, 258, 
259]. Despite the apparent advantages of this strategy, it is still important to evaluate 
potential alterations in the CAM pathway. This applies especially in the case of NPD since 
these cells are deficient in ASM, which is required for CAM-mediated endocytosis [78].  
At a time point (1 h) when caveolae-mediated uptake of CTB and clathrin-mediated 
uptake of Tf were significantly impaired (Figures 4 and 5 for CTB, and [57] for Tf), a 
significant decrease in the absolute number of anti-ICAM NCs internalized by diseased 
cells was also observed compared to healthy, control cells (77% of control; Figure 11A). 
Similarly, the percentage of internalized NCs from the total cell-associated (surface-bound 
+ internalized) NCs was slightly reduced (although not statistically significant) in diseased 
cells (88% of control; Figure 11B). Therefore, the CAM pathway is in fact also impaired 










Figure 11. Anti-ICAM NC uptake in diseased cells. Healthy (Control) and imipramine-treated 
(diseased) brain endothelial cells were pre-treated with TNFα to mimic inflammation-like 
conditions typical in type A NPD. The cells were then incubated for 1 h at 37°C with green 
fluorescent anti-ICAM NCs. Surface-bound versus internalized NCs were distinguished using the 
immunolabeling technique described in Section 3.2.7. (A) The total number of NCs internalized 
per cell and (B) internalized NCs as a percentage of total cell-associated NCs. Data are the mean ± 
SEM. *Comparison to control (p < 0.05 by Student’s t-test).  
 
3.3.6. Comparison of Cargo Uptake by Receptor-Mediated Pathways 
By comparing endocytic uptake of Tf, CTB, or anti-ICAM NCs at the 1 h time point 
in healthy and diseased cells, it is clear that all three pathways are altered in the disease 
scenario (Figure 12). However, the CAM pathway was least affected in diseased cells 
compared to the two classical endocytic routes (clathrin and caveolar) in terms of absolute 
cargo internalization and the percentage of cargo internalization (Figures 12A-B). 
Specifically, absolute cargo uptake in diseased cells relative to healthy controls was 36%, 
47%, and 77% for the clathrin, caveolar, and CAM pathways, respectively (Figure 12A), 
while the percentage of cargo internalization relative to controls was 79%, 74%, and 88%, 
respectively (Figure 12B). Therefore, endocytic alterations in LSDs present an additional 
obstacle to sufficient enzyme delivery via the classical endocytic routes (clathrin and 
caveolar), as well as the non-classical CAM pathway. Nevertheless, the CAM pathway 





Figure 12. Comparison of cargo uptake by receptor-mediated pathways in diseased cells. 
Type A NPD fibroblasts or imipramine-treated (diseased) brain endothelial cells were incubated 
for 1 h at 37°C with fluorescent Tf (clathrin pathway), CTB (caveolar pathway), or anti-ICAM NCs 
(CAM pathway). Uptake of Tf, CTB, and anti-ICAM NCs was assessed and quantified as described 
previously. (A) Absolute cargo internalization and (B) the percentage of cargo internalization 
relative to that found for wild-type fibroblasts or control endothelial cells, respectively (indicated 
by the horizontal dashed lines). Data are the mean ± SEM. *Comparison to control (p < 0.05 by 
Student’s t-test). Tf data were extracted from previously published work [57].  
 
3.3.7. Transcytosis via Receptor-Mediated Pathways 
 Given that nearly half of all LSDs associate with neurological dysfunction [1, 9], 
we next examined whether transcytosis via the clathrin, caveolar, and CAM pathways is 
also impaired in diseased brain endothelial cells. Between 3 and 24 h of incubation, the 
absolute amount of Tf, CTB, or free anti-ICAM transcytosed across diseased cells ranged 
from 2.2-2.7 ng per well (Figure 13A). While the CAM pathway transcytosed the greatest 
amount of cargo, there was no statistical difference found between the three pathways, 
suggesting that each pathway may be unaffected or similarly impacted in the diseased cells. 
Interestingly though, when this amount of transcytosed cargo was expressed relative to the 
levels found in healthy cells between the same time frame, free anti-ICAM transcytosis via 
the CAM pathway was diminished (72% of healthy control), while CTB transcytosis via 
the caveolar pathway was unaffected (98% of healthy control), and Tf transcytosis via the 




control (122% of healthy control) (Figure 13B). However, looking at this same parameter 
(cargo transcytosed in diseased cells as a percentage of the healthy controls) over the entire 
24 h incubation period, each pathway was in fact slightly impaired: 90%, 91%, and 81% 
of healthy controls for the clathrin, caveolar, and CAM pathways, respectively (Figure 
13C). The discrepancy between the two data sets (Figures 13B-C) suggest that the kinetics 
of Tf transcytosis differ in healthy versus diseased cells. Specifically, the data indicate 
diseased cells had diminished Tf transcytosis during the initial 3 h time period, likely 
caused by diminished Tf uptake [57]. Then, between 3 and 24 h of incubation, internalized 
Tf in diseased cells was able to traverse the cell barrier, resulting in a greater amount of Tf 
transcytosed by 24 h. In contrast, healthy cells transcytosed the majority of cell-bound Tf 
during the initial 3 h, so that additional transcytosis of Tf between 3 and 24 h was minimal. 
As such, the fraction of Tf transcytosed between 3 and 24 h appears greater for diseased 
cells (Figure 13B). Yet, over the duration of the entire experiment, more Tf was actually 
transcytosed in healthy cells (Figure 13C). Interestingly, these differences did not apply 
to CTB transcytosis via the caveolar route or anti-ICAM transcytosis via the CAM 
pathway. Overall though, transcytosis was relatively unaffected in diseased cells via the 
three routes tested, and the reductions in transcytosis (if any) were much less acute than 
that observed for uptake in the case of the clathrin and caveolar pathways, while uptake 










Figure 13. Comparison of transcytosis by receptor-mediated pathways in diseased cells. 
Healthy (control) or imipramine-treated (diseased) brain endothelial cells seeded on 1.0 µm-pore 
transwell inserts were incubated for 30 min at 37°C with 125I-labeled Tf (clathrin pathway), CTB 
(caveolar pathway), or free anti-ICAM (CAM pathway) to allow binding to cells, followed by 
removal of the non-bound fraction via washing both apical and basolateral chambers, and 
incubation in fresh medium for additional time up to 24 h at 37°C. The absolute amount of cargo 
transcytosed (ng/well) was quantified as described in Section 3.2.8. (A) Absolute cargo 
transcytosed between 3 and 24 h of incubation in diseased cells. (B) Cargo transcytosed between 3 
and 24 h of incubation in diseased cells as a percentage of that found in control endothelial cells 
(indicated by the horizontal dashed line). (C) Cargo transcytosed after 24 h incubation in diseased 
cells as a percentage of that found in control endothelial cells (indicated by the horizontal dashed 
line). Data are the mean ± SEM. *Comparison to control; #comparison to the CAM pathway (p < 





 Non-specific fluid-phase and receptor-mediated uptake, intracellular trafficking, 
and transcytosis are rather ubiquitous in mammalian cells, where they regulate a plethora 
of physiological functions and represent viable routes for drug delivery [47, 53, 260]. 
Therefore, altered endocytic transport may affect cell and tissue homeostasis, as well as 
delivery of therapeutics. Yet, information on the relative activity of individual endocytic 
pathways in diseased cells is still scarce. Recently, our laboratory reported aberrant 
clathrin-mediated endocytosis in type A NPD cells, which limited uptake of therapeutic 
ASM [57]. To evaluate alternative endocytic routes that may be amenable for LSD 
therapies, here we examined caveolae-, macropinocytic-, and CAM-mediated uptake in 
these diseased cells, as well as transcytosis via the clathrin, caveolar, and CAM pathways.  
As previously found for the clathrin route [57], uptake of a model ligand (CTB) of 
the caveolar route was also impaired in type A NPD cells. Specifically, the rate of CTB 
uptake and the absolute number of CTB-positive vesicles was reduced in diseased cells 
compared to healthy controls (Figures 4A and 5). Yet, because CTB levels at the cell-
surface were comparable to those of healthy cells (Figure 4A) and because fluid-phase 
caveolar uptake does not associate with specific receptors, the observed defect seems to be 
due to an aberrant capability for internalization rather than an abnormal availability of 
caveolar receptors, as described for receptors of the clathrin route [21, 57]. Nevertheless, 
we have not compared the GM1 levels (to which CTB binds) on these cells, and it is 
possible that altered biosynthesis, trafficking to the cell-surface, and/or recycling of plasma 




 Additional work by our laboratory also found that the cellular distribution of the 
machinery regulating caveolar vesicle formation (e.g., caveolin-1) is disrupted in diseased 
cells [252], which may have contributed to decreased uptake via this pathway. Briefly, 
caveolin-1 was found to locate proximal to the nucleus in diseased cells and there was very 
minimal colocalization of CTB with caveolin-1 [252], suggesting alterations in 
endogenous trafficking and/or recruitment to caveolar-binding ligands, as was also the case 
for clathrin heavy chain recruitment to sites of Tf binding [57]. Notably though, we still 
observed CTB uptake by diseased cells at a level that was 47% of healthy levels after 1 h 
(Figure 4A), which seems high considering the drastic alteration in caveolin-1 distribution 
observed by our group [252]. This difference may be due to uptake contributed by 
compensatory pathways. For example, small fractions of GM1 could be taken up in 
clathrin-coated vesicles [250, 251]. However, this route is altered in this disease [57] and 
would contribute only minimally to CTB uptake, as shown using single and combination 
inhibitors for the clathrin and caveolar routes (Figure 4B). An alternative pathway involves 
dynamin-independent vesicles formed in lipid rafts and trafficked to the ER, as observed 
for CTB and simian virus 40 [261]. Whether this pathway compensates for CTB uptake in 
these diseased cells remains to be determined. Nevertheless, finding aberrant caveolar 
uptake is supported by previous studies that suggest abnormal intracellular trafficking via 
this route in LSD cells [116, 119]. In agreement, we observed that internalized CTB 
distributed differently in healthy and diseased cells: localizing to perinuclear versus more 
punctate and widespread compartments, which is consistent with the Golgi versus 




In conjunction with diminished CTB uptake, lower uptake of dextran in diseased 
cells was observed relative to healthy cells (Figure 6B), suggesting a generalized defect in 
fluid-phase pinocytic activity. Further, dextran uptake via the clathrin and caveolar routes 
were similar in diseased cells, indicating these two routes contribute equally to uptake 
(Figure 7A). Hence, the endocytic defect may stem from a common cause (e.g., aberrant 
lysosomal storage and/or particular lipid accumulation). Recent work demonstrated 
endocytic dysfunction despite having genetic and lysosomal profiles that differ from type 
A NPD [115, 120]. Therefore, numerous factors may play a role, such as cytoskeletal 
abnormalities, impaired cytosolic diffusion of molecules, and/or altered lipid metabolism 
[10, 116, 117, 119, 236, 238]. In particular, NPD-associated changes of the lipid 
composition (sphingomyelin and cholesterol [239]) in membranes along the biosynthetic 
and endocytic routes could disrupt the biophysical properties of lipid raft domains and other 
regions, altering the association of integral and peripheral proteins that act as receptors, 
adaptors, signaling molecules, and others in both the caveolar and clathrin pathway. This 
may cause a disturbance in elements associated with vesicular fusion/fission, sorting, 
trafficking, and so forth [108, 120, 262]. In fact, our results showed reduced colocalization 
of internalized ligands of the clathrin (Tf) and caveolar (CTB) pathways with early 
endosomes and lysosomes (Figure 10). Others have also reported defects in other vesicular 
trafficking mechanisms, such as lysosomal exocytosis, which is required for plasmalemma 
recycling and proper display of membrane proteins, including endocytic receptors [262].  
EGF-induced macropinocytosis was also reduced in diseased cells (Figure 9). 
Although there is less information on this direction, several reports have suggested 




some intracellular bacteria, exploit macropinocytosis-like routes to invade cells [263-268], 
where ASM activity (deficient in type A NPD) modulates such pathogen-host cell 
interactions [264-267]. Further, ASM increases the ceramide content of the plasmalemma, 
providing both the biophysical properties and actin reorganization required to sustain 
formation of large macropinocytic engulfment structures [263-265, 267, 269]. 
Macropinocytosis is also linked to the formation of foamy macrophages in lipid metabolic 
alterations [270], both of which are observed to occur in NPD [239]. Hence, it is plausible 
that ASM deficiency leading to lipid storage in NPD results in altered macropinocytic 
uptake, as observed here.  
 Approaches to bypass altered routes may help improve the therapeutic efficacy of 
ERT. As described in Section 2.3.2, ICAM-1 is an attractive target due to its widespread 
expression and activation during inflammation (a hallmark of NPD and other LSDs [66, 
239]), because it undergoes uptake via a clathrin- and caveolae-independent pathway [64, 
68], and because ICAM-1 has no endocytic ligands endogenous to the body; thus, there are 
no competitors for the induction and progress of this pathway. However, uptake of anti-
ICAM NCs was also diminished in diseased cells (Figure 11), most likely because secreted 
ASM activity is required for ceramide enrichment and derived signaling events upon 
carrier binding on the cell-surface [78]. However, previous work by our group has 
demonstrated that coupling recombinant ASM to anti-ICAM NCs provides the necessary 
activity to restore full function of this pathway [77, 78].  
 In comparing the endocytic uptake of all three pathways, it is clearly evident that 
the CAM pathway is least impacted in diseased cells (Figure 12). Multivalent binding of 




efficient in receptor clustering and inducing endocytic signals than classical non-
multivalent binding strategies [271]. However, uptake of NCs coated with antibodies 
against the Tf receptor (anti-TfR NCs) was found to be significantly reduced compared to 
anti-ICAM NCs in prior work [65]. In fact, monomeric Tf is more readily internalized than 
anti-TfR NCs, while the opposite is observed in the case of anti-ICAM [65, 271]. 
Therefore, the observed differences here are not solely due to an effect of valency, but are 
more likely influenced by the biological function of the targeted receptor [47]. 
Furthermore, although the clathrin and caveolar pathways share some commonalities (e.g., 
use of dynamin and actin [53]), there are also major differences between these pathways 
that may account for the slight variance observed between these two routes. For instance, 
the caveolar pathway is not directly involved in the biosynthetic or endocytic transport of 
lysosomal enzymes as is the clathrin pathway [272], and caveolar trafficking is known to 
bypass the lysosome in many cases in favor of Golgi and ER targets [273]. Therefore, the 
caveolar pathway may be somewhat less affected by lysosomal alterations, as we observed.  
 In contrast to uptake, the impact of disease on transcytosis (if any) was less acute 
for the clathrin, caveolar, and CAM pathways, and there was little difference between the 
three routes (Figure 13). This suggests the transcytosis route may bypass defects associated 
with impaired uptake and/or intracellular trafficking associated with the endo-lysosomal 
pathway. Although, it is also possible minimal differences were observed between these 
three pathways due to the relative affinities of the respective ligands used. For example, 
lowering the affinity of an antibody targeting the Tf receptor was found in the literature to 
enhance transcytosis across the BBB with increased accumulation in the brain parenchyma 




[274]. Here, we evaluated clathrin-mediated transcytosis using human Tf ligand, which is 
likely to have much lower affinity than in the case of the monoclonal antibody against 
ICAM-1 used for assessment of the CAM pathway. Since ICAM-1 has no endogenous 
ligands that are specific, monomolecular and soluble (in contrast to the Tf receptor), anti-
ICAM was utilized for the CAM pathway so we could comparatively test transcytosis of 
monomeric binding to receptors for all three routes. Therefore, it is possible that 
transcytosis via the clathrin and caveolar pathways was minimally reduced due to lower 
ligand affinity, in contrast to the CAM pathway which showed a greater reduction in 
transcytosis due to the higher affinity associated with antibodies.  
Currently, no work has been published regarding the status of receptor-mediated 
transcytosis in LSDs. Although we only observed slight alterations in transcytosis via each 
of the three pathways tested, this finding is in tune with other studies showing diminished 
transcytosis across endothelial cells in conditions such as hyperlipidemia and 
hyperglycemia [275, 276]. Interestingly, inhibition of endogenous ceramide production, 
which also occurs in NPD due to the inactivity of ASM, significantly decreased 
transcytosis of oxidized low-density lipoprotein across vascular endothelial cells by 
reducing the expression of membrane proteins involved in the transcytosis process [275]. 
Consequently, there was a reduction in lipoprotein accumulation in the vascular wall, a 
feature known to cause atherosclerosis [275]. While this contradicts the high prevalence of 
arthrosclerosis found in NPD patients [277], due to the complexity and numerous 
pathological changes that associate with this disorder, the development of atherosclerosis 
cannot be minimalized to the relationship between ceramide and lipoprotein transcytosis 




epithelial cells is dependent on the structure of the ceramide domain, and this pathway is 
independent from that of retrograde transport through the TGN or ER [278]. Therefore, 
ceramide seems to play an important role in transcytosis via all three pathways [78, 275, 
278, 279]. As such, alteration in ceramide production, activity, structure, distribution, etc. 
as a result of ASM deficiency could reduce transcytosis via each route.  
   
3.5. Conclusions  
 Variations in uptake, intracellular trafficking, and transcytosis in healthy versus 
diseased cells represent important considerations for therapeutic delivery targeted to 
endocytic routes that regulate these processes. A summary of the findings presented in this 
chapter are depicted in Figure 14. While clathrin activity is essential for conventional ERT 
via the M6P receptor [11] and several other strategies targeted to clathrin-dependent 
receptors [9], uptake via this pathway was most affected in diseased cells (Figure 12) and 
not significantly better than the other two pathways in regard to transcytosis (Figure 13). 
Therefore, it may not be the best route for ASM delivery across the BBB and uptake into 
cells of the CNS. Targeting the caveolar route could be an alternative, but uptake via this 
pathway was also impaired and material internalized via this pathway often avoids 
lysosomes [51, 273]. As well, the caveolar route seems minimally involved in transport 
across the BBB [199, 280], making it unsuitable as a universal treatment for all LSDs. 
Strategies involving macropinocytosis may be possible using certain signaling molecules 
(e.g., EGF), but because this is not a receptor-mediated pathway, cargo would remain 
dissolved in the fluid-phase, preventing specific or concentrated cargo from reaching the 




most amenable for therapeutic delivery since it rendered transcytosis across a diseased 
model of the BBB similar to the other routes (Figure 13) and had the greatest uptake by 
diseased cells (Figure 12). Although ASM activity is required, resulting in slight 
impairment of uptake and transcytosis, this pathway is a receptor-mediated process that 
allows for specific targeting and concentration of an enzyme cargo on the NC surface [64, 
68, 78]. As well, coupling recombinant ASM to anti-ICAM NCs provides the necessary 
activity to recover this endocytic route [77, 78]. Hence, in the next chapter we focused on 
better understanding regulation of the CAM pathway in order to optimize therapeutic 
enzyme delivery via anti-ICAM NCs.  
 
 
Figure 14. Relative efficiency of vesicular transport routes across and into cells in type A 
NPD. The cartoon depicts the efficiency of the clathrin, caveolar, and CAM pathways in regard to 
transcytosis across diseased endothelial cells and endocytic uptake by subjacent diseased tissue 
cells. The thickness of each black arrow represents the efficiency of transcytosis or endocytosis for 
each route, where increasing arrow thickness corresponds to greater efficiency. Taking into 





Chapter 4: Regulation of the CAM Pathway to Optimize 
Therapeutic Enzyme Delivery for Type A NPD3 
 
4.1. Introduction  
 
As described in Section 2.2, drug carriers targeted to endothelial cell-surface 
receptors involved in endocytic transport are broadly exploited for numerous therapeutic 
applications. In designing such carriers, selection of the endothelial cell-surface receptor 
for targeting must be carefully determined with consideration of a number of biological 
factors that impact their therapeutic efficacy, including competition by natural ligands for 
binding to the endothelial target, the expression level and distribution of the target receptor 
in the pathological condition requiring intervention, as well as the activity of the targeted 
endocytic pathway and the fate of the internalized material [47].  
To improve treatment of type A NPD and other LSDs, which is the overall focus 
of this dissertation, delivery of lysosomal enzymes via anti-ICAM NCs is a viable option 
with great therapeutic potential. As described in prior sections, this is because ICAM-1 has 
widespread and enhanced expression in LSDs, and anti-ICAM NC binding permits 
transcytosis across cellular barriers with trafficking to lysosomes in tissue cells, both via 
the non-classical CAM pathway, resulting in enhanced enzyme delivery and reduction of 
substrate storage [57-72, 252, 257]. As well, the findings presented in Chapter 3 and other 
work highlight the ability of this pathway to bypass classical routes (e.g., clathrin and 
caveolar), whose endocytic activity was found to be impaired in type A NPD [57, 252, 
                                                 
3Chapter 4 contains text and figures reproduced in part with permission from: Manthe, R.L.* and Serrano, 
D.*, et al. How carrier size and valency modulate receptor-mediated signaling: understanding the link 
between binding and endocytosis of ICAM-1-targeted carriers. Biomacromolecules, 2016. 17(10): p. 3127-




257]. Given these advantageous features, the goal of this chapter was to further elucidate 
regulation of the CAM pathway in order to optimize anti-ICAM NCs for this application.  
Apart from selection of the endothelial cell-surface receptor for targeting, other 
design parameters also affect the success of therapeutic carriers, such as carrier size, shape, 
chemistry, and bulk concentration [47, 59, 62, 78, 79, 176, 259]. In regard to targeting 
ICAM-1, our laboratory has demonstrated the CAM pathway permits endothelial binding 
and uptake of carriers within a wide range of carrier sizes (from 100 nm to < few µm) and 
geometries (spherical, elongated, and irregular) in cell culture and mice [62, 78, 79]. This 
is in stark contrast to therapeutics and/or their carriers targeted to the clathrin or caveolar 
pathways, since they are restricted by the size of clathrin-coated pits (~100-200 nm in 
diameter) and caveoli invaginations (~50-100 nm in diameter) that form in these routes 
[51, 54]. For instance, spherical submicrometer (~200-250 nm in diameter) and 1 µm anti-
ICAM carriers are both readily internalized by endothelial cells [79], although 1 µm 
carriers require a greater extent of cell-associated signaling for plasmalemma deformation 
and cytoskeletal remodeling during uptake [62, 68, 78, 79]. The great flexibility in carrier 
design likely stems from the physiological role of ICAM-1 in mediating the adhesion and 
extravasation of leukocytes, which are much larger entities [66, 67]. In fact, as in the case 
of multivalent leukocyte binding and extravasation, multivalent anti-ICAM carriers or 
conjugates are internalized more efficiently by vascular endothelial cells compared to 
monomeric counterparts [65, 271]. However, transcytosis of anti-ICAM was found to be 
similar to that of multivalent anti-ICAM NCs [281]. Therefore, in addition to carrier size, 
valency (i.e., number of targeting molecules per carrier) is also likely to play an important 




For clinical treatment of LSDs, NCs (~200-250 nm in diameter) are more relevant 
since they are trafficked more efficiently to lysosomes [62], and their small size does not 
impede delivery to capillaries and post-capillary venules, where carrier binding, intra- and 
transendothelial transport are most prominent due to minimal shear stress in these areas 
[176, 259]. The influence of valency using anti-ICAM NCs has been explored to some 
extent, although most work has focused primarily on valency effects pertaining to targeting 
and uptake [79, 176, 177, 180]. However, how valency influences cell-signaling events 
related to CAM-mediated uptake upon binding to ICAM-1 is not well-understood. Further, 
to our knowledge there is little information pertaining to the role of anti-ICAM valency on 
lysosomal trafficking and transcytosis across the BBB, which are two important processes 
for treatment of LSDs. Apart from the role of valency on these events, in general the 
relationship between lysosomal trafficking and transcytosis is not well-understood. While 
transcytosis most often implies avoidance of these compartments [198, 199], the CAM 
pathway permits both lysosomal trafficking and transcytosis [62-64, 70, 71]. Therefore, we 
investigated this caveat as well in order to better understand the mechanism(s) regulating 
the CAM pathway.  
Lastly, whether mediated via classical or independent pathways, to the best of our 
knowledge there have been no studies on the mechanism(s) by which receptor-targeted 
drug carriers disengage from the basolateral endothelium after transcytosis across this 
lining. Some natural ligands, like iron-transporting Tf, dissociate from their receptors due 
to conformational changes occurring between the ligand-cargo in the bound versus 
unbound state (i.e., iron-bound versus iron-unbound Tf) [282]. Yet, this has never been 




not apply to ligands (e.g., antibodies) used for targeting of drug carriers. Other natural 
ligands, including antibodies, can dissociate from their receptors due to changes in pH 
experienced during transit through endo-lysosomal compartments [283, 284]. However, as 
mentioned above, transcytosis most often implies avoidance of these compartments [198, 
199]. Therefore, the multivalency of interaction and high avidity of targeted carriers may 
make it even more difficult to detach from a cell after transcytosis. This is of key 
importance since, even if transcytosis is efficient, a lack of detachment from the engaged 
receptor will result in carriers remaining bound to the basolateral side of the endothelium, 
thereby inhibiting carriers from being delivered to the underlining tissue. 
 In this context, proteolytic cleavage of the extracellular region of receptors, which 
has been observed in other instances [285], may permit basolateral detachment of targeted 
carriers after transendothelial transcytosis. In particular, matrix metalloproteinases 
(MMPs), zinc-dependent endopeptidases secreted by numerous cell types [286] are 
implicated in the shedding of cell-surface molecules to regulate a number of cellular events, 
including leukocyte-endothelial interactions and interactions between cells and the 
extracellular matrix [286-290]. Among MMPs, the gelatinases (MMP-9 and MMP-2) are 
implicated in cell migration across endothelial barriers [287-290]. Moreover, MMP-9 
localized at the cell-surface has been shown to cleave the extracellular domain of ICAM-1 
resulting in release of sICAM-1 [288, 291]. In fact, it has been speculated that shedding of 
ICAM-1, other endothelial CAMs, and their leukocyte co-receptors may help disengage 
both cell types after extravasation [292]. Although MMP-2 is not known to cleave ICAM-
1, it may indirectly play a role in this process since MMP-2 is involved in cleavage of pro-




As such, in this chapter we explored how valency impacts anti-ICAM NC binding 
and associated cell-signaling, uptake, lysosomal trafficking, and transcytosis. As proof-of-
concept, we also examined the therapeutic implications of valency in regard to anti-ICAM 
NC delivery of recombinant ASM (deficient in type A NPD) across the BBB in cell culture 
and mice. Moreover, we made significant efforts to decipher the link between lysosomal 
trafficking and transcytosis, as well as investigated the potential for proteolytic cleavage 
of surface ICAM-1 by MMP-9 or MMP-2 for anti-ICAM NC detachment from the 
basolateral cell-surface following transcytosis, along with speculation about the role of 
valency in mediating this process. Ultimately, this work will guide optimization of anti-
ICAM NCs for treatment of type A NPD and other LSDs, as well as additional disorders 
requiring delivery across the BBB.  
 
4.2. Materials and Methods 
4.2.1. Antibodies and Reagents 
 Mouse monoclonal anti-human ICAM-1 (clone R6.5) [243] and rat monoclonal 
anti-mouse ICAM-1 (clone YN1) [295] were from American Type Culture Collection 
(Manassas, VA). Non-specific mouse IgG was from Jackson ImmunoResearch (West 
Grove, PA). Mouse IgM anti-ceramide was from Sigma-Aldrich (St. Louis, MO). Rabbit 
anti-human PKC (H-300), rabbit anti-human GAPDH, and FITC-labeled goat anti-mouse 
IgM were from Santa Cruz Biotechnology (Dallas, TX), Rabbit anti-phosphorylated human 
PKCα (phospho T638) was from Abcam (Cambridge, United Kingdom). Horseradish 
peroxidase (HRP)-linked anti-rabbit IgG was from GE Healthcare (Pittsburgh, PA). Texas 




Fluor 350-labeled secondary antibodies were from Invitrogen (Carlsbad, CA). 
Recombinant human ASM was kindly provided by Dr. Edward Schuchman (Department 
of Genetics and Genomics Sciences, Mount Sinai School of Medicine, New York, NY). 
Polystyrene beads were from Polysciences (Warrington, PA). Cell culture reagents were 
from Gibco-BRL (Grand Island, NY) or Cellgro (Manassas, VA). Porous transwell inserts 
(1.0 µm-pore) were from Thermo Fisher Scientific (Waltham, MA). 125I and Iodogen pre-
coated tubes were from Perkin Elmer (Waltham, MA) and Thermo Fisher Scientific 
(Waltham, MA), respectively. H-7 dihydrochloride, an inhibitor of protein kinase C (PKC), 
MMP-9 Inhibitor I (MMP-9i), and MMP-2 Inhibitor I (MMP-2i) were from EMD 
Millipore (Billerica, MA). Recombinant human MMP-9 (67 kDa) and MMP-2 (62 kDa) 
were from EMD Millipore (Billerica, MA) and Sigma-Aldrich (St. Louis, MO), 
respectively. Pre-cast 4-15% polyacrylamide gels were from Biorad (Hercules, CA) and 
PVDF membranes were from Pall Life Sciences (Port Washington, NY). Unless stated 
otherwise, all other reagents were from Sigma-Aldrich (St. Louis, MO).  
 
4.2.2. Cell Cultures 
HBMECs from Applied Cell Biology Research Institute (Kirkland, WA) were 
cultured in RPMI 1640 basal medium supplemented with 20% FBS, 2 mM L-glutamine, 
30 µg/mL ECGS, 100 µg/mL heparin, 100 U/mL penicillin, and 100 µg/mL streptomycin. 
HBMECs were grown to confluence at 37°C, 5% CO2, and 95% relative humidity on either 
1% gelatin-coated coverslips or uncoated 1.0 µm-pore transwell inserts, both in 24-well 
plates. Alternatively, human umbilical vein endothelial cells (HUVECs) from Lonza 




2 mM L-glutamine, 15 µg/mL ECGS, 100 µg/mL heparin, 100 U/mL penicillin, and 100 
µg/mL streptomycin. Cells were grown at 37°C, 5% CO2, and 95% relative humidity on 
1% gelatin-coated coverslips. Where indicated, cells were stimulated overnight with 10 
ng/mL TNFα to induce endothelial activation, as found in LSDs [9, 239]. 
 
4.2.3. Preparation and Characterization of Anti-ICAM Carriers  
Model polymer carriers were prepared by coating polystyrene beads (100 nm or 1 
µm in diameter) via surface adsorption with anti-ICAM or non-specific IgG alone, 
mixtures containing different anti-ICAM to IgG mass ratios (100:0 versus 50:50 versus 
25:75), or mixtures containing different anti-ICAM to ASM mass ratios (95:5 versus 50:50 
anti-ICAM/ASM NCs) as described in Section 3.2.6 and in prior work [64, 79]. For the 
antibody or ASM coat to be characterized, either anti-ICAM, IgG, or ASM were 
conjugated to 125I, and the amount of radiolabeled antibody or enzyme per carrier was 
determined using a gamma counter (2470 Wizard2, Perkin Elmer; Waltham, MA), as 
described [247]. The size of carriers was measured by dynamic light scattering or particle 
tracking (Nanosight LM10, Malvern Instruments; Westborough, MA), and the PDI and ζ-
potential were obtained by dynamic light scattering and electrophoretic mobility, 
respectively (Zetasizer Nano-S90, Malvern Instruments; Westborough, MA).  
Again, while non-degradable polystyrene carriers are not clinically relevant, they 
are used in this work to avoid potential confounding effects of concomitant NC degradation 
during intracellular trafficking and transcytosis. However, as mentioned in Section 3.2.6, 
these carriers have been shown to be comparable to biodegradable PLGA counterparts [58, 




physical properties or the ability of anti-ICAM to target cells [58, 81]. Prior work by our 
laboratory has also demonstrated minimal release of therapeutic enzymes from the NC 
surface under mechanical stress and physiological-like conditions [60, 61], while providing 
release in lysosomes for reduced accumulation of substrate storage [57, 60-62, 64]. 
 
4.2.4. Avidity and Binding Specificity of Anti-ICAM NCs  
To test the avidity and binding specificity of green fluorescent anti-ICAM NCs with 
different valencies (~200 nm in diameter; 2,058 to 7,703 anti-ICAM molecules/µm2 carrier 
surface) while avoiding confounding effects associated with NC uptake, TNFα-activated 
HBMECs seeded on coverslips were first fixed with 2% paraformaldehyde. To assess 
avidity, cells were then incubated with anti-ICAM NCs at different concentrations (from 
22.5 to 3,780 pM) for 1 h at room temperature, followed by removal of non-bound NCs by 
washing. Similarly, binding specificity was examined by incubating anti-ICAM NCs with 
fixed, TNFα-activated HBMECs for 15 min to 24 h at room temperature using an 
intermediate NC concentration (113 pM). All samples were then washed, stained with 
DAPI to label cell nuclei, and mounted on slides for analysis by fluorescence microscopy 
as described in Section 3.2.3. Using a customized algorithm in Image-Pro 6.3 that detects 
fluorescent pixels over a background threshold, the number of NCs was then computed 
based on the number of pixels that theoretically correspond to the size of a single particle. 
Regression analysis was performed with SigmaPlot 11.0 (Systat Software Inc.; San Jose, 




4.2.5. Ceramide Enrichment at Sites of Carrier-Cell Binding  
 Red or non-fluorescent anti-ICAM carriers of different sizes (250 nm or 1 µm in 
diameter) and valencies (from 800 to 30,000 anti-ICAM molecules/µm2) were incubated 
for 15 or 30 min at 37°C with TNFα-activated HUVECs seeded on coverslips. Non-bound 
carriers were washed off, cells were fixed with 2% paraformaldehyde, and surface-bound 
carriers were immunostained blue with an Alexa Fluor 350-labeled secondary antibody. 
The cells were then permeabilized with 0.2% Triton X-100, and ceramide, a signaling 
molecule associated with the CAM pathway [77, 78] was immunostained in green. Cells 
were then visualized using fluorescence microscopy. Image-Pro 6.3 was used to determine 
ceramide fluorescence at sites of carrier binding, as described previously [77, 78]. Briefly, 
ceramide fluorescence intensity at the plane of a carrier “equator” was determined around 
the carrier circumference (membrane engulfment area) and outside the region of carrier 
binding (background), from which the ceramide enrichment associated with carrier binding 
was calculated (i.e., engulfment - background).  
 
4.2.6. PKC Signaling Upon Cell Binding of Targeted Carriers 
 Green or non-fluorescent anti-ICAM carriers of different sizes (250 nm or 1 µm in 
diameter) and valencies (8,000 to 13,000 anti-ICAM molecules/µm2) were incubated for 
10 or 30 min at 37°C with TNFα-activated HUVECs seeded on coverslips. Non-bound 
carriers were washed off, cells were fixed with 2% paraformaldehyde, and surface-bound 
carriers were stained blue with an Alexa Fluor 350-labeled secondary antibody. In parallel 
experiments, the cells were then permeabilized with 0.2% Triton X-100 and either total 




fluorescence microscopy, from which total PKC and pPKCα enrichment at sites of carrier-
cell binding were calculated as described above for ceramide enrichment. In addition, 
pPKCα present in the lysate of cells incubated in the absence versus presence of anti-ICAM 
carriers (250 nm or 1 µm in diameter; 10,000 to 30,000 anti-ICAM molecules/µm2) was 
separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). 
This was followed by Western blot to immunodetect and normalize the level of pPKCα to 
that of the housekeeping protein GAPDH. For both fluorescence and Western blot assays 
testing PKC signaling, two different times (10 and 30 min) were analyzed and averaged to 
estimate signal enrichment. This is because PKC is involved in both endocytosis upon 
carrier binding to ICAM-1 and also subsequent intracellular trafficking [62, 68], events 
that occur sequentially. Since the uptake and intracellular trafficking kinetics of 
submicrometer carriers is slightly different from that of micrometer carriers, averaging the 
signal at two different time points minimizes potential confounding effects of a dual 
(uptake and trafficking) signal.  
 
4.2.7. Uptake of Anti-ICAM NCs  
To evaluate the effect of valency on NC internalization, green fluorescent anti-
ICAM NCs (~200 nm in diameter; 2,058 to 7,703 anti-ICAM molecules/µm2) were 
incubated with TNFα-activated HBMECs seeded on coverslips at 37°C for 5 min, 15 min, 
or 30 min to permit NC binding. After 30 min (pulse), non-bound NCs were removed by 
washing and further incubated in fresh medium at 37°C for additional time up to 24 h to 
allow uptake of surface-bound NCs (chase). At select time points, cells were fixed with 2% 




Texas Red-labeled secondary antibody, which recognizes both the anti-ICAM and mouse 
IgG coated on the NCs. Since NCs contain a green-fluorescent label, this renders yellow 
surface-bound NCs (red + green = yellow) versus green internalized NCs, as previously 
described [247]. Similar experiments were performed in the presence of 25 µM MMP-9 
inhibitor (MMP-9i) or 25 µM MMP-2 inhibitor (MMP-2i). 
Alternatively, uptake of green fluorescent anti-ICAM NCs (~200 nm in diameter; 
7,703 anti-ICAM molecules/µm2) was quantified in TNFα-activated HBMECs seeded on 
1.0 µm-pore transwell inserts following a 30 min binding period at 37°C (pulse), and 
uptake for an additional 30 min or 1.5 h in carrier-free medium (chase). As in the coverslip 
model, cells were then washed, fixed, and immunostained to distinguish surface-bound 
versus internalized NCs. Cells were visualized using a LSM 710 confocal laser scanning 
microscope with a 100x Plan-APOCHROMAT objective and 405, 488, and 555 lasers 
(Zeiss; Oberkochen, Germany). Z-stacks were obtained starting from the basolateral cell-
surface in contact with the transwell membrane and moving up to the apical cell-surface at 
a width of 0.37 µm per z-section. Then, z-stacks of the entire cell body (apical to basolateral 
surface) or z-stacks corresponding to only the basolateral cell-surface (1.11 µm width)  
were converted into three-dimensional color composites using Image J software. 
For both the coverslip and transwell models, the algorithm described in Section 
4.2.4 was used to quantify the number of internalized NCs per cell based on the green 
fluorescent pixels, and the percentage of NC internalization was quantified as the green 
fluorescent pixels over the total cell-associated fluorescence. Where loss of total 
fluorescence over time occurred (as a result of three-dimensional stacking of internalized 




the 30 min binding period was multiplied by the percentage of NC internalization to 
quantify the respective number of internalized NCs at each subsequent time point. 
Regression analysis was performed for each valency in the coverslip model using 
SigmaPlot 11.0.  
 
4.2.8. Transcytosis of Anti-ICAM NCs or Anti-ICAM/ASM NCs  
125I-labeled anti-ICAM NCs (~200 nm in diameter; 2,058 to 7,703 anti-ICAM 
molecules/µm2) were added to the apical chamber of 1.0 µm-pore transwell inserts above 
a monolayer of TNFα-activated HBMECs. NCs were incubated with cells for 30 min 
(pulse) at 37°C to allow binding to cells.  NCs that did not bind to cells or those that leaked 
across the HBMEC monolayer were then removed by washing both the apical and 
basolateral chambers. Bound NCs were then incubated with cells in fresh medium at 37°C 
for additional time up to 30 h to allow transcytosis across the cell monolayer (chase). At 
select time points, the 125I content in the cell fraction (bound and internalized NCs) and in 
the basolateral chamber below cells (transcytosed NCs) was measured using a gamma 
counter, and the number of NCs in each fraction was then calculated based on the CPM/NC. 
Further, the number of anti-ICAM NCs was corrected by subtraction of free 125I in each 
fraction as determined by trichloroacetic acid (TCA) precipitation [247]. Regression 
analysis was performed for each valency using SigmaPlot 11.0. As well, similar 
experiments were performed in the presence of one of the following: 25 µM MMP-9i; 25 
µM MMP-2i; 800 pg/mL recombinant MMP-9; 114 ng/mL recombinant MMP-2. To 
observe the effect of valency on delivery of a model therapeutic cargo, 125I-labeled anti-




Lastly, the relationship between lysosomal trafficking and transcytosis was 
evaluated in two ways. First, 125I-labeled anti-ICAM NCs (7,703 anti-ICAM 
molecules/µm2) were added to the apical chamber of 1.0 µm-pore transwell inserts above 
a monolayer of TNFα-activated HBMECs. NCs were incubated with cells for 30 min at 
37°C to allow binding to cells, non-bound NCs were removed by washing both chambers, 
and the cells were incubated for an additional 30 min in fresh medium to allow NC uptake. 
Afterwards, the cells were washed again and incubated in fresh medium supplemented with 
10 µM H-7 (inhibits lysosomal trafficking) for another 4 h at 37°C. Alternatively, non-
radiolabeled anti-ICAM NCs were added to cells and incubated for 30 min at 37°C to allow 
NC binding, followed by washing both chambers to remove non-bound NCs, and 
incubation for an additional 1.5 h at 37°C in fresh medium to allow NC uptake and 
trafficking to lysosomes. Afterwards, 125I-labeled anti-ICAM NCs were added to cells for 
30 min at 37°C for NC binding, followed by washing, and additional incubation for 4.5 h 
in fresh medium. The same procedure and corrections described above were then 
performed.  
 
4.2.9. Lysosomal Trafficking of Anti-ICAM NCs   
To examine lysosomal trafficking, TNFα-activated HBMECs seeded on coverslips 
were first incubated with Texas Red-labeled dextran (10,000 MW) for 45 min at 37°C, 
followed by washing and additional incubation at 37°C for 45 min to allow dextran 
trafficking to lysosomes. Anti-ICAM NCs (~200 nm in diameter; 2,058 to 7,703 anti-
ICAM molecules/µm2) were then added to cells for 30 min (pulse), followed by washing 




at 37°C to allow trafficking of NCs to lysosomes (chase). At select time points, cells were 
fixed with 2% paraformaldehyde. Green NCs colocalized with red lysosomes appear 
yellow in color versus NCs that are not in lysosomes which appear single-labeled in green 
[64]. Alternatively, colocalization of anti-ICAM NCs (7,703 anti-ICAM molecules/µm2) 
with lysosomes was quantified in TNFα-activated HBMECs seeded on 1.0 µm-pore 
transwell inserts using the same procedure described above for the coverslip model. 
Imaging was performed via confocal microscopy in the same manner as described in 
Section 4.2.7.  
For both models, the number of NCs colocalized with lysosomes per cell was 
quantified based on the yellow (green + red) fluorescent pixels, and the percentage of either 
total cell-associated or internalized NCs (as indicated) colocalized with lysosomes was 
quantified as the yellow fluorescent pixels over the total or internalized fluorescence, where 
the internalized fraction was quantified by multiplying the total cell-associated 
fluorescence by the percent internalization at each respective time point. Similar to NC 
uptake, where loss of total fluorescence over time occurred, the internalized fluorescence 
at the 30 min binding period was multiplied by the percentage of NC colocalization with 
lysosomes to quantify the respective number of NCs colocalized with lysosomes per cell 
at each subsequent time point. Regression analysis was performed for each valency in the 
coverslip model using SigmaPlot 11.0. Further, the total number of dextran-occupied 
lysosomes per cell was counted, as well as the number of NCs located within the pores of 





4.2.10. Biodistribution of Anti-ICAM/ASM NCs in Mice 
 Wild-type C57Bl/6 mice from Jackson Laboratory (Bar Harbor, ME) were 
anesthetized by intraperitoneal injection of a ketamine/xylazine cocktail. Once under 
anesthesia, 125I-labeled anti-ICAM/ASM NCs (95:5 versus 50:50 mass ratios) were 
injected into the jugular vein (~1.5 x 1013 NCs/kg of body weight). These antibody to 
enzyme ratios yield high valency NCs (~7,703 anti-ICAM molecules/µm2 and 28 ± 2 ASM 
molecules/NC) and intermediate valency NCs (~4,145 anti-ICAM molecules/µm2 and 203 
± 5 ASM molecules/NC). The total ASM injected was ~52 µg/kg for the high valency and 
~378 µg/kg for the intermediate valency. Blood samples were collected 1, 15, and 30 min 
post-injection via the retro-orbital sinus, and organs of interest (brain, liver, and spleen) 
were collected after euthanasia at 30 min post-injection. The weight and 125I content of all 
samples were measured to calculate the following: percent injected dose (% ID), percent 
injected dose per gram of tissue (% ID/g), and number of ASM molecules. Experiments 
were conducted following IACUC protocols with humane care guidelines, as approved by 
the University of Maryland, College Park.  
 
4.2.11. Statistics 
Fluorescence microscopy experiments encompassed a total sample size of n ≥ 12. 
Western blot data were n = 6. For transcytosis studies, data were n ≥ 4. Animal data were 
n ≥ 5. Data were calculated as the mean ± SEM, where statistical significance was 






4.3.1. Characterization of Anti-ICAM NCs with Different Valencies  
 For most of the work presented below, the effect of targeting valency on the CAM 
pathway was assessed using 100 nm polystyrene beads coated with anti-ICAM and non-
specific IgG in three different mass ratios (100:0, 50:50, and 25:75) as shown in Table 3. 
Each formulation had similar physical properties with diameters ranging from 178 to 182 
nm, PDI of 0.17 to 0.19, and ζ-potential (surface charge) of -27.4 to -28.1 mV. By antibody 
radiolabeling, we also verified that only the targeting valency varied, while the total 
number of antibodies (anti-ICAM + IgG) on the NC surface remained similar (Table 3). 
Covering the NC surface with saturating levels of anti-ICAM rendered 7,703 anti-ICAM 
molecules/µm2 of NC surface (valency 1), while addition of IgG to the coating mixture in 
increasing amounts resulted in 4,145 anti-ICAM molecules/µm2 (valency 2; 55% anti-










Table 3. Characterization of anti-ICAM NCs with different valencies. 















Uncoated NCs 113 ± 2 0.06 ± 0.01 -38.5 ± 2.1 - - - - 
Valency 1        
Mouse IgG NCs 169 ± 4 0.19 ± 0.01 -27.4 ± 0.5 6,190 ± 286 - - - 
Anti-ICAM NCs 178 ± 4 0.19 ± 0.00 -27.4 ± 0.2 7,703 ± 244 7,703 ± 244 14,681 ± 859  177.2 ± 37.7 
Valency 2        
Anti-ICAM/IgG NCs 182 ± 2 0.18 ± 0.01 -28.1 ± 0.3 7,493 ± 240 4,145 ± 240 13,141 ± 766 218.7 ± 44.8 
Valency 3        
Anti-ICAM/IgG NCs 181 ± 2 0.17 ± 0.01 -28.1 ± 0.5 6,792 ± 110 2,058 ± 110 12,465 ± 592 401.4 ± 59.8 
















The reduction in valency among the three formulations correlated well with a 
decrease in their respective avidities toward fixed, activated brain endothelial cells: the 
binding constant (Kd) was 177, 219, and 401 pM for valencies 1, 2, and 3, respectively 
(Table 3). However, the absolute number of NCs bound at saturation was similar among 
all three valencies tested (Table 3 and Figure 15), suggesting the number of cell-surface 
ICAM-1 accessible for NC binding is the limiting factor. 
  
 
Figure 15. Role of valency on anti-ICAM NC avidity toward brain endothelial cells.  Fixed, 
TNFα-activated HBMECs were incubated for 1 h at room temperature with varying concentrations 
(22.5 to 3,780 pM) of anti-ICAM NCs with different valencies, where the inset shows NC binding 
up to 300 pM. NC binding per cell was quantified by fluorescence microscopy as described in 
Section 4.2.4.  Data are the mean ± SEM, for which regression curves were fitted. Statistical 




4.3.2. Endothelial Binding of Anti-ICAM NCs with Different Valencies  
 Next, we used fixed, activated brain endothelial cells to assess anti-ICAM NC 
binding without concomitant uptake. As shown in Figure 16, NCs bound faster as anti-




Specifically, anti-ICAM NCs with high valency (7,703 anti-ICAM/µm2) had a half-time 
(t1/2) to maximal binding of 1.4 h, while the intermediate valency (4,145 anti-ICAM/µm
2) 
was 2.4 h, and the low valency (2,058 anti-ICAM/µm2) rendered a t1/2 of 6.6 h (Table 4). 
Yet again, all three valencies reached similar saturation levels and were comparable to 
those found for NC avidity (Tables 3 and 4), providing additional support that the number 









Figure 16. Role of valency on anti-ICAM NC binding to brain endothelial cells. (A) 
Fluorescence microscopy images showing binding of green fluorescent anti-ICAM NCs with 
different valencies to fixed, TNFα-activated HBMECs after 1 h incubation at room temperature. 
Cell nuclei were stained blue with DAPI and dashed lines mark the cell borders, as observed by 
phase-contrast microscopy. Scale bar = 10 µm. (B) Anti-ICAM NC binding to cells was quantified 
over a period of 24 h at room temperature, where the inset shows the first 1 h of incubation. Data 
are the mean ± SEM, for which regression curves were fitted. Statistical significance is not shown 










Table 4. Summary of regression curve data for anti-ICAM NCs with different valencies. 
 Valency 1 Valency 2 Valency 3 
Anti-ICAM Molecules/NC µm2: 7,703 Ab/µm2 4,145 Ab/µm2 2,058 Ab/µm2 
Binding    
t1/2 (h) 1.40 ± 0.26 2.43 ± 0.76 6.62 ± 2.16 
Bmax (NCs Bound/Cell) 15,486 ± 837 17,003 ± 1,754 19,629 ± 2,615 
Internalization    
t1/2 (h) 0.47 ± 0.11 0.65 ± 0.16 0.80 ± 0.16 
Imax (NCs Internalized/Cell) 2,292 ± 101 2,413 ± 126 1,674 ± 71 
Transcytosis    
t1/2 (h) 3.30 ± 0.60 1.66 ± 0.56 2.98 ± 1.00 
Tmax (NCs Transcytosed/Cell) 10,081 ± 508   7,129 ± 519   9,094 ± 821  
Lysosomal Colocalization    
t1/2 (h) 1.65 ± 0.38 2.12 ± 0.53 1.84 ± 0.40 
Lmax (NCs Colocalized/Cell) 1,803 ± 102 1,942 ± 128 1,258 ± 69 
Data are the mean ± SEM. All R2 > 0.95. 
 
4.3.3. Endothelial Cell-Signaling Induced by Binding of Anti-ICAM Carriers with 
Different Valencies  
 Upon anti-ICAM carrier binding to cell-surface ICAM-1, there is a cascade of 
signaling events induced through the sodium proton exchanger 1 (NHE1) and ASM (see 
Figure 3) [68, 78, 227]. Briefly, ASM hydrolyzes sphingomyelin to ceramide at the cell-
surface, causing modification of the lipid composition and biophysical properties of the 
plasma membrane at regions of anti-ICAM carrier binding [78]. Protein kinase C (PKC) 
has also been reported to contribute to this signaling, which along with the ceramide signal 
culminates in rearrangement of actin into stress fibers and carrier uptake [62, 68, 73, 77, 
78, 227]. Here, we examined the correlation between anti-ICAM valency on carriers and 




prepared model anti-ICAM carriers of different sizes (250 nm versus 1 µm in diameter) 
and valencies (800 to 30,000 anti-ICAM molecules/µm2).  
 First, we found a linear correlation between ceramide enrichment and anti-ICAM 
valency regardless of carrier size or concentration of carriers added to cells (Figure 17). 
Specifically, ceramide enrichment increased with a greater density of ICAM-1 
engagement, which was calculated as the number of anti-ICAM molecules/µm2 multiplied 
by a factor of two, since anti-ICAM is bivalent and each antibody molecule can 
theoretically engage two ICAM-1 molecules on a cell. In the case of micrometer carriers, 
decreasing anti-ICAM valency from 30,000 to 13,000 anti-ICAM molecules/µm2 
significantly reduced ceramide enrichment (2-fold decrease; points indicated by red arrows 
in Figure 17). Similarly, submicrometer carriers (12,000 versus 1,600 anti-ICAM 
molecules/µm2) showed a 1.5 fold-reduction in ceramide enrichment (points indicated by 
purple arrows and circles in Figure 17). Despite having lower ceramide enrichment, 
submicrometer carriers with saturating valency had an enhanced rate of uptake compared 
to the larger carriers (data not shown, presented in [79]). Therefore, submicrometer carriers 
require less signal for uptake to occur. Interestingly, ceramide enrichment was comparable 
for anti-ICAM carriers (1 µm and 30,000 anti-ICAM molecules/µm2) incubated with 
activated endothelial cells at different concentrations (1.2-fold difference; circled in blue 
in Figure 17), despite having significantly different levels of binding (19-fold difference; 
data not shown, presented in [79]). As such, ceramide enrichment is mediated by each one 
carrier as opposed to being dependent on the total number of carriers bound. Furthermore, 
carriers of different sizes (1 µm versus 250 nm) but similar valencies (13,000 versus 12,000 




difference; points circled in green in Figure 17) even though submicrometer anti-ICAM 
NCs bind to a significantly greater extent (12-fold difference; data not shown, presented in 
[79]). Therefore, it is the valency density (i.e., targeting molecules per carrier surface area) 
that regulates cell-signaling upon anti-ICAM NC binding, and not the absolute valency 
(i.e., targeting molecules per carrier). However, for carriers of identical size, the surface 
area is the same and, therefore, only changes in absolute valency are possible. Since NCs 
of the same size are evaluated in the other sections of this chapter, valency is equivalent to 
valency density in this case. 
 
 
Figure 17. Role of valency on ceramide enrichment induced by anti-ICAM carrier binding to 
endothelial cells. Anti-ICAM carriers of different sizes (250 nm versus 1 µm in diameter) and 
valencies (800 to 30,000 anti-ICAM molecules/µm2) were incubated with TNFα-activated 
HUVECs at 37°C for 15 min or 30 min and the enrichment of ceramide at sites of carrier-cell 
binding was measured as described in Section 4.2.5. The graph shows the relationship between 
ceramide enrichment and the density of ICAM-1 engagement, which was calculated as the number 
of anti-ICAM molecules/µm2 multiplied by a factor of two, since anti-ICAM is bivalent and each 
antibody molecule can theoretically engage two ICAM-1 molecules on a cell. The line represents 
a linear regression, for which R2 = regression coefficient. Data are the mean. *Comparison between 
the carriers indicated (p < 0.05 by Student’s t-test). Micrometer carrier data were collected by Dr. 





To further validate that valency density rules signaling upon carrier binding, we 
then examined PKC recruitment and activation at anti-ICAM carrier binding sites using an 
immunofluorescence approach similar to that for ceramide enrichment. Using an antibody 
capable of detecting all PKC isoforms regardless of their activation status, we found that 
total PKC enrichment at carrier binding sites depended on valency density, but not carrier 
size (Figure 18A; black bars). For instance, carriers with similar valencies (13,000 and 
12,000 anti-ICAM molecules/µm2) but very different sizes (1 µm versus 250 nm) rendered 
similar total PKC enrichment (1.05-fold difference; two left black bars in Figure 18A). 
Instead, for carriers of the same size (250 nm), lowering the valency from 12,000 to 8,000 
anti-ICAM molecules/µm2 decreased total PKC recruitment by 1.5-fold (two right black 
bars in Figure 18A). This pattern persisted when we evaluated a more specific marker of 
PKC signaling: active (phosphorylated)-PKCα (pPKCα), the main form related to ICAM-
1 signaling [73]. As in the case of total PKC, very different sizes (1 µm versus 250 nm) but 
comparable valencies (13,000 versus 12,000 anti-ICAM molecules/µm2) generated similar 
pPKCα enrichment (1.1-fold difference; two left white bars in Figure 18A), while carriers 
with the same size (250 nm) but different valencies (8,000 versus 12,000 anti-ICAM 
molecules/µm2) rendered different enrichment (1.4-fold difference; two right white bars in 
Figure 18A). Western blot analysis of pPKCα, to confirm this result by a different method, 
suggested a similar trend when comparing carriers of the same size (1 µm) and different 
valencies (30,000 versus 13,000 anti-ICAM molecules/µm2), which rendered different 
signal (1.24-fold; two left bars in Figure 18B). Carriers with different sizes (1 µm versus 
250 nm) but more similar valencies (13,000 and 10,000 anti-ICAM molecules/µm2) 




despite Western blot not being ideal for this type of analysis, since it does not allow 
distinction between surface-bound and internalized carriers (in contrast to fluorescence 
visualization), and the goal is to relate binding valency to signals preceding endocytosis. 
Hence, the fact that Western blot results paired relatively well with fluorescence imaging 










Figure 18. Role of valency on PKC signaling induced by anti-ICAM carrier binding to 
endothelial cells. (A) Fluorescence microscopy (top panel, with magnified insets showing 1 µm 
anti-ICAM carriers) and image quantification (bottom panel) of the enrichment of either total PKC 
or pPKCα upon incubation of anti-ICAM carriers with TNFα-activated HUVECs at 37°C 
(enrichment at 10 min and 30 min was averaged). Different carrier sizes (250 nm versus 1 µm in 
diameter) and anti-ICAM valencies (8,000 to 13,000 anti-ICAM molecules/µm2) are shown. Scale 
bar = 10 µm (full) or 1 µm (inset). (B) Western blot (top panel) and densitometric quantification 
(bottom panel) showing pPKCα normalized to GAPDH levels, in cells incubated with anti-ICAM 
carriers (250 nm or 1 µm in diameter; 10,000 to 30,000 anti-ICAM molecules/µm2) as in (A). Data 
are the mean ± SEM. *Comparison to carriers of the same size but different valencies (p < 0.05 by 




4.3.4. Endothelial Uptake of Anti-ICAM NCs with Different Valencies 
 Next, we examined the effect of valency on anti-ICAM NC uptake by activated 
brain endothelial cells (Figure 19). To do so, we utilized a pulse-chase method in which 
anti-ICAM NCs were permitted to bind to cells for 30 min, followed by washing to remove 
non-bound NCs, and incubation in fresh medium for additional time up to 24 h (chase) in 
order to track uptake of bound NCs. As seen in Table 4 and Figure 19B, regardless of the 
difference in valencies, anti-ICAM NC uptake is a much faster process than binding: the 
half-time (t1/2) for maximal NC uptake was less than 1 h for all valencies compared to the 
1.4-6.6 h required for binding (Table 4). Hence, the data indicate that anti-ICAM NC 
binding is the rate limiting step in the CAM pathway. In accord, the half-time to maximal 
uptake increased along with a reduction in anti-ICAM valency: 28 min, 39 min, and 48 
min for the high, intermediate, and low valencies, respectively, which was expected given 
the same trend in their binding rates (Table 4). However, maximal anti-ICAM NC uptake 
was approximately 30% less for the low valency (2,058 anti-ICAM molecules/µm2) (Table 
4 and Figure 19B), despite having similar levels of binding at saturation (Figure 16). This 
could be attributed to a reduction in the total number of anti-ICAM NCs bound after the 
30 min pulse (~1,600 NCs bound for the low valency versus ~2,200 NCs bound for the 
intermediate and high valencies; data not shown). Looking at Figure 19C, we also found 
a similar trend between valency and anti-ICAM NC uptake expressed as a percentage of 
total cell-associated NCs. Nevertheless, the differences between these valencies were much 
less acute than that of NC binding, and uptake via the CAM pathway was found to be a 
very efficient process, given there was 100% NC internalization at saturation for all three 





Figure 19. Role of valency on anti-ICAM NC uptake by brain endothelial cells. (A) 
Fluorescence microscopy showing internalization of green fluorescent anti-ICAM NCs with 
different valencies by TNFα-activated HBMECs after 30 min pulse at 37°C to permit NC binding, 
and an additional 30 min incubation in carrier-free medium to allow NC uptake (1 h total). Surface-
bound versus internalized NCs were distinguished using an immunolabeling technique (see Section 
4.2.7) that renders surface-bound NCs yellow (red + green; arrows) versus green internalized NCs 
(arrowheads). Cell nuclei were stained blue with DAPI and dashed lines mark the cell borders, as 
observed by phase-contrast microscopy. Scale bar = 10 µm. Anti-ICAM NC internalization by cells 
was assessed using this pulse-chase method up to a total time of 24 h. (B) Absolute number of anti-
ICAM NCs internalized per cell over this time period. (C) Anti-ICAM NCs internalized as a 
percentage of total cell-associated (surface-bound + internalized) NCs over this time period. (B, C) 
Insets show the first 1 h of incubation. Data are the mean ± SEM, for which regression curves were 
fitted. Statistical significance is not shown for simplicity, but it was obtained and considered in the 
description of the results. 
 
4.3.5. Transcytosis of Anti-ICAM NCs with Different Valencies 
 To subsequently investigate the influence of valency on anti-ICAM NC transcytosis 
across brain endothelial cells, we utilized the more physiologically-relevant transwell 
model that permits separation of the apical and basolateral compartments. First, we verified 




As seen in Figure 20, the total number of cell-associated anti-ICAM NCs was significantly 





Figure 20. Specificity of anti-ICAM NC binding to brain endothelial cells on transwell inserts. 
Binding of 125I-labeled anti-ICAM NCs or 125I-labeled IgG NCs to TNFα-activated HBMECs 
grown on transwell inserts after 30 min incubation at 37°C. Data are the mean ± SEM. *Comparison 
to IgG NCs (p < 0.05 by Student’s t-test). 
 
 With this validation in place, we assessed the role of valency on anti-ICAM NC 
transcytosis using the same pulse-chase technique described in the prior section to 
eliminate potentially confounding results due to NCs that may have passively leaked across 
the endothelial monolayer. Anti-ICAM NC transcytosis was found to be a very efficient 
process, as approximately 70-80% of all cell-associated NCs were transcytosed to the 
basolateral chamber at saturation (Figure 21B). As seen in Figure 21A and the 
corresponding data in Table 4, absolute anti-ICAM NC transcytosis was slower than NC 
uptake and within the same time range as NC binding. At first glance, it appears the 
efficiency of NC transcytosis was not linearly correlated with valency, but rather had a 




(7,703 anti-ICAM molecules/µm2), 1.7 h (4,145 anti-ICAM molecules/µm2), and 3 h 
(2,058 anti-ICAM molecules/µm2) (Table 4). However, this is because the transcytosis 
process and data measured also encompasses binding and uptake. Therefore, since the 
intermediate and low valencies (4,145 and 2,058 anti-ICAM molecules/µm2, respectively) 
had slower rates of NC binding and uptake (Table 4 and Figure 22A), the data for 
transcytosis actually suggest this process was more efficient for lower valencies, indicating 
an inverted linear dependency between valency and NC transcytosis when considered as 
an independent event (Figure 22B). Overall then, given the opposite relationships between 
anti-ICAM valency and NC binding/uptake or transcytosis as isolated processes (Figures 
22A-B), the efficiency of the entire transport process as a sequence of these events (binding 
 uptake  transcytosis) produces the bell-shaped curve described earlier (Figure 22C). 
As such, an intermediate valency seems to be the best for therapeutic delivery because it 









Figure 21. Role of valency on anti-ICAM NC transcytosis across brain endothelial cells. 
Transcytosis of 125I-labeled anti-ICAM NCs with different valencies across a monolayer of TNFα-
activated HBMECs after 30 min apical binding at 37°C, removal of non-bound NCs by washing 
both apical and basolateral chambers, and incubation in fresh medium at 37°C for additional time 
up to 30 h total. (A) Quantification of the absolute number of NCs transcytosed per cell to the 
basolateral chamber over time. (B) Percentage of NCs transcytosed with respect to the total number 
of NCs (cell-associated + transcytosed). Data are the mean ± SEM, for which regression curves 
were fitted. Statistical significance is not shown for simplicity, but it was obtained and considered 







Figure 22. Model of dependence between targeting valency and NC transcytosis. (A) There is 
a direct linear correlation between increasing anti-ICAM valency and the efficiency of both NC 
binding and uptake. However, (B) considering NC transcytosis as an isolated event, there is an 
inverse linear relationship with valency. Therefore, (C) the entire transport process, encompassing 
sequential binding, uptake, and transcytosis, produces a bell-shaped curve (in green), resulting in 
an intermediate valency being the most efficient at the intersection of these processes (indicated by 





4.3.6. Lysosomal Colocalization of Anti-ICAM NCs with Different Valencies 
 Based on the aforementioned findings, we questioned how anti-ICAM valency 
could modulate the efficiency of NC transcytosis. Given the propensity for anti-ICAM NCs 
and other drug delivery systems to traffic to lysosomes [47, 63, 64], we decided to examine 
whether valency impacts this process in brain endothelial cells using the same pulse-chase 
technique described previously (Figure 23). Using a coverslip model we observed that, 
regardless of valency, the colocalization of internalized anti-ICAM NCs with lysosomes 
was slower than NC uptake and faster than transcytosis (Table 4 and Figure 23B): the 
half-time to maximal colocalization of anti-ICAM NCs with lysosomes was 1.7 h (7,703 
anti-ICAM molecules/µm2), 2.1 h (4,145 anti-ICAM molecules/µm2), and 1.8 h (2,058 
anti-ICAM molecules/µm2). Upon examining the percentage of internalized anti-ICAM 








Figure 23. Role of valency on anti-ICAM NC trafficking to lysosomes in brain endothelial 
cells. (A) Fluorescence microscopy showing green fluorescent anti-ICAM NCs with different 
valencies colocalized with red lysosomes in TNFα-activated HBMECs on coverslips after 30 min 
pulse at 37°C to permit NC binding, and an additional 30 min incubation in carrier-free medium to 
allow NC uptake and trafficking to lysosomes (1 h total). Lysosomes were pre-loaded with Texas 
Red-labeled dextran, resulting in colocalization of internalized NCs with lysosomes to appear 
yellow (red + green; arrows) versus green (surface-bound + internalized) NCs (arrowheads). 
Dashed lines mark the cell borders, as indicated by phase-contrast microscopy. Scale bar = 10 µm. 
Anti-ICAM NC colocalization with lysosomes was assessed using this pulse-chase method up to a 
total time of 24 h. (B) Absolute number of anti-ICAM NCs colocalized with lysosomes per cell 
over this time period. (C) Internalized anti-ICAM NCs colocalized with lysosomes as a percentage 
of the total internalized NCs over this time period. (B, C) Insets show the first 1 h of incubation. 
Data are the mean ± SEM, for which regression curves were fitted. Statistical significance is not 
shown for simplicity, but it was obtained and considered in the description of the results. 
 
As can be seen by the data for lysosomal colocalization (Table 4), although not 
statistically different among the valencies tested, the relationship between anti-ICAM NC 
valency and lysosomal colocalization was opposite to that found for transcytosis with 
slower lysosomal colocalization corresponding to the intermediate valency (Figure 24). 




(most efficient), while the high and low valencies were slower (less efficient) and 
comparable to each other (Table 4 and Figure 24A). However, for lysosomal 
colocalization, the intermediate valency had the slowest rate of lysosomal trafficking (least 




Figure 24. Relationship between valency and efficiency of NC transcytosis or lysosomal 
colocalization. (A) As presented in Figure 22C, the efficiency of transcytosis (considering the 
entire transport process) produced a bell-shaped curve due to the opposing trends in NC binding 
and uptake versus transcytosis when each process was independently evaluated. However, (B) the 
efficiency of NC lysosomal colocalization showed an inverse relationship with valency. 
 
 
 Moreover, maximal colocalization of anti-ICAM NCs with lysosomes at saturation 
was around 70% (Figure 23C), which is comparable to the maximal NC transcytosis at 
saturation (70-80%; Figure 21B). Altogether, these findings raised questions regarding the 
relationship between lysosomal trafficking and transcytosis, particularly whether they are 
independent processes or sequential events, as well as the role of valency in regulating 
these processes. Specifically, we postulated three scenarios of NC lysosomal trafficking 
and transcytosis that could be influenced by anti-ICAM valency (Figure 25). Each of these 
scenarios were explored in the more physiologically-relevant transwell model and are 






Figure 25. Models for the potential relationship between lysosomal trafficking and 
transcytosis of anti-ICAM NCs. In scenario (A), NCs undergo both lysosomal trafficking and 
transcytosis after uptake. These routes are independent from each other and valency may dictate 
the efficiency of each one independently. In scenario (B), NC trafficking to lysosomes or related 
compartments is a prerequisite for transcytosis, whereby the influence of valency on transcytosis 
is dictated by the preceding effect of valency on lysosomal trafficking. In scenario (C), NCs 
transcytosed to the basolateral cell-surface may be internalized again and trafficked to lysosomes, 
e.g., if they are unable to dissociate from their bound receptors, and the influence of valency on 
lysosomal trafficking is dependent on the earlier effect of valency on transcytosis.  
  
4.3.7. Uptake of Anti-ICAM NCs in the Transwell Model 
Before examining lysosomal colocalization in the transwell system, we first sought 
to examine whether anti-ICAM NC uptake was similar between the coverslip and transwell 
models. To do so, we incubated high valency anti-ICAM NCs (7,703 anti-ICAM 
molecules/µm2) with a monolayer of activated brain endothelial cells in transwell inserts 
using the same pulse-chase technique used for coverslips. Confocal microscopy was used 
to acquire z-stacks that were analyzed as color composites of either the whole cell body 
(apical to basolateral surface) or just the basolateral cell-surface (see Section 4.2.7). As in 




and there was increased uptake over time (Figure 26). However, in comparison to 
coverslips, the percentage of total cell-associated NCs internalized was significantly less 
in the transwell model (1.6-2.3-fold difference). This finding was expected and does not 
mean NC uptake is less efficient in the transwell model compared to coverslips. Instead, it 
is because basolateral secretion of internalized NCs after transcytosis reduces the number 
of internalized NCs that contribute to this measurement and, hence, the percentage of 
internalized NCs with respect to total cell-associated NCs is reduced.  
 
 
Figure 26. Anti-ICAM NC uptake by brain endothelial cells on coverslips versus transwell 
inserts. TNFα-activated HBMECs seeded on coverslips or transwell inserts were incubated with 
green fluorescent anti-ICAM NCs (7,703 anti-ICAM molecules/µm2) for 30 min pulse at 37°C, 
followed by additional incubation in carrier-free medium up to 2 h total to allow NC uptake. 
Surface-bound versus internalized NCs were distinguished using the immunolabeling technique 
previously described. The graph shows anti-ICAM NCs internalized as a percentage of total cell-
associated (surface-bound + internalized) NCs at each time point. Data are the mean ± SEM. 
*Comparison to coverslips at each time point (p < 0.05 by Student’s t-test). 
 
Upon examining the transwell data further, we observed the total number of NCs 
(surface-bound + internalized) in the whole cell was significantly greater (6-17-fold) than 
that of the basolateral cell-surface, as expected (Figure 27A). Over time, total NCs 




27A), which is similar to the percentage of NCs transcytosed at this time (~20% NCs 
transcytosed; Figure 21B). In contrast, the total number of anti-ICAM NCs on the 
basolateral cell-surface remained relatively steady over time (Figure 27A), suggesting that 
the rate of transcytosis across the cell body is constant. Supporting this conclusion, the 
fraction of internalized anti-ICAM NCs in the whole cell was similar over time (212-262 
NCs/cell; Figure 27B), while the number of surface-bound NCs significantly decreased in 
a linear fashion (R2=0.991; regression curve not shown), which is likely a consequence of 
NCs being released from the basolateral cell-surface after transcytosis (50% reduction from 
30 min to 2 h; Figure 27B). In fact, surface-bound NCs as a percentage of total cell-
associated NCs on the basolateral surface also decreased with time in a similar manner 
(Figure 27C), thereby providing further evidence of anti-ICAM NC detachment from the 
basolateral cell-surface after transcytosis. Moreover, since surface-bound NCs could be 
distinguished on the basolateral endothelium via immunostaining, this provides 
verification that the targeting antibody (anti-ICAM) remains (to some degree) associated 
with the NC after transcytosis. This is imperative for subsequent NC binding and uptake 
by other cell types in the brain, which has been observed in co-culture models of the BBB 
(endothelial cells + astrocytes or pericytes) [71], as well  as in the brains of mice with NPD 






Figure 27. Anti-ICAM NC uptake by brain endothelial cells on transwell inserts. TNFα-
activated HBMECs seeded on transwell inserts were incubated with green fluorescent anti-ICAM 
NCs (7,703 anti-ICAM molecules/µm2) for 30 min pulse at 37°C, followed by additional incubation 
in carrier-free medium up to 2 h total to allow NC uptake. Surface-bound versus internalized NCs 
were distinguished using the immunolabeling technique previously described. (A) Total cell-
associated NCs for the whole cell versus basolateral cell-surface (see Section 4.2.7). (B) Surface-
bound versus internalized NCs for the whole cell. (C) Surface-bound NCs as a percentage of total 
cell-associated (surface-bound + internalized) NCs on the basolateral cell-surface. Data are the 
mean ± SEM. *Comparison to 30 min; #comparison to 1 h; %comparison to surface-bound NCs at 




4.3.8. Lysosomal Trafficking of Anti-ICAM NCs in the Transwell Model  
 Next, we examined lysosomal trafficking of anti-ICAM NCs in the transwell model 
by confocal microscopy (Figure 28). As found in coverslips, internalized anti-ICAM NCs 
colocalized with lysosomes in cells seeded on transwell inserts and there was increased 
colocalization over time (12-40% colocalization; Figure 28B). Although, similar to that of 
uptake, the degree of colocalization in transwells was reduced compared to coverslips (1.3-
2.4-fold difference; Figure 28B). However, using the internalized NC fraction to calculate 
the percentage of lysosomal colocalization in the transwell model does not account for NCs 
that were internalized and subsequently transcytosed, since these NCs would be stained 
and quantified as basolateral surface-bound NCs. Therefore, using total cell-associated 
NCs in this quantification more accurately reflects lysosomal colocalization, and 
consequently, an even greater difference was observed between the two models (2.0-4.6-
fold difference; Figure 28C). In accord with this finding, the absolute number of NCs 
colocalized with lysosomes per cell was significantly diminished in the transwell model, 











Figure 28. Lysosomal trafficking of anti-ICAM NCs in coverslips versus transwell inserts. (A) 
Fluorescence microscopy showing colocalization of green fluorescent anti-ICAM NCs (7,703 anti-
ICAM molecules/µm2) with red lysosomes in TNFα-activated HBMECs on coverslips versus 
transwell inserts after 30 min pulse at 37°C to permit NC binding, and an additional 30 min 
incubation in carrier-free medium to allow NC uptake and trafficking to lysosomes (1 h total). 
Lysosomes were pre-loaded with Texas Red-labeled dextran, resulting in colocalization of 
internalized NCs with lysosomes to appear yellow (red + green; arrows) versus green (surface-
bound + internalized) NCs (arrowheads). Dashed lines mark the cell borders, as indicated by phase-
contrast microscopy. Scale bar = 10 µm. Anti-ICAM NC colocalization with lysosomes was 
assessed using this pulse-chase method up to a total time of 2 h. (B) Percentage of internalized NCs 
colocalized with lysosomes. (C) Percentage of total cell-associated (surface-bound + internalized) 
NCs colocalized with lysosomes. (D) Absolute number of anti-ICAM NCs colocalized with 
lysosomes per cell. Data are the mean ± SEM. *Comparison to 30 min in each model; #comparison 
to 1 h in each model; %comparison to coverslips at each time point (p < 0.05 by Student’s t-test). 
 
Based on the data presented thus far, it appears nearly all anti-ICAM NCs were 
trafficked to lysosomes in the coverslip model because no apical versus basolateral 
polarization is possible, while both lysosomal trafficking and transcytosis are permitted in 
the transwell system. In agreement, the total number of lysosomes per cell was significantly 




Figure 29A), which is likely given the prevalence of lysosomal trafficking in this model. 




Figure 29. Anti-ICAM NC distribution in lysosomes and transwell pores. Lysosomes in TNFα-
activated HBMECs seeded on coverslips or transwell inserts were pre-loaded with Texas Red-
labeled dextran, followed by incubation with green fluorescent anti-ICAM NCs (7,703 anti-ICAM 
molecules/µm2) for 30 min pulse at 37°C, and additional incubation in carrier-free medium up to 2 
h total to allow NC uptake. (A) Total number of dextran-filled lysosomes per cell in either the 
coverslip or transwell model after 30 min. (B) Number of anti-ICAM NCs colocalized with dextran-
filled lysosomes or the number of NCs found in the pores of transwell inserts after 30 min. (C) 
Confocal microscopy showing in the left panel a green fluorescent anti-ICAM NC (arrow) entering 
a transwell pore (arrowheads) after 1 h. Scale bar = 10 µm. The right panel is the magnified inset 
showing a green fluorescent anti-ICAM NC colocalized with a red dextran-filled lysosome and a 
NC in a transwell pore. Scale bar = 1 µm. (D) Anti-ICAM NCs in transwell pores as a percentage 
of total cell-associated NCs. Data are the mean ± SEM. (A) *Comparison to coverslips; (B) 
*Comparison to NCs in lysosomes; (D) *Comparison to 30 min (p < 0.05 by Student’s t-test). 
 
 
In scenario A (Figure 25), we speculated anti-ICAM NCs can be independently 
trafficked to both lysosomes and transcytosed across the cell body following uptake. The 
fact that NCs were detected in both lysosomes and transwell pores at early time points 




over time also indicates they are transcytosed into the basolateral chamber (Figure 29D), 
which validates the radiotracing data presented in Figure 21. Further, this is in contrast 
with increased NC colocalization with lysosomes over time (Figure 28), which is expected 
since these model NCs are non-biodegradable and, hence, will keep accumulating in 
lysosomes. Although we did not experimentally address the role of valency on lysosomal 
colocalization, because transport to lysosomes and transcytosis are independent processes 
in this scenario, they may also be independently modulated by valency. Hence, we cannot 
rule out scenario A (Figure 25).  
  
4.3.9. Dependency between Lysosomal Trafficking and Transcytosis of Anti-ICAM 
NCs  
As shown in Figure 25, it may be possible that lysosomal trafficking and 
transcytosis depend on each other. In scenario B, we postulated that transcytosis may 
require previous lysosomal (or related) trafficking where cells secrete materials to the 
basolateral space that were previously transported to lysosomes, while in scenario C 
lysosomal trafficking would follow transcytosis, e.g., when anti-ICAM NCs are not able 
to detach from the receptor.  
A priori, it seems that scenario B (Figure 25) may be ruled out, because if 
lysosomal trafficking preceded transcytosis then the influence of targeting valency on NC 
trafficking to lysosomes would be the same for transcytosis, yet they are in fact opposite 
(Figure 24). To confirm this, we tested whether anti-ICAM NC trafficking to lysosomes 
is a prerequisite to transcytosis using radiotracing techniques. First, we assessed if 




in the presence of H-7, an inhibitor of PKC that hinders lysosomal trafficking [62, 68]. 
Briefly, since PKC inhibition can also hinder uptake [68], anti-ICAM NCs were first 
permitted to bind to and be internalized by cells using the pulse-chase technique described 
earlier. Then, cells were incubated in fresh medium supplemented with H-7 for another 4 
h to assess the effect of inhibiting lysosomal trafficking on transcytosis. As seen in Figure 
30A, inhibition of lysosomal trafficking did not affect NC degradation (measured as the 
percentage of free 125I) in either the cell fraction or basolateral (i.e., transcytosed) fraction 
as compared to the control condition (108% and 100% of control, respectively). As well, 
the absolute number of NCs associated with cells or those transcytosed to the basolateral 
chamber were not significantly impacted (109% and 86% of control, respectively), and this 
was the same case when expressed as the percentage of NCs in either fraction with respect 
to the total number of NCs present (cell-associated + transcytosed) (105% and 82% of 
control, respectively). Hence, it appears that transcytosis does not require pre-lysosomal 
transport.  
In a parallel experiment, we attempted to pre-load lysosomes with an initial dose of 
non-radiolabeled anti-ICAM NCs, which would hinder transcytosis of a second dose of 
125I-labeled anti-ICAM NCs if passage through lysosomes was first required. However, as 
seen in Figure 30B this was not the case and the results showed a similar trend to that 
found in the case with H-7 treatment. More specifically, NC degradation was not 
significantly affected in both the cell and basolateral fractions (90% and 75% of control, 
respectively). As well, the absolute number of NCs associated with cells or those 
transcytosed were not affected (89% and 109% of control, respectively), nor was the 




these findings confirm anti-ICAM NC transcytosis across brain endothelial cells is not 




Figure 30. Effect of H-7 and dual NC dosing on anti-ICAM NC transcytosis. TNFα-activated 
HBMECs were grown to confluence on transwell inserts. (A) 125I-labeled anti-ICAM NCs (7,703 
anti-ICAM molecules/µm2) were added to the apical chamber for 30 min at 37°C to permit binding, 
non-bound NCs were removed by washing both chambers, and the cells were incubated for an 
additional 30 min in fresh medium to allow uptake. Afterwards, the cells were washed again and 
incubated in fresh medium supplemented with H-7 for an additional 4 h at 37°C to inhibit lysosomal 
trafficking. (B) An initial dose of non-radiolabeled anti-ICAM NCs (7,703 anti-ICAM 
molecules/µm2) was added to the apical chamber for 30 min at 37°C to allow NC binding, followed 
by washing both chambers to removed non-bound NCs, and incubated for an additional 1.5 h in 
fresh medium to allow uptake and trafficking to lysosomes. Then, 125I-labeled anti-ICAM NCs were 
added to the apical chamber for 30 min, non-bound NCs were removed by washing, and cells were 
incubated for an additional 4.5 h in fresh medium. The data presented in (A) and (B) show NC 
degradation measured as the percentage of free 125I, the number of NCs, and NC distribution as a 
percentage of total (cell-associated + transcytosed) NCs relative to their respective controls: (A) 
lack of H-7 and (B) no initial dose of non-radiolabeled NCs (indicated by the horizontal dashed 
lines). Data are the mean ± SEM. No statistical significance was found.  
 
 With respect to scenario C (Figure 25), this postulated that transcytosis occurs prior 
to lysosomal transport, e.g., where NCs unable to effectively detach from their bound 
receptors may be removed by cells and trafficked to lysosomes. This hypothesis is 





4.3.10. Role of Valency on Lysosomal Trafficking and the Mechanism of Anti-
ICAM NC Detachment after Transcytosis 
 Recalling the data presented in Table 4, the high and low valencies (7,703 and 
2,058 anti-ICAM molecules/µm2, respectively) had more efficient trafficking to lysosomes 
than the intermediate valency NCs (4,145 anti-ICAM molecules/µm2) (summarized in 
Figure 24B). However, there was an inverse linear relationship between targeting valency 
and transcytosis when evaluated as an isolated process, where high valency NCs were least 
efficient and low valencies were more efficient (Table 4 and Figure 22B). This could be 
due to either concomitant, yet independent NC trafficking to lysosomes and transcytosis, 
wherein targeting valency would independently impact either transport (scenario A; Figure 
25), or lysosomal trafficking being subsequent to transcytosis (scenario C; Figure 25). This 
would be possible if NCs remained bound to receptors long enough after transcytosis, e.g., 
if their high binding valency hinders their detachment from the cell after this process. In 
looking at the intracellular degradation of anti-ICAM NCs via radiotracing (Figure 31), 
there was very little intracellular degradation (< 20% degradation) and it was similar among 
the three valencies tested, which further supports transcytosis being largely independent of 
lysosomal trafficking. However, the high valency NCs had slightly greater degradation 
than the other two valencies (Figure 31), especially after 5 h when a large fraction of NCs 
are transcytosed across cells (Figure 21A). Hence, it appears there is a tendency for high 
valency NCs to be retained in the cell, which is consistent with enhanced anti-ICAM NC 






Figure 31. Intracellular degradation of anti-ICAM NCs in brain endothelial cells. 125I-labeled 
anti-ICAM NCs with different valencies were added to the apical chamber of transwell inserts for 
30 min at 37°C to permit binding to TNFα-activated HBMECs. Non-bound NCs were removed by 
washing both chambers, and cells were incubated in fresh medium for additional time up to 24 h 
total. At select time points, the cells were washed, and the percentage of free 125I (representative of 
intracellular NC degradation) was measured in cells by TCA precipitation (see Section 4.2.8). Data 
are the mean ± SEM. *Comparison to 7,703 anti-ICAM molecules/µm2; #comparison to 4,145 anti-
ICAM molecules/µm2 (p < 0.05 by Student’s t-test). 
 
In light of these findings, we began to speculate that multivalent interactions may 
also impact detachment of anti-ICAM NCs from the basolateral cell-surface after 
transcytosis, where NCs that cannot efficiently detach from their bound receptors are 
measured as cell-associated (not transcytosed) NCs, and those that effectively detach are 
measured as transcytosed (NCs recovered in the basolateral chamber). As such, the valency 
of anti-ICAM NCs could influence the efficacy of this detachment. Specifically, higher 
valency implies enhanced avidity to the receptor (Table 3) and, consequently, could hinder 
basolateral detachment following NC transcytosis. If this is the case, high valency NCs that 
are unable to detach from the basolateral cell-surface may be trafficked back to lysosomes 
(scenario C in Figure 25). Based on data presented in Chapter 5 and [291], efficient 
detachment of NCs from the basolateral cell-surface may require cleavage of the ICAM-1 




cleavage of ICAM-1 as measured by the release of sICAM-1 (Chapter 5 and [291]). 
Therefore, we tested the influence of these molecules on anti-ICAM transcytosis by either 
inhibition of these MMPs or by addition of recombinant MMPs. First, inhibition of either 
MMP-9 or MMP-2 (MMP-9i or MMP-2i, respectively) did not affect the interaction of 
anti-ICAM NCs with cells (99% and 95% of control, respectively; Figure 32A). However, 
inhibition of MMP-9 was found to markedly decrease anti-ICAM NC transcytosis in terms 
of absolute NCs transcytosed and the percentage of total cell-associated NCs transcytosed 
(80% and 47% of control, respectively; Figure 32B). In agreement with the role of MMP-
9 in ICAM-1 cleavage, addition of recombinant, active MMP-9 also enhanced absolute NC 
transcytosis (138% of control; Figure 32C). In contrast, inhibition of MMP-2 or addition 
of recombinant, active MMP-2 did not significantly impact NC transcytosis (Figures 32B-
C). Hence, based on the data obtained pertaining to modulating MMP-9 activity, valency 
may inversely influence anti-ICAM NC transcytosis based on the number of ligand-
receptor complexes required to be cleaved for NC detachment from the basolateral cell-
surface. Given that valency directly influences binding and uptake needed prior to 
transcytosis, this explains why the intermediate valency may be optimal for therapeutic 
delivery: the intermediate valency provides enough avidity for efficient binding and 
uptake, while not hindering basolateral detachment after NC transcytosis. Therefore, 
although scenario A may occur, scenario C (Figure 25) is the most plausible explanation 
or the highest contributor for the observed differences in lysosomal trafficking and 





Figure 32. Anti-ICAM NC detachment from the basolateral cell-surface after transcytosis. 
(A) TNFα-activated HBMECs grown on coverslips were incubated with green fluorescent anti-
ICAM NCs (7,703 anti-ICAM molecules/µm2) for 30 min at 37°C, followed by washing to remove 
non-bound NCs, and incubation for an additional 30 min (1 h total). Incubations were done in 
control medium or medium supplemented with MMP-9 inhibitor (MMP-9i) or MMP-2 inhibitor 
(MMP-2i). The total number of cell-associated NCs was quantified by fluorescence microscopy as 
described in prior sections. (B, C) TNFα-activated HBMECs grown on transwell inserts were 
incubated for 30 min at 37°C with 125I-labeled anti-ICAM NCs (7,703 anti-ICAM molecules/µm2) 
to permit binding to cells, followed by washing both chambers to remove non-bound NCs, and 
incubation in fresh medium for an additional 4.5 h (5 h total). Incubations were done in control 
medium, or medium containing (B) MMP inhibitors or (C) recombinant (rh) MMPs. Data show 
quantification of the absolute number of NCs transcytosed to the basolateral chamber or NC 
transcytosis as a percentage of the total (cell-associated + transcytosed) NCs relative to the control 
condition, as indicated by the horizontal dashed lines. Data are the mean ± SEM. *Comparison to 




4.3.11. Effect of Valency on Therapeutic ASM Delivery in Cells and Mice  
To further evaluate the efficiency of intermediate valency NCs, we examined 
delivery of therapeutic ASM coated on anti-ICAM NCs (anti-ICAM/ASM NCs) with high 
or intermediate valency across activated brain endothelial cells in a transwell model 
(Figure 33). In comparison to the high valency (7,703 anti-ICAM molecules/µm2), 
transcytosis of anti-ICAM/ASM NCs with intermediate valency (4,145 anti-ICAM 
molecules/µm2) was markedly enhanced in terms of the absolute number of NCs 
transcytosed per cell (1.5-fold increase, Figure 33A), as well as the percentage of NC 
transcytosis with respect to the total (cell-associated + transcytosed) number of NCs (1.8-
fold increase; Figure 33B). Importantly, since an intermediate valency permits a greater 
number of ASM molecules to be coupled to the NC surface (203 ± 5 versus 28 ± 2 ASM 
molecules/NC for the intermediate versus high valency, respectively), there was further 
enhancement in the number of ASM molecules transported across the brain endothelial 










Figure 33. Role of valency on ASM delivery across brain endothelial cells by anti-ICAM NCs. 
125I-labeled anti-ICAM/ASM NCs with high or intermediate targeting valency (7,703 versus 4,145 
anti-ICAM molecules/µm2, respectively) were incubated with TNFα-activated HBMECs for 30 
min to permit apical binding, followed by washing both chambers to remove non-bound NCs, and 
incubation in fresh medium for additional time up to 24 h total. The number of NCs associated with 
the cell fraction and those transcytosed to the basolateral chamber were measured using a gamma 
counter. (A) Quantification of the absolute number of NCs associated with the cell fraction (bound 
+ internalized NCs) and basolateral fraction (transcytosed NCs). (B) NC distribution in each 
fraction as a percentage of the total number of NCs (cell-associated + transcytosed). (C) 
Distribution of ASM molecules in the cell and basolateral fractions. Data are the mean ± SEM. 
*Comparison to the high valency (7,703 anti-ICAM molecules/µm2) for each fraction (p < 0.05 by 




Next, we evaluated ASM delivery in mice to ultimately prove the efficiency of 
intermediate anti-ICAM valency NCs in a complex physiological model. In agreement with 
the aforementioned cell culture findings, we observed a similar outcome following 
intravenous injection of anti-ICAM/ASM NCs with high or intermediate valency. For both 
valencies, anti-ICAM/ASM NCs were rapidly removed from the circulation: < 5% of the 
injected dose (% ID) remained in blood 15 min following administration (data not shown), 
which is important to avoid degradation and recognition by the immune system. However, 
the intermediate valency resulted in enhanced NC delivery to the brain compared to that 
found for the high valency in terms of both the % ID and the percent injected dose per gram 
of brain tissue (% ID/g) (Figure 34A). Specifically, anti-ICAM/ASM NCs with an 
intermediate valency showed 1.5-fold greater % ID and 1.6-fold greater %ID/g for the brain 
as compared to the high valency (Figures 34A-B). In accord with enhanced brain 
accumulation, NCs with intermediate valency had diminished non-specific clearance via 
the spleen (39% reduction in % ID and 33% reduction in % ID/g; Figure 34B); although, 
this same trend was not observed in the liver, which is another major clearance organ [58] 
(Figure 34B). This is possible given the liver is significantly larger in size than the spleen 
and, hence, a reduction in clearance will be less pronounced in this organ. Nevertheless, as 
in the case of the cell culture results shown above, the intermediate valency permitted a 
significant increase in the number of ASM molecules delivered to the brain (Figure 34C). 
In fact, there was an 11-fold increase in ASM molecules measured in the brain with the 
intermediate valency, which is the same enhancement found in the cell culture model. 
Therefore, therapeutic ASM delivery via anti-ICAM NCs with an intermediate valency 




likely to improve enzyme replacement for other LSDs, as well as treatment of similar 
disorders that are currently hampered by insufficient transport across the BBB, which is of 





Figure 34. Role of valency on ASM delivery into the brains of mice by anti-ICAM NCs.  Wild-
type mice were intravenously injected with 125I-labeled anti-ICAM/ASM NCs with high or 
intermediate targeting valency (7,703 versus 4,145 anti-ICAM molecules/µm2, respectively). 
Organs were collected 30 min post-injection, weighed, and the 125I content in each was measured 
using a gamma counter. (A) The percent injected dose (% ID) and percent injected dose per gram 
of tissue (% ID/g) in the brain. (B) The % ID and % ID/g for intermediate valency NCs in the brain, 
liver, and spleen as a percentage of that found for the high valency NCs. (C) Absolute number of 
ASM molecules distributed to the brain for both valencies. Data are the mean ± SEM. *Comparison 






 Valency is a very important parameter in the design of targeted drug carriers. While 
the effect of valency has mainly been studied in regard to binding and uptake, subsequent 
processes (i.e., uptake, lysosomal trafficking, and transcytosis) also warrant full 
consideration for optimal therapeutic efficacy. In this work, we examined the effect of 
valency on each of these events in order to optimize therapeutic delivery via anti-ICAM 
NCs for treatment of type A NPD and other disorders. To this end, we used anti-ICAM 
NCs with high, intermediate, or low targeting valency: 7,703 versus 4,145 versus 2,058 
anti-ICAM molecules/µm2, respectively. Based on the characterization data presented in 
Table 3, all three valencies were similar in size, PDI, ζ-potential, and the total number of 
antibodies (anti-ICAM + non-specific IgG) per NC surface area. Therefore, the findings 
presented herein are the result of valency alone and not due to the physiochemical 
properties of each carrier. 
The rate of anti-ICAM NC binding to activated brain endothelial cells increased 
linearly with higher valency (Table 4 and Figure 16), which was expected due to their 
enhanced avidity (Table 3 and Figure 15). While higher valency seems optimal for 
targeting, it increases the likelihood of binding to off-site areas that may also express the 
targeted receptor, even if at low levels [47, 180]. While this possibility does not pose a 
significant problem for treatment of LSDs (since they are characterized by whole body 
dysfunction), this could be detrimental for treatment of more localized diseases or 
diagnostic applications [180]. High valency may also diminish targeting due to steric 
hindrances [47, 79, 177, 180]. This is especially relevant in the case of ICAM-1 since 




[68, 73, 79, 177]. Given sufficient time though, all three valencies reached similar binding 
levels at saturation (Figure 16), indicating that expression of ICAM-1 is a limiting factor. 
In contrast to binding, NC uptake was a much faster process, rendering smaller 
differences in the rate of uptake among the three valencies tested (Table 4 and Figure 19). 
Yet, there was also a linear correlation between increasing valency and faster uptake, which 
is in agreement with the linear relationship found between valency and enrichment of cell-
signaling molecules associated with the CAM pathway, namely ceramide, PKC, and 
pPKCα (Figures 17 and 18). Therefore, at least for anti-ICAM NCs within this range of 
valencies, the cell-signaling induced upon binding to ICAM-1 was sufficient to induce 
rapid and efficient uptake of all cell-bound NCs. As well, additional analysis conducted in 
the Muro Laboratory verified there was no correlation when comparing ceramide 
enrichment to the total cell-surface area that all bound carriers occupied on a cell, the cell-
surface area occupied by each single carrier, the estimated total ICAM-1 engaged by all 
carriers bound on a cell, or the estimated ICAM-1 engagement by each single carrier [79]. 
Therefore, it is the valency density (or absolute valency in the case of carriers of similar 
size) that regulates cell-signaling conducive to anti-ICAM NC uptake.  
As mentioned in the introduction, the more pressing focus of this work was to 
examine the effect of valency on lysosomal trafficking and transcytosis, as well as whether 
these processes are linked. For instance, focusing on transcytosis, it appeared a priori that 
there was no linear relationship with valency. However, this was not the case after more 
detailed examination: transcytosis alone showed a linear, yet inverse relationship with 
valency, with lower valency NCs being more efficient at transcytosis (Figure 22B). 




depend directly on valency (Figure 22A), the combined effect produced a bell-shaped 
curve with intermediate valency NCs having maximal efficiency at the intersection of the 
binding/uptake and transcytosis plots (Figure 22C). In contrast, the opposite trend was 
observed in the case of lysosomal trafficking, resulting in an inverted bell-shaped curve 
(Figure 24B). Specifically, there was a trend toward enhanced lysosomal trafficking for 
the high valency NCs tested (Table 4), which paired well with slightly higher intracellular 
degradation for this valency (Figure 31).  
To explain these findings, we speculated high valency NCs (i.e., those with a 
greater number of ligand-receptor interactions) have impaired detachment from the 
basolateral endothelium after transcytosis, with transport back to lysosomes (scenario C in 
Figure 25). In support of this premise, high affinity antibodies targeting the Tf receptor 
(anti-TfR) were shown in the literature to have diminished transcytosis across the BBB, 
and in subsequent work was found to be due to enhanced lysosomal trafficking of high 
affinity anti-TfR as compared to low affinity counterparts [274, 296]. Similarly, gold NCs 
bearing human Tf ligands at a high valency showed reduced brain accumulation in mice 
compared to low valency particles due to their enhanced retention on or within the 
endothelium, which the authors speculated was due to inefficient detachment from the 
basolateral surface [179]. To investigate this aspect, we examined proteolytic cleavage via 
MMP-9 or MMP-2 as a potential mechanism for anti-ICAM NC detachment after 
transcytosis. Our findings presented in Figure 32 suggest that MMP-9, which is secreted 
by endothelial cells upon ICAM-1 engagement [297], may contribute to this later stage of 
transcytosis by cleaving ICAM-1 from the basolateral endothelial surface [288, 291], 




In addition to scenario C, it is likely that scenario A (Figure 25) also occurs as 
discussed in Section 4.3.8, where NCs independently traffic to both lysosomes and are 
transcytosed. Therefore, lysosomal transport may occur via two routes, one from the apical 
surface following NC uptake (scenario A) versus from the basolateral surface after 
“frustrated” NC transcytosis (scenario C). The basolateral route depends on NC 
detachment after transcytosis, resulting in enhanced lysosomal transport of high valency 
NCs. In contrast, lysosomal transport from the apical surface is likely more efficient for 
lower valency, perhaps because these carriers take longer to be internalized or trafficked 
through the cell. However, since the bell-shaped curves for lysosomal transport and 
transcytosis are inverted seems to indicate that scenario C is the dominating process. In 
agreement, anti-ICAM NCs with intermediate valency were found to be optimal since they 
have sufficient targeting valency to provide both effective binding and uptake (limiting 
steps for low valency NCs), while it is not high enough to impair anti-ICAM NC 
detachment from the basolateral cell-surface after NC transcytosis (the limiting step for 
high valency NCs). Consequently, therapeutic ASM coated on anti-ICAM NCs with 
intermediate valency had significantly enhanced transcytosis across a cell culture model of 
the BBB as compared to high valency NCs (Figure 33).  
In accord with the cell culture results, anti-ICAM/ASM NCs with intermediate 
valency showed enhanced brain accumulation in mice following intravenous injection 
(Figure 34), which is in agreement with  recent work demonstrating lower anti-ICAM NC 
valency improved brain delivery of α-galactosidase deficient in Fabry disease [59]. 
Although the percent injected dose found in the brain was very low (< 1%), ASM delivery 




fold enhancement [60]) or when coupled to other targeted NCs, such as in the case of anti-
TfR NCs (2.5-fold enhancement [65]). Importantly, the intermediate valency also permits 
greater enzyme loading on each NC. In conjunction with enhanced NC delivery, this 
resulted in a significant increase in the number of ASM molecules transported across the 
BBB (11-fold increase in cell culture and mice), which is of great translational relevance 
for the treatment of type A NPD and other disorders.  
While not demonstrated in this work, 1 µm anti-ICAM NCs with 4,100 anti-ICAM 
molecules/µm2 (similar to the intermediate valency tested herein) were also found to 
efficiently target and remain bound to endothelial cells within the range of shear stresses 
experienced in small arteries, capillaries, and venules [259]. Further, previous work has 
demonstrated that perfusion prior to organ harvesting does not significantly impact anti-
ICAM NC accumulation in organs (~90% retention in the brain after perfusion) [61]. 
Therefore, the enhanced brain delivery observed in our study is not likely due to poorly 
bound NCs or retention of NCs in the circulation. Although capillary depletion could be 
used to verify transendothelial transport and localization of NCs within the brain 
parenchyma, anti-ICAM/enzyme NCs have been observed to cross the BBB with 
internalization by subjacent cells both by transmission electron microscopy and 
immunohistochemistry in a mouse model of NPD (unpublished data; Muro Laboratory).  
Overall, this is the first time the influence of targeting valency on lysosomal 
trafficking and transcytosis has been examined mechanistically in a systematic manner. 
Hence, this work is of great importance to the rationale design of therapeutic carriers 
because it increases knowledge in the field of drug delivery about how targeted carriers 




postulated that shedding of ICAM-1, other endothelial CAMs, and their leukocyte co-
receptors may help disengage both cell types after extravasation [292]. Since MMP 
secretion and cleavage of the extracellular domain of other endothelial receptors is 
common to diverse pathological states [285, 298, 299], it is likely that proteolytic cleavage 
may not only impact transcytosis via the CAM pathway, but may also regulate cell 
detachment of other ligand-receptor complexes, thereby broadly impacting drug delivery 
across endothelial linings. It is also possible that alternative mechanisms may contribute to 
the later stages of transcytosis mediated via clathrin pits or caveoli, warranting further 
investigation.  
Lastly, although an intermediate valency was found to be most effective in this 
work, the optimal valency is expected to be different for each particular drug carrier design, 
taking into consideration their size, shape, the receptor targeted, the affinity moiety, type 
and length of linkers coupling these moieties to the carrier surface, etc. [177, 300-307]. 
Therefore, the best valency must be empirically determined for an intended application. 
 
4.5. Conclusions 
In the context of using anti-ICAM NCs for treatment of type A NPD and other 
LSDs, sufficient binding and uptake needs to be balanced with maximum NC detachment 
after transendothelial transport and the level of trafficking to lysosomes. In Figure 35, the 
role of valency on each of these processes is summarized. Ultimately, we found anti-ICAM 
NCs with an intermediate valency to be the best option among the valencies tested. By 
lowering valency, enzyme loading could be increased, which enhanced therapeutic 




make these NCs especially favorable for treating neurological LSDs, representing for the 
first time an effective means to tackle these disorders. Consequently, this strategy also 
offers an opportunity for less frequent doses, which is beneficial for minimizing 
immunogenicity and reducing treatment costs. To the best of our knowledge, this is also 
the first time the mechanism subsequent to transcytosis of any receptor-targeted drug 
carrier has been examined, which is highly significant and relevant to the drug delivery 
community. Ultimately, knowing the molecular regulation that enables receptor-bound 
carriers to effectively detach from the basolateral side of the endothelium after transcytosis 
will enable manipulation of the responsible cell-signaling molecules to enhance this 
outcome. Overall then, this work sheds critical insight into fundamental pathways and 
parameters ruling biological processes, as well as their potential translational applications 







Figure 35. Model for the role of valency on NC transcytosis. The cartoon depicts the efficiency 
of anti-ICAM NC transport at each step: binding, uptake, lysosomal trafficking, and detachment 
from the basolateral surface after transcytosis. The thickness of each black arrow represents the 
efficiency of the step indicated, where increasing arrow thickness corresponds to greater efficiency. 
Black dashed arrows are the hypothesized efficiency of NC trafficking from the apical surface to 
lysosomes based on the comparison between lysosomal colocalization and binding/uptake data, 
although this was not assessed in the transwell model. Similarly, the orange dotted lines indicate 
that NCs are trafficked across the cell body, yet the effect of valency on the efficiency of this 
process was not assessed and, hence, the thickness of the arrows does not implicate the level of 
efficiency in this case. Although high valency NCs are efficient in binding and uptake, their high 
avidity impairs basolateral detachment, resulting in enhanced lysosomal trafficking. In contrast, the 
reduced avidity of low valency NCs hinders binding and uptake, while they are efficiently detached 
from the basolateral surface after transcytosis. Alternatively, an intermediate valency is optimal 





Chapter 5:  Effect of ICAM-1-Targeted Carriers on Endothelial 
Release of an Inflammatory Mediator4 
 
5.1. Introduction 
Being at the interface between the circulation and subjacent tissues, vascular 
endothelial cells contribute to important physiological functions, including transport of 
metabolites and signaling molecules that communicate between these two compartments, 
regulation of vascular tone, hemostatic function, inflammatory response, and so on [308]. 
Hence, in many diseases, including LSDs, endothelial cells represent both an important 
target for therapeutic intervention, as well as a barrier to treatment of subjacent tissues, as 
previously discussed [10, 308]. An illustration of this relevance is the fact that numerous 
drug delivery strategies are being explored to target pharmaceuticals to the endothelium, 
either for endothelial-surface release into the circulation, uptake into endothelial cells to 
treat endothelial maladies, or transport across this lining [52, 309].   
By contributing to the adhesion of leukocytes to the endothelium, their 
extravasation into sites of disease and other associated signaling cascades, ICAM-1 plays 
an important role in the inflammatory processes that underlie most maladies [66, 67, 73-
75]. Interestingly, engagement of ICAM-1 by NCs coated with anti-ICAM antibodies or 
peptides, such as the case of liposomes, nanoparticles, dendrimers, micelles, protein 
conjugates, etc., induces a series of signal cascades and actin reorganization in endothelial 
cells, leading to vesicular transport both into and across these cells via the CAM pathway 
[68, 70, 71, 78]. As discussed in prior chapters, the CAM pathway is effective across a 
                                                 
4Chapter 5 text, table, and figures reproduced with permission from: Manthe, R.L. and Muro, S. ICAM-1-targeted 
nanocarriers attenuate endothelial release of soluble ICAM-1, an inflammatory regulator. Bioeng Transl Med, 




broad spectrum of carrier sizes (from the nano- to the micro-scale), in contrast to clathrin- 
or caveolae-mediated pathways that associate with much smaller vesicles [62, 78]. This 
correlates well with the fact that ICAM-1 contributes to mobilization of leukocytes [310]. 
Similarly, the signal cascades that associate with endothelial uptake of anti-ICAM NCs 
involve PKC, Src kinases, Rho, Ca2+, sphingomyelinase-mediated generation of ceramide, 
etc., which are reminiscent of those elicited upon leukocyte binding to endothelial cells 
during inflammation [68, 73, 78]. As well, the actin reorganization observed in both events 
are analogous and consist with mobilization of cortical into actin stress fibers [68, 73, 78]. 
Ultimately, endothelial targeting and vesicular-mediated transport via ICAM-1 has shown 
promise for diagnostic imaging and drug delivery applications in the context of cancer, 
LSDs, pulmonary, cardiovascular, and other diseases [61, 230-235]. 
However, due to the role of ICAM-1-mediated leukocyte adhesion and signaling in 
inflammation [66, 74, 75], the secondary effects of engaging this receptor and/or blocking 
it from its natural counterparts are not known. In fact, this aspect has not been carefully 
examined yet for most of the targeted drug delivery systems described in the literature. 
Given that cell-surface receptors and markers are typically involved in complex functions 
and/or signaling processes important to maintaining homeostasis, it is logical to assume 
that engagement by targeted drug carriers could lead to either beneficial or detrimental side 
effects, depending on their specific patho-physiological role. In the case of ICAM-1, it has 
been postulated that engagement by antibodies or drug carriers could lower the availability 
of this marker for engagement by its natural “ligands” (β2 integrins, LFA-1 and Mac-1, 
present on the leukocyte surface) [74], therefore attenuating inflammation, which may 




leukocytes initiates pro-inflammatory cascades, including release of cytokines, generation 
of reactive oxygen species, expression of other CAMs, alteration of endothelial 
permeability, and so on [66, 75]; hence, ICAM-1 engagement by NCs could result in 
similar side effects.  
In this context, an interesting biological process associated with ICAM-1 
overexpression during inflammation and its engagement by leukocytes is that of 
endothelial release of the ectodomain of ICAM-1, which can then circulate as the “soluble” 
form of this molecule (sICAM-1) [75, 76]. Release of sICAM-1 is believed to occur via 
cleavage of the ICAM-1 ectodomain by proteases, such as MMP-9, as examined in 
Chapter 4 for detachment of anti-ICAM NCs after transendothelial transport [288]. 
Additional proteases (e.g., TNFα-converting enzyme (TACE/ADAM-17) and neutrophil 
elastase) may also be directly involved in ICAM-1 cleavage [312-314], or others may 
indirectly play a role in this process, such as in the case of MMP-2, which again is involved 
in cleavage of latent MMP-9 into its active form [293, 294].  
The literature describes sICAM-1 as an inflammatory marker and regulator, which 
can promote the inflammatory response [75, 76]. Serum sICAM-1 appears to be low in 
healthy individuals, but its levels increase in many pathologies, associating with the disease 
progression and severity, as in the case of cancer, cardiovascular disease, immune 
syndromes and, generally, maladies involving chronic inflammation, including LSDs [75, 
76, 315]. This association is not merely circumstantial, but sICAM-1 appears functionally 
involved in these diseases [76]. For instance, sICAM-1 aids in tumor progression by 




a pro-inflammatory phenotype by inducing the production of factors such as MIP-1α, IL-
6, or TNFα [76, 316-319].  
Therefore, in this chapter we began studying aspects relative to the potential 
secondary effects of endothelial ICAM-1 targeting, focusing on the influence of anti-ICAM 
NCs on endothelial release of sICAM-1. The results we obtained will help rationally inform 
the future design of drug carriers and selection of potential applications using this strategy. 
 
5.2. Materials and Methods 
5.2.1. Antibodies and Reagents  
Monoclonal mouse anti-human ICAM-1 (clone R6.5) [243] was from American 
Type Culture Collection (Manassas, VA) and phycoerythrin-labeled monoclonal mouse 
anti-human ICAM-1 (clone LB-2) was from Santa Cruz Biotechnology (Dallas, TX). Alexa 
Fluor 350-labeled secondary antibodies were from Invitrogen (Carlsbad, CA). Non-
specific mouse IgG was from Jackson ImmunoResearch (West Grove, PA). Green 
Fluoresbrite® 100 nm diameter polystyrene beads were from Polysciences (Warrington, 
PA). Porous transwell inserts (1.0 µm-pore) were from Thermo Fisher Scientific (Waltham, 
MA). Human sICAM-1 ELISA kits were from Invitrogen (Carlsbad, CA). 125I and Iodogen 
pre-coated tubes were from PerkinElmer (Waltham, MA) and Thermo Fisher Scientific 
(Waltham, MA), respectively. MMP-9 Inhibitor I and MMP-2 Inhibitor I were from EMD 
Millipore (Billerica, MA). Unless specified, all other reagents were from Sigma-Aldrich 




5.2.2. Preparation and Characterization of Anti-ICAM NCs  
Model polymer NCs were prepared by coating via surface absorption unlabeled or 
125I-labeled anti-ICAM or non-specific IgG onto 100 nm, green fluorescent polystyrene 
beads (anti-ICAM NCs versus IgG NCs), as described in Section 3.2.6. The diameter of 
coated NCs was measured using particle tracking (Nanosight LM10, Malvern Instruments; 
Westborough, MA), while the PDI and ζ-potential were obtained by dynamic light 
scattering and electrophoretic mobility, respectively (Zetasizer Nano-S90; Malvern 
Instruments; Westborough, MA). The resulting antibody coat was assessed as described in 
Section 4.2.3.  
 
5.2.3. Cell Cultures  
HUVECs (Lonza Walkersville, Inc.; Walkersville, MD) were cultured in M-199 
(Invitrogen; Carlsbad, CA) supplemented with 15% FBS, 2 mM L-glutamine, 15 µg/mL 
ECGS, 100 µg/mL heparin, 100 U/mL penicillin, and 100 µg/mL streptomycin. Cells were 
grown at 37°C, 5% CO2, and 95% relative humidity on either 1% gelatin-coated coverslips 
or uncoated 1.0 µm-pore transwell inserts. Where indicated, cells were stimulated 
overnight with 10 ng/mL TNFα to induce endothelial activation, as found in LSDs [9, 239]. 
 
5.2.4. Binding and Uptake of Anti-ICAM NCs by Activated Endothelial Cells 
TNFα-activated HUVECs grown on coverslips were incubated for 30 min at 37°C 
with green fluorescent anti-ICAM NCs or non-specific IgG NCs, followed by washing off 
non-bound carriers. The cells were fixed with 2% paraformaldehyde, stained with a Texas-




and cell nuclei were stained blue with DAPI. Samples were visualized by fluorescence 
microscopy as described in prior sections. As in previous studies, the total number of NCs 
associated per cell (total green NC signal) and the number of NCs internalized within cells 
(total green signal minus green signal that colocalized with “surface” red signal) were 
quantified. This was achieved using an algorithm that normalizes the area of specific 
fluorescence (over a threshold background) to the number of pixels that correspond to the 
size of a single NC [247]. 
To assess NC interaction with TNFα-activated HUVECs in transwell models, 125I-
labeled anti-ICAM or IgG NCs were added to the apical chamber and incubated for 30 min 
at 37°C (pulse). Non-bound carriers were then removed by washing both chambers to 
eliminate any NCs that may have leaked across the cell monolayer. Cells were then 
incubated for additional time in carrier-free medium up to a total time of 5 h to allow 
transcytosis of bound NCs (chase). After both time points, 125I-labeled anti-ICAM or IgG 
NCs associated with the endothelial layer were quantified using a gamma counter as 
described previously. Free 125I was determined using TCA precipitation and subtracted 
from these measurements, to eliminate any contribution of free tracer [247].  
 
5.2.5. Release of sICAM-1 by Endothelial Cells 
Quiescent versus TNFα-activated HUVECs, grown on coverslips or transwells, 
were incubated at 37°C in the absence versus presence of anti-ICAM or non-specific IgG 
NCs. For transwell experiments, NCs were added to the apical chamber for 30 min (pulse), 
followed by washing to remove non-bound NCs, and incubation for additional time in 




was collected and centrifuged at 3,000g for 5 min, followed by 1 min centrifugation at 
17,000g to remove residual NCs, cells, and debris. The supernatants were used to quantify 
sICAM-1 by ELISA according to the manufacturer’s instructions, followed by colorimetric 
detection using a SpectraMax M2e microplate reader (Molecular Devices; Sunnyvale, CA) 
at 450 nm. Similar experiments were performed in the presence of 3 mM amiloride, which 
inhibits CAM-mediated transport [68, 78], and 25 µM MMP-9 or MMP-2 inhibitors 
(MMP-9i; MMP2i), individually or in combination (Mixed MMPi).  
 
5.2.6. Validation of sICAM-1 Differential Shedding versus Diffusion in Transwell 
Models 
To verify lack of diffusion (indicative of differential release) of sICAM-1 across 
the endothelial cell monolayer, exogenous sICAM-1 was added to either the apical or 
basolateral chambers (2 ng/mL added) and incubated at 37°C for 4.5 h. The amount of 
sICAM-1 in each chamber was then measured by ELISA, as described above. To calculate 
the amount of sICAM-1 in each chamber as a percentage of sICAM-1 added, sICAM-1 
that was released from activated endothelial cells during this time (obtained from control 
experiments where exogenous sICAM-1 was not added) was subtracted from the readings, 
and then the percentage was calculated.  
 
5.2.7. Uptake of Membrane ICAM-1 versus sICAM-1 by Activated Endothelial 
Cells Incubated with Anti-ICAM NCs 
TNFα-activated HUVECs grown on coverslips were incubated for 30 min at 37°C 




NCs. The cells were fixed with 2% paraformaldehyde, stained with a blue Alexa Fluor 350-
labeled secondary antibody to label NCs bound on the cell-surface (not internalized), and 
then permeabilized with 0.1% Triton X-100 and stained with a phycoerythrin-labeled anti-
ICAM-1 (clone LB-2) antibody (pseudocolored red) to label both cell-surface and 
internalized NCs. Hence, cell-surface NCs appear white (green + blue + red), internalized 
membrane ICAM-1 complexed with NCs appear yellow (green + red), and internalized 
NCs without internalized membrane ICAM-1 appear green alone. Images were captured as 
described previously. Alternatively, after NC removal by washing, cells were lysed and the 
amount of sICAM-1 in these cell lysates was measured via ELISA, as described above.    
 
5.2.8. Statistics 
Experiments encompassed a total sample size of n ≥ 4. Data were calculated as the 
mean ± SEM. Statistical significance was determined as p < 0.1 by Student’s t-test or by 
the Mann-Whitney Rank Sum test, as indicated. 
 
5.3. Results 
5.3.1. Release of sICAM-1 by Endothelial Cells and Differential Apical versus 
Basolateral Distribution 
Endothelial cells increase their release of sICAM-1 when activated during 
inflammation [76, 288, 316]. Hence, we first validated our detection of this phenomenon 
using endothelial cells grown on coverslips, the most common model used in prior sICAM-
1 studies in cell culture. We incubated endothelial cells overnight with the pro-




incubations in fresh medium (release chase). As expected, TNFα enhanced sICAM-1 
release by endothelial cells compared to non-activated counterparts: a 1.5-fold increase in 
a period of 30 min (Figure 36A). Then, we repeated this assay using endothelial cells 
grown as a monolayer on transwell inserts, a model that better reflects the natural status of 
endothelial cells by separating apical and basolateral compartments. Total sICAM-1 
release in this model seemed similar or slightly enhanced to the coverslip model (1.4-fold 
at 30 min; Figure 36A). This setting also allowed us to independently examine sICAM-1 
release from the apical versus basolateral sides of the endothelial cell monolayer. 
Unexpectedly, we observed a preferential release into the basolateral chamber underneath 
the cells (75% of total sICAM-1, 3-fold over the apical fraction; Figure 36A). The release 
of sICAM-1 continued increasing up to 1 h (2.7-fold over 30 min), then it seemed to 
saturate (at 5 h it was 1.1-fold over 1 h; Figure 36B). During all this time, the pattern of 
preferential basolateral release was maintained and, at saturation (5 h), basolateral sICAM-






Figure 36. Release of sICAM-1 by endothelial cells. (A) HUVECs were grown on coverslips or 
transwell inserts in control medium versus medium containing TNFα (overnight; ~16 h). Cells were 
then washed and sICAM-1 release into the cell medium (apical (AP), basolateral (BL), and total 
(AP+BL)) was examined after 30 min, using ELISA. (B) Cumulative distribution of sICAM-1 
release by TNFα-activated HUVECs grown on transwells was similarly measured at 30 min, 1 h, 
or 5 h. Data are the mean ± SEM. *Comparison to non-activated ECs; #comparison between apical 
and basolateral chambers at each time point; &comparison to 30 min (one symbol is p < 0.1 by 
Student’s t-test and two symbols is p < 0.1 by Mann-Whitney Rank Sum test). Figure adapted from 
[291]. 
 
To validate the specificity of this differential pattern, we tested the passive 
permeability of the endothelial cell monolayer and the transwell filter (Figure 37A). In the 
absence of cells, addition of exogenous sICAM-1 to the apical chamber resulted in a similar 
distribution in both compartments (56% apical and 64% basolateral; Figures 37A-B). This 




exogenous sICAM-1 to either the apical or basolateral chambers separated by endothelial 
cells, and sICAM-1 was measured in either chamber after 4.5 h. Opposite to the pattern of 
sICAM-1 release by cells, addition of exogenous sICAM-1 to the apical side resulted in a 
specific increase of the sICAM-1 level in this chamber, i.e., 3.4-fold over the basolateral 
side (Figures 37A-B). This was 6.9-fold greater than the amount released by cells in this 
chamber, while detection in the basolateral chamber did not vary (1.2-fold over that of cells 
alone; Figure 37C). Conversely, exogenous sICAM-1 addition to the basolateral chamber 
resulted in an even greater enhancement in this chamber (24-fold over the apical side; 
Figures 37A-B). This addition rendered a minor increase in the level of sICAM-1 in the 
apical chamber (1.5-fold over cells alone) and a slightly greater increase in the basolateral 
fraction (2.3-fold; Figure 37C). Since cells alone release more sICAM-1 to the basolateral 
side, it was expected that adding exogenous sICAM-1 to this chamber would enhance 
sICAM-1 to a lesser extent than adding it to the apical side (Figure 37C). Yet, when 
comparing the absolute amount of exogenous sICAM-1 recovered from the basolateral 
versus apical chambers (middle bars in Figure 37B), it is clear that this corresponds to 
almost all sICAM-1 added. These results indicate that there is minimal (if any) passive 
leakage of sICAM-1 across endothelial cell monolayers and the levels of sICAM-1 
detected in this model correspond to differential basolateral and apical release by 






Figure 37. Validation of differential sICAM-1 release versus diffusion in the transwell model. 
Exogenous sICAM-1 was added to the apical (AP) or basolateral (BL) chambers of transwell inserts 
where TNFα-activated HUVEC monolayers had been grown, and sICAM-1 was measured in both 
chamber after 4.5 h at 37°C. Data show (A) relative distribution of exogenous sICAM-1 in the 
presence versus absence of cells, (B) exogenous sICAM-1 detected in these chambers (total 
sICAM-1 in each chamber minus sICAM-1 contributed to each chamber from cellular release) and 
(C) the fold difference in sICAM-1 detection over basal detection (no addition of exogenous 
sICAM-1) for each chamber. Data are the mean ± SEM. #Comparison between apical and 
basolateral chambers (p < 0.1 by Student’s t-test). Figure adapted from [291]. 
 
 
5.3.2. MMP Mechanism of sICAM-1 Release by Endothelial Cells 
It has been reported that release of sICAM-1 by endothelial cells may be in part 
contributed by shedding of ICAM-1 expressed at the cell-surface, a phenomenon also 
observed for other endothelial CAMs [76, 316-319]. This is believed to be mediated via 
cleavage of the ICAM-1 ectodomain by proteases, such as the case for MMP-9 [288]. 




distribution of sICAM-1 across activated endothelial cell monolayers, we measured release 
in the presence of MMP-9 and/or MMP-2 inhibitors, whereby MMP-2 was meant to serve 
as a control. We focused on the first 30 min after removal of the TNFα pulse, as this had 
shown active release rather than saturation (Figure 36B). As expected, MMP-9 inhibition 
led to a 37% decrease in total sICAM-1 by activated endothelial cells (Figure 38A). MMP-
2 inhibition also reduced total sICAM-1 (by 22%, not significant), and simultaneous 
inhibition of MMP-9 and MMP-2 behaved as MMP-9 inhibition alone (34% reduction; 
Figure 38A).  
 
 
Figure 38. Effect of MMP inhibition on sICAM-1 release by activated endothelial cells. TNFα-
activated HUVECs grown on transwell inserts were incubated in control medium or medium 
containing inhibitors of MMP-9 (MMP-9i), MMP-2 (MMP-2i), or a mixture of both (Mixed MMPi) 
for 30 min. (A) Total (apical + basolateral) and (B) apical versus basolateral release of sICAM-1, 
as measured by ELISA and expressed as the percentage of control without inhibitors (horizontal 
dashed lines). (C) Inhibition of apical or basolateral release of sICAM-1 relative to the total 
inhibition observed (horizontal dashed line). Data are the mean ± SEM. *Comparison to control for 
each condition and chamber; #comparison between apical and basolateral chambers; !comparison 




Interestingly, compared with respective controls in each chamber, the effect caused 
by MMP-9 was greater in the apical versus basolateral chamber (48% versus 73% of 
respective chamber controls; Figure 38B). Comparing the absolute amount of sICAM-1 
contributed by MMP-9 to either chamber (Figure 38C), we observed that inhibition of this 
proteinase more readily decreased sICAM-1 in the apical versus basolateral chamber (78% 
versus 35% contribution). MMP-2 inhibition also decreased apical sICAM-1 release (56% 
of control), although no effect was observed with regard to basolateral release (96% of 
control; Figure 38B). In fact, when comparing the absolute amount of sICAM-1 
contributed by MMP-2 in these chambers, only apical activity was found (114% versus 8% 
contribution; Figure 38C). Despite observing MMP-9 and MMP-2 effects in the apical 
chamber, simultaneous inhibition of both proteinases did not render enhanced or additive 
effects on this side (37% of control, statistically similar to MMP-9 inhibition alone) and 
little inhibition arose in the basolateral chamber (92% of control; Figure 38B). Altogether, 
these results suggest that both MMPs are functionally involved in sICAM-1 release to the 
apical space, with MMP-9 contributing to a greater extent, while MMP-9 alone contributes 
to basolateral sICAM-1 release and this contribution is lower than that at the apical side. 
This finding correlates well with the role of MMP-9 in basolateral detachment of anti-
ICAM NCs after transendothelial transport, while MMP-2 had no effect (Figure 32). 
 
5.3.3. Effect of Anti-ICAM NCs on sICAM-1 Release by Endothelial Cells 
In addition to pro-inflammatory factors alone, sICAM-1 release has been postulated 
to associate with other events. For instance, binding of leukocytes to endothelial CAMs is 




disengagement of both cell types after leukocyte extravasation [287-290, 292]. In this 
context, leukocyte binding to endothelial CAMs seems to result in both leukocyte and 
endothelial secretion of MMPs, as well as sICAM-1 release [73]. Therefore, it is plausible 
that binding of ICAM-1-targeted NCs to endothelial ICAM-1 may result in a similar effect. 
To examine this, we used model polystyrene NCs coated with anti-ICAM (anti-
ICAM NCs) versus non-specific IgG (IgG NCs). Although not biodegradable, these NCs 
allows us to examine ICAM-1 targeting and sICAM-1 release events without confounding 
results that may arise from simultaneous NC degradation. As described in prior chapters, 
these formulations are relatively stable (i.e., lack of aggregation, antibody detachment, and 
albumin coating) [61] and render binding, endocytosis, intracellular trafficking, and in vivo 
circulation and biodistribution comparable to biodegradable PLGA carriers [58, 81]. The 
characterization data for anti-ICAM and IgG NCs can be seen below in Table 5.  
Table 5. NC characterization.  
Data are the mean ± SEM. Table reproduced from [291]. 
 
As described previously [61, 68], fluorescence microscopy showed that anti-ICAM 
NCs specifically bound to and were internalized by activated endothelial cells grown on 
coverslips: 241-fold and 456-fold over non-specific IgG NCs, respectively, after only 30 
min incubation (Figure 39A). In addition, radioisotope tracing of 125I-labeled anti-ICAM 
NCs showed that this formulation also bound specifically to activated endothelial cells 
grown on transwell inserts, e.g., 30-fold over 125I-labeled IgG NCs after 30 min incubation 




Uncoated NCs 109.3 ± 1.8 0.06 ± 0.01 -35.5 ± 1.2 N/A 
Anti-ICAM NCs 156.8 ± 2.3 0.18 ± 0.01 -27.4 ± 0.3 267 ± 10 




(Figure 39B). A similar specificity was found after 5 h incubation (31-fold over IgG NCs). 
Yet, at this time the absolute amount of NCs associated with cells decreased below that 
observed at 30 min (3.1-fold decrease for anti-ICAM NCs), which is consistent with 
transendothelial transport previously observed in this model (Chapter 4 and [71]). 
 
Figure 39. Specific interaction of anti-ICAM NCs with activated endothelial cells. (A) TNFα-
activated HUVECs were incubated for 30 min at 37°C with green fluorescent anti-ICAM or IgG 
NCs. Non-bound NCs were removed by washing, and surface-bound NCs were immunostained 
using a Texas-Red secondary antibody, which renders non-internalized NCs in yellow (green + red; 
arrows) versus green internalized NCs (arrowheads). Images and quantification of total cell-
associated (surface-bound + internalized) and internalized NCs are shown. Scale bar = 10 µm. (B) 
TNFα-activated HUVECs grown on transwell inserts were incubated for 30 min at 37°C with 125I-
labeled anti-ICAM or IgG NCs. Non-bound NCs were removed by washing both chambers, and 
cells were incubated in fresh medium up to 5 h total. NCs associated with the cell fraction were 
quantified using a gamma counter at both time points. Data are the mean ± SEM. *Comparison 
between anti-ICAM and IgG NCs; #comparison between 30 min and 5 h (p < 0.1 by Student’s t-




Next, we focused on the effect of anti-ICAM NCs on sICAM-1 release by activated 
endothelial cells. As in the absence of NCs (Figure 36B), preferential release of sICAM-1 
to the basolateral versus apical side was also observed in the presence of anti-ICAM NCs 
(Figure 40). However, surprisingly, NCs significantly inhibited this process (Figure 41): 
after 30 min incubation, anti-ICAM NCs reduced total sICAM-1 release by 50% in the 
coverslip model and by 60% in the transwell model, which was specific compared to IgG 
NCs (13% and 24% reduction, respectively; Figure 41A). This effect persisted with time 
and was observed in both the apical and basolateral compartments (Figures 41B-C and 
Figure 42).  
 
 
Figure 40. Release of sICAM-1 by activated endothelial cells incubated with anti-ICAM NCs. 
Cumulative distribution of sICAM-1 release by TNFα-activated HUVECs grown on transwell 
inserts and incubated with anti-ICAM NCs for 30 min (pulse), followed by removal of non-bound 
NCs and incubation in carrier-free medium for additional time up to 1 h or 5 h total. Data are the 
mean ± SEM. #Comparison between apical and basolateral chambers at each time point; 
&comparison to 30 min (one symbol is p < 0.1 by Student’s t-test and two symbols is p < 0.1 by 








Figure 41. Attenuation of sICAM-1 release by anti-ICAM NCs. (A) Total sICAM-1 release by 
TNFα-activated HUVECs grown on coverslips or transwell inserts after incubation with anti-ICAM 
or non-specific IgG NCs for 30 min. Data are presented as a percentage of cells incubated in the 
absence of NCs (control; horizontal dashed line). (B, C) Cumulative distribution of sICAM-1 
release by activated HUVECs grown on transwell inserts and incubated in control medium (Ctrl) 
or medium containing anti-ICAM NCs. Incubations were for 30 min (pulse), followed by NC 
removal and incubation in fresh medium for additional time up to 1 h or 5 h total. Total sICAM-1 
in (A) and (B) represents the apical + basolateral fractions. Data are the mean ± SEM. *Comparison 
to control; !comparison between anti-ICAM and IgG NCs; #comparison between apical and 
basolateral chambers at each time point; &comparison to 30 min (one symbol is p < 0.1 by Student’s 






Figure 42. Reduction of sICAM-1 release by endothelial cells incubated with anti-ICAM NCs. 
Cumulative distribution of sICAM-1 release by TNFα-activated HUVECs grown on transwell 
inserts and incubated with anti-ICAM NCs for 30min (pulse), followed by removal of non-bound 
NCs and incubation in carrier-free medium for additional time up to 1 h or 5 h total. (A-C) Data 
show sICAM-1 release as a percentage of cells incubated in the absence of anti-ICAM NCs 
(control; horizontal dashed lines). Data are the mean ± SEM. *Comparison to control (one symbol 
is p < 0.1 by Student’s t-test and two symbols is p < 0.1 by Mann-Whitney Rank Sum test). Figure 





  Reduction of sICAM-1 release by NCs was greater in the apical compartment 
versus the basolateral side: e.g., at 30 min, respective reductions of 73% versus 55% were 
observed (Figures 42B-C). However, over time the inhibitory effect of anti-ICAM NCs 
was more balanced between the two chambers (66% apical and 55% basolateral reduction 
by 5 h; Figures 42B-C). Importantly, anti-ICAM NCs reduced release of sICAM-1 at a 
greater extent than MMP inhibitors (Figure 43). At 30 min when active sICAM-1 release 
was occurring, anti-ICAM NCs reduced total sICAM-1 by 60% compared to 37%, 22%, 
and 34% reductions rendered by inhibiting MMP-9, MMP-2, or both simultaneously. This 
was also the case for attenuation of sICAM-1 at the apical side (73% reduction by NCs 
versus 52%, 44%, and 63% decrease for inhibitors of MMP-9, MMP-2, and both) and the 
basolateral side (55% reduction by NCs versus 27%, 4%, and 8% decrease for inhibitors 





Figure 43. Comparative reduction of sICAM-1 by anti-ICAM NCs versus MMP inhibitors. 
Reduction in sICAM-1 release by TNFα-activated HUVECs grown on transwell inserts and 
incubated for 30 min with MMP inhibitors (MMP-9i, MMP-2i, or a mixture of both (Mixed 
MMPi)) or with anti-ICAM NCs. Data show sICAM-1 release as a percentage of controls (absence 
of inhibitors and NCs; indicated by the horizontal dashed lines). Data are the mean ± SEM. 
*Comparison to control; #comparison between anti-ICAM NCs and inhibitors (one symbol is p < 
0.1 by Student’s t-test and two symbols is p < 0.1 by Mann-Whitney Rank Sum test). Figure 





5.3.4. Mechanism by which Anti-ICAM NCs Reduce sICAM-1 Release by 
Endothelial Cells  
A possible explanation for the inhibitory effect observed is that sICAM-1 could be 
captured by anti-ICAM NCs. Binding of sICAM-1 to anti-ICAM NCs would outcompete 
NC binding to cells and these sICAM-1-bound NCs would remain in the cell medium. 
Subsequently, they would be removed by centrifugation prior to the ELISA measurement 
used to detect sICAM-1. To test this, we washed endothelial cells after the initial 30 min 
incubation with anti-ICAM NCs to remove the NCs that did not bind to cells (and may 
contain sICAM-1), and continued the incubation in NC-free medium for another 30 min (1 
h data shown in Figures 41B-C and Figure 42). Despite the absence of anti-ICAM NCs 
in the milieu, the same reduction in sICAM-1 was observed in the total, apical, or 
basolateral chambers (compare the first 30 min to the second 30 min (1 h) in Figure 42 or 
respective slopes in Figures 41B-C). For instance, 73% and 55% reductions were seen in 
the apical and basolateral sides in the presence of anti-ICAM NCs in the milieu (first 30 
min), and 75% and 57% reductions were observed if removed from the milieu (second 30 
min (1 h)). Since the number of NCs interacting with cells at 30 min is the same as at 1 h 
(no more binding was possible since NCs had been removed from the milieu), this indicates 
that reduction of sICAM-1 is not caused by anti-ICAM NCs in the milieu, but by NCs 
interacting with cells.  
Supporting this, it has been shown that when anti-ICAM NCs bind to cell-
membrane ICAM-1, this receptor-NC complex is internalized, which reduces the level of 
ICAM-1 displayed at the membrane [80] (Figure 44A also validates this previous finding). 




ICAM-1 available for shedding from the plasmalemma. To test this alternative, we 
examined the effect of anti-ICAM NCs on sICAM-1 release in the presence of amiloride 
(Figures 44B-C), an inhibitor of the CAM pathway [68, 78]. It was expected that inhibiting 
NC uptake would also inhibit uptake of membrane ICAM-1 and, hence, the inhibitory 
effect of NCs on sICAM-1 release would be lost. Figure 44B shows that this is the case: 
at 30 min when active uptake of anti-ICAM NCs occurred (see Figure 39A), amiloride 
enhanced apical sICAM-1 by 2.5-fold compared to cells incubated with anti-ICAM NCs 
in the absence of this inhibitor, while no effect of amiloride was found at 5 h (0.88-fold) 
when both active sICAM-1 release and NC endocytosis had saturated and these processes 
were no longer active. Instead, no increase was observed at the basolateral side at either 
time point (0.73-fold and 0.95-fold, respectively; Figure 44C). In addition, negligible 
amounts of sICAM-1 were found in the cell lysates after 30 min incubation with anti-ICAM 
NCs, implying that reduced sICAM-1 release by NCs is not due to uptake of the cleaved 
receptor (0.003 ± 0.001 ng/well internalized sICAM-1 versus 1.5 ± 0.3 ng/well sICAM-1 
released into the cell medium). Therefore, attenuation of sICAM-1 release in the presence 








Figure 44. Inhibition of anti-ICAM NC uptake attenuates sICAM-1 release. (A) Image of 
TNFα-activated HUVECs grown on coverslips and incubated for 30 min at 37°C with green 
fluorescent anti-ICAM NCs. Non-bound NCs were removed by washing, and then the cells were 
fixed and immunostained (see Section 5.2.7) to render surface-bound NCs triple labeled in green 
+ blue + red (white color; arrowheads). Instead, internalized membrane ICAM-1 complexed with 
NCs double labeled in green + red (yellow color; arrows) and internalized NCs without membrane 
ICAM-1 are labeled in green alone. Scale bar = 10 µm. (B) Apical and (C) basolateral release of 
sICAM-1 by TNFα-activated HUVECs grown on transwell inserts and incubated with anti-ICAM 
NCs in the presence of amiloride, an inhibitor of CAM endocytosis. Incubations were for 30 min 
(pulse), followed by anti-ICAM NC removal and incubation for additional time up to 5 h total. Data 
are expressed relative to the absence of amiloride (control; indicated by the horizontal dashed lines). 






Targeting of imaging agents and drug NCs to endothelial ICAM-1 holds promise 
in the context of diagnostic and therapeutic interventions focused at the vascular 
endothelium [61, 230-235]. Binding of drug NCs to ICAM-1 on the endothelial surface 
induces signaling conducive to NC transport into and across this lining [68, 71, 78]. 
Although numerous cell culture and in vivo studies suggest that no acute toxicity associates 
with this strategy [61, 230-235], potential side effects must be carefully examined for 
further translational development. This work investigated the influence of ICAM-1 
targeting on endothelial release of sICAM-1, a marker of inflammation that associates with 
a variety of maladies [76], revealing an unexpected benefit of anti-ICAM NCs.  
During inflammation, which underlies most pathologies, including type A NPD and 
other LSDs, ICAM-1 becomes overexpressed on the surface of activated endothelial cells 
and, concomitantly, sICAM-1 levels increase in serum [76, 315]. TNFα and other pro-
inflammatory factors (IL-1β, IL-6, IFN-γ, angiotensin II, etc.) induce such an outcome [76, 
316, 320]. The mechanism for sICAM-1 release is not fully characterized, yet the soluble 
form of this molecule can arise from proteolytic cleavage of the ectodomain of cell-surface 
ICAM-1 [288, 316, 320]. We reproduced this by treating endothelial cells with TNFα, 
using both a solid-surface model and a transwell filter model. While the first model is 
commonly described [312-314, 320], sICAM-1 release on polarized linings has been 
predominantly reported for epithelial cells, not endothelial cells [321, 322]. From our 
study, it appears that activated endothelial cells separating apical and basolateral 
compartments released slightly greater levels of sICAM-1 than those not polarized (Figure 




comparisons on both models in the literature, work showing independent experiments 
using solid-surface and transwells seems to support our finding [323]. Also, preferential 
basolateral secretion is supported by previous studies [324]. The fact that, in vivo, sICAM-
1 has been found not only in serum but it has also been implicated in angiogenesis, 
migration of vascular smooth muscle cells, and other events involving the basolateral space 
[75], indicates that its differential distribution reflects a functional purpose. Hence, both 
apical and basolateral release events must be considered.  
In accord with the results found in Chapter 4, MMP-9 was involved in endothelial 
release of sICAM-1 upon inflammatory stimulation (Figure 38), which is also in 
agreement with the literature [288]. It has been shown that ICAM-1 provides cell-surface 
docking for pro-MMP-9, the latent form of MMP-9 [288], and then the active enzyme can 
cleave ICAM-1 at its membrane-proximal domain [288]. Yet, our results also suggest that 
the contribution of MMP-9 to this event was partial and there must be other factors 
involved. Inhibition of MMP-2 seemed to influence sICAM-1 release and this could be an 
additional mechanism. However, simultaneous inhibition of MMP-9 and MMP-2 did not 
render an enhanced effect, ruling out this option, in accord with the fact that ICAM-1 is 
not known to be an MMP-2 substrate. Yet, MMP-2 may indirectly play a role in this process 
since it can cleave pro-MMP-9 into MMP-9 [293, 294]. This would explain why MMP-2 
inhibition resulted in a reduction of sICAM-1 release similar to MMP-9 inhibition, but no 
additive effects were found when inhibiting both (Figure 38). Hence, additional factors 
must contribute to sICAM-1 release in our assays. Other studies have shown mRNA 
transcripts specifically encoding sICAM-1 [325, 326], but our assays involve pulse-chase 




play a major role. Other molecules that may be involved in this process include TNFα-
converting enzyme (TACE/ADAM-17) and neutrophil elastase, as seen previously [288, 
312-314].   
While inhibiting MMPs was expected to decrease sICAM-1 release, the inhibitory 
effect of anti-ICAM NCs on this event (Figures 41 and 42) was unexpected, based on the 
fact that ICAM-1 binding by its natural ligands, leukocytes, elicits (instead of reduces) 
sICAM-1 release. This may help dynamic detachment of leukocyte-endothelial 
engagement in areas where the leukocyte “samples” the endothelial surface prior to 
extravasation [73, 287-290, 292]. It may also play a role in loosening leukocyte-endothelial 
attachment after extravasation and to subsequently downregulate cell-surface ICAM-1 [73, 
287-290, 292]. Because the signaling cascades induced in endothelial cells by NC binding 
to ICAM-1 are reminiscent of those induced by leukocytes [73], an increase in sICAM-1 
release was expected. However, the reduction observed can be understood based on the 
fact that anti-ICAM NCs are rapidly internalized by endothelial cells and, since they bind 
to ICAM-1, their internalization removes ICAM-1 from the plasmalemma, as we have 
previously shown [80]. In fact, we have observed that most cell-surface ICAM-1 is 
internalized during this event (as verified in Figure 44A) and then, once within cells, NCs 
traffic to lysosomes or are transcytosed, whereas a fraction of internalized ICAM-1 
recycles back to the plasmalemma after 1 h [70, 71, 80]. Hence, by reducing the availability 
of membrane ICAM-1 on the cell-surface, anti-ICAM NCs reduced sICAM-1 release. This 
was demonstrated by the fact that inhibiting NC uptake with amiloride counteracted the 
inhibitory effects on sICAM-1 release (Figures 44B-C) and that only negligible amounts 




amiloride decreased endocytosis of anti-ICAM NCs without affecting their binding [68, 
78]; hence, validating this mechanism. In addition, the time and location of this inhibitory 
effect (predominant on the apical side at 30 min; Figure 41) pairs well with a role for anti-
ICAM NC endocytosis in lowering surface ICAM-1 and sICAM-1 release.  
 
5.5. Conclusions 
Given that elevated sICAM-1 is considered a pathological marker implicated in the 
development of numerous pathologies (inflammation, atherosclerosis, cancers, 
neurological disorders, autoimmune diseases, LSDs, etc.) [75, 76, 315], attenuation of its 
release may benefit these conditions. Interestingly, inhibition of sICAM-1 release by anti-
ICAM NCs surpassed that of MMP inhibitors in the apical and basolateral compartments 
(Figure 43), which suggests translational relevance. As said, multiple factors appear to 
contribute to sICAM-1 release from activated endothelial cells and their individual 
inhibition only partially reduces this event. Using a cocktail of inhibitors to improve their 
outcome requires knowing all factors involved in each pathological situation (currently 
unknown), and would pose serious risk as they regulate multiple processes apart from 
ICAM-1 cleavage. Instead, reducing sICAM-1 release may be a bonus of targeting ICAM-
1 for drug delivery applications, whereby NCs may combine the action of their therapeutic 
cargo with this secondary effect. Anti-ICAM NCs reduce sICAM-1 by decreasing cell-
surface ICAM-1 during endocytosis (Figure 45), regardless of the factors involved in 
ICAM-1 cleavage and without inhibiting their activity in other necessary functions. 







Figure 45. Endothelial release of sICAM-1 in the absence and presence of anti-ICAM NCs. 
During inflammation (e.g., TNFα activation), endothelial cells overexpress ICAM-1 and undergo 
enhanced shedding of its “soluble” ectodomain (sICAM-1), which acts as an inflammatory 
regulator. Anti-ICAM NCs significantly reduce sICAM-1 release by mobilizing ICAM-1 from the 
cell-surface into intracellular vesicles during NC transport into the endothelium. Since elevated 
levels of sICAM-1 associate with numerous diseases, this effect may provide a secondary benefit 


















Chapter 6:  Final Remarks and Future Directions5 
 In summary, this dissertation examined (1) the status of vesicular-mediated 
transport in type A NPD, which indicates the CAM pathway is an advantageous route for 
therapeutic enzyme delivery; (2) the influence of targeting valency on regulation of the 
CAM pathway, thereby enabling us to optimize therapeutic enzyme delivery to the brain; 
and (3) the effect of ICAM-1 engagement by anti-ICAM NCs on reducing endothelial 
release of sICAM-1, which indicates a secondary anti-inflammatory effect of this approach.  
With regard to the status of vesicular-mediated transport in type A NPD, we 
observed impaired caveolae-mediated endocytosis and EGF-induced macropinocytosis 
similar to that found previously for clathrin-mediated endocytosis [57]. Further, bulk fluid-
phase uptake was altered, as well as fluid-phase uptake via the clathrin and caveolar 
pathways. In agreement, intracellular trafficking of ligands associated with these pathways 
was also distorted. However, anti-ICAM NC uptake via the CAM pathway was minimally 
impacted in diseased cells. Interestingly, transcytosis of model ligands for the clathrin, 
caveolar, and CAM pathways was relatively unaffected in the disease scenario. Ultimately 
though, the CAM pathway seems the most viable alternative to classical endocytic routes 
for lysosomal enzyme delivery given that it allows specific targeting, enhanced loading of 
an enzyme cargo, and is the least impaired pathway in regard to uptake and transcytosis. 
                                                 
5Chapter 6 contains text reproduced in part with permission from: (1) Rappaport, J., Manthe, R.L., et al., 
Altered clathrin-independent endocytosis in type A Niemann-Pick disease cells and rescue by ICAM-1-
targeted enzyme delivery. Mol Pharm, 2015. 12(5): p. 1366-76; © 2015 American Chemical Society. (2) 
Manthe, R.L.* and Rappaport, J.*, et al., A comparative study on the alterations of endocytic pathways in 
multiple lysosomal storage disorders. Mol Pharm, 2016. 13(2): p. 357-68; © 2015 American Chemical 
Society. (3) Manthe, R.L.* and Serrano, D.*, et al. How carrier size and valency modulate receptor-
mediated signaling: understanding the link between binding and endocytosis of ICAM-1-targeted carriers. 
Biomacromolecules, 2016. 17(10): p. 3127-37; © 2016 American Chemical Society. (4) Manthe, R.L. and 
Muro, S. ICAM-1-targeted nanocarriers attenuate endothelial release of soluble ICAM-1, an inflammatory 




As well, this strategy has been demonstrated to provide delivery to lysosomes, resulting in 
enhanced enzyme accumulation and substrate reduction [57, 60-64, 69, 252, 257].  
While we examined alterations in endocytic behavior in type A NPD, this work and 
others [21, 115, 117-120, 252, 257] indicate endocytic function occurs rather widely in 
LSDs. In particular, endocytic pathways may be affected differently in LSDs that are 
characterized by different genetic defects and primary storage materials [257]. As such, 
advancing treatment of each LSD will require thorough characterization of their endocytic 
activity for more informed selection of appropriate therapeutic approaches. This applies to 
enzyme replacement, including administration of recombinant enzymes and viral vectors 
[16, 21, 57] that rely on receptor-mediated uptake to gain entry into cells, as well as other 
agents that may rely on pinocytic uptake.  
Moreover, this work highlighted the implications of lysosomal storage and 
endocytic/trafficking dysfunction, as lysosomal dysfunction arising from drugs and 
materials employed in drug delivery may render a similar phenotype. For example, non-
degradable drug carrier materials, such as quantum dots, gold, titanium dioxide, and others, 
have been shown to accumulate and impact lysosomal/autophagic compartments [327-
331]. Intracellular delivery of lipids or slow-degrading polymers used in liposomes and 
other carrier formulations could also render side effects consistent with lysosomal storage 
[328, 332]. As an alternative, combining such therapies with strategies to decrease 
lysosomal storage or restore endocytic trafficking by other means may be beneficial. For 
example, induction of lysosomal exocytosis via treatment with the minor vitamin E species, 
δ-tocopherol, has shown to be a promising strategy to alleviate storage of undigested 




a study in our laboratory examining the effect of δ-tocopherol on vesicles internalized via 
different endocytic pathways [333]. We found that induction of lysosomal exocytosis to 
remove substrate storage temporarily impairs several endocytic routes, resulting in reduced 
uptake of  therapeutic ASM, which is an important finding in regard to utility of this 
approach in combination therapies for LSD treatment [333]. Ultimately, awareness of 
lysosome function in regulating vesicular-mediated transport will improve therapeutic 
efficacy and diminish the toxicity of future drug carriers, including not only those aimed 
at treating LSDs, but also other diseases requiring endocytic entry within and across cells.  
The second part of this dissertation significantly enhanced our understanding of the 
effects of targeting valency on regulation of the CAM pathway. In regard to ICAM-1 
targeting, valency density appears to be the main parameter controlling the cell-associated 
signaling conducive to CAM-mediated endocytosis [79]. In future work, it will be 
important to examine this regulation for other receptors and their associated pathways in 
order to extract more general conclusions. However, other routes associated with signaling 
common to the CAM pathway, including ceramide and PKC enrichment, are key to 
multiple events for phagocytic and macropinocytic pathways, intracellular invasion of 
pathogens, leukocyte adhesion and extravasation, and certain events of transcytosis [265, 
334-338]. Therefore, the findings presented herein [79] may broadly apply to the use of 
other routes for drug delivery.  
In regard to NC transcytosis, there was an inverse linear relationship with valency, 
but since this process depends on the preceding events of binding and uptake, an 
intermediate valency was found to be most efficient. In contrast, there was an inverted 




basolateral endothelium after transcytosis are trafficked to lysosomes. In addition to 
lysosomal transport from the basolateral cell-surface after transcytosis (scenario C in 
Figure 25), NC transport to lysosomes from the apical surface independent of transcytosis 
is also possible (scenario A in Figure 25). However, since the bell-shaped curves for 
lysosomal trafficking and transcytosis are inverted suggests scenario C contributes more to 
the observed differences in these processes for anti-ICAM NCs with different valencies. 
Nevertheless, since these two processes seem to influence NC trafficking to lysosomes, 
this may also explain why lysosomal transport is slightly faster than transcytosis. Further, 
since NC transport to lysosomes and transcytosis are independent processes, we deduced 
they may be independently influenced by valency as well. However, this should be verified 
experimentally in future work. Further, independent lysosomal and transcellular transport 
could explain why minimal differences were found in Chapter 3 for examination of altered 
transcytosis via the clathrin, caveolar, and CAM pathways in diseased cells. Therefore, 
defects associated with the endo-lysosomal route that impair ligand uptake may not 
significantly influence the transcytosis pathway.  
In addition to elucidating the role of targeting valency on carrier binding, cell-
signaling conducive to endocytic uptake, as well as lysosomal trafficking and transcytosis, 
this work described for the first time a mechanism for detachment of targeted carriers from 
their bound receptor following transendothelial transport. Specifically, proteolytic 
cleavage of MMP-9 was found to influence the release of sICAM-1, which correlated well 
with modulation of anti-ICAM NC transcytosis by MMP-9 inhibition or addition of active 
MMP-9 to the cell culture medium. While we did not provide direct evidence that valency 




the effects of high valency on anti-ICAM NC transcytosis and brain delivery support this 
claim. However, for additional validation, transcytosis of anti-ICAM NCs with different 
valencies in the presence of MMP inhibitors or recombinant MMPs could be tested. 
Further, in contrast to using pharmacological inhibitors, siRNA for gene silencing of 
MMP-9 or MMP-2 may be a better method to clarify the role of these molecules in this 
process. As further validation, anti-ICAM NC biodistribution could be examined in MMP-
9 or MMP-2 knockout mice. Additionally, it is worth testing other proteases that may be 
involved in ICAM-1 cleavage, such as TACE/ADAM-17 [314], in order to expose all 
potential players involved in detachment of anti-ICAM NCs following transcytosis.  
Since MMP-9 and MMP-2 are also involved in degrading the extracellular matrix 
(ECM) of the vascular wall [339], these molecules may also permit NC penetration for 
access to subjacent tissues. While anti-ICAM NCs have been observed to accumulate in 
tissues such as the lungs and brain (unpublished data; Muro Laboratory), how these and 
other drug carriers traverse the ECM is not understood, representing an important and novel 
question. Therefore, further exploration of ECM penetration by anti-ICAM NCs may 
enable the design of drug carriers capable of greater tissue accumulation.  
Apart from valency, a number of other parameters can influence the efficacy of 
therapeutic carriers and warrant investigation [47, 59, 62, 78, 79, 176, 259]. For example, 
work by our laboratory has found increasing anti-ICAM carrier size enhances transcytosis 
and reduces lysosomal trafficking [62, 305]. Therefore, effects of modulating both carrier 
size and valency should be elucidated in order to design carriers that are more amenable 
for specific disorders, such as those requiring enhanced accumulation in the vascular 




[229] versus therapeutic delivery across biological barriers (for LSDs and other 
neurological disorders). Importantly, studies to assess phenotypic changes in type A NPD 
or other LSDs (e.g., motor skills, cognition, survival, etc.) in animal models following 
enzyme therapy via anti-ICAM NCs is necessary to further prove utility of this strategy. 
These findings could also be further validated by examination of lysosomal storage and 
other morphological features in tissues and organs primarily affected. 
To further improve anti-ICAM carriers for clinical use, targeting moieties that are 
smaller and/or are derived from human components, such as antibody fragments, peptides 
(γ3 derived from fibrinogen), etc. could be used to reduce immune recognition and 
associated toxicity that limits utilization of whole antibodies [305, 340]. Along similar 
lines, anti-ICAM NCs coupled with CD47, a self-recognition marker that signals “don’t 
eat me” to phagocytic cells, could improve enzyme delivery by diminishing immune 
recognition and clearance ([47] and unpublished data; Muro Laboratory). Overall, 
additional cell culture and in vivo work is necessary to determine the extent of 
immunogenicity and toxicity associated with different anti-ICAM carrier formulations. 
For the purposes of this work, we assessed CAM-mediated transport using non-
degradable polystyrene NCs to avoid confounding effects of carrier degradation. Yet, for 
clinical use, carriers should be composed of biodegradable materials based on the potential 
for undesirable lysosomal accumulation as described above. Apart from being 
biodegradable and FDA-approved, PLGA is an ideal material for LSD treatment since its 
degradation enhances the acidic environment in lysosomes [341, 342] and, consequently, 
aids in proper lysosomal enzyme activity and restoration of lysosomal acidification found 




be encapsulated in porous or hollow PLGA carriers, providing the opportunity to control 
the rate of enzyme release, and further reduce the potential immunogenicity associated with 
these recombinant enzymes [25, 38-40].  
Additionally, since ICAM-1 binding by natural ligands (leukocyte integrins) results 
in release of sICAM-1, an inflammatory regulator, we investigated the influence of anti-
ICAM NCs on this process in the third aim. In the absence of NCs, endothelial cells 
released sICAM-1 when treated with the pro-inflammatory cytokine, TNFα. This was 
reduced by inhibiting MMP-9 or MMP-2, yet inhibiting both did not render additive 
effects. Overall, additional molecules involved in this process need to be investigated. 
Interestingly, anti-ICAM NCs reduced sICAM-1 to a greater extent than MMP inhibition, 
both at the apical and basolateral sides. This effect was enhanced with time, although NCs 
had been removed after binding to cells, ruling out a “trapping” effect of NCs. Instead, 
inhibiting anti-ICAM NC endocytosis counteracted their inhibition on sICAM-1 release. 
Hence, anti-ICAM NCs inhibited sICAM-1 release by mobilizing ICAM-1 from the cell-
surface into intracellular vesicles. Therefore, it would worth testing whether valency of 
anti-ICAM NCs could be used to control the extent of sICAM-1 release. Nevertheless, 
since elevated sICAM-1 levels associate with numerous diseases, this effect represents a 
secondary benefit of using ICAM-1-targeted NCs for drug delivery. As such, this 
potentially beneficial effect deserves further attention and careful examination in animal 
models of disease such as LSDs.  
Lastly, peripheral or brain endothelial cell monolayers grown in transwell inserts 
represent a simple, yet valuable model to evaluate transcytosis as it permits separation of 




cells. Since the degree of barrier restriction is higher in vivo, we used the pulse-chase 
technique in our experiments to mitigate any potential leakage. As observed in Chapter 5, 
even sICAM-1 (< 110 kDa) did not freely diffuse across these cell monolayers. As such, 
this method provides good evaluation of transcytosis for only cell-bound cargos and NCs. 
Further, our in vivo findings in Chapter 4 were consistent with those obtained in our cell 
culture model of the BBB and, hence, we trust the results obtained in this work. However, 
in vivo, the barrier function of the BBB encompasses additional features [343, 344], and 
future work may focus on incorporating these features in order to best mimic the 
physiological situation. For example, recently developed dynamic, three-dimensional and 
microfluidic-based BBB models allow inclusion of subendothelial cell types, such as 
astrocytes and pericytes that influence the formation, integrity, and function of the 
endothelial barrier, and these systems also permit evaluation of the effects of flow/shear 
stress [343-346]. As well, the polarization status of the cells in these models warrants 
investigation since this may influence the localization, distribution, and/or function of 
cellular components (e.g., tight junction proteins, receptors, lipid raft domains, PKC and 
other signaling molecules, transporters, enzymes, etc.) [344, 346, 347] that regulate 
transcytosis and other events, such as the release of sICAM-1. 
Overall, this dissertation has rendered significant knowledge pertaining to the 
utility and optimization of anti-ICAM NCs for therapeutic delivery. Specifically, this 
research will guide translational enzyme replacement strategies for treatment of type A 
NPD and other LSDs, as well as many other disorders that require similar delivery. While 
these carriers and application are relevant, the work shown herein can be taken as an 




for therapeutic applications. In the field of drug delivery, chemical and physical parameters 
of therapeutic carriers are somewhat understood, but very limited work has examined 
biological crosstalk between carriers and cells/tissues. In this work, we demonstrated that 
modulating just one parameter (valency) markedly influences cellular interaction and 
transport of NCs, resulting in significant differences in therapeutic delivery. While 
improving binding and uptake with higher valency, the ability to cross the BBB is 
diminished. In contrast, although lowering valency correlates with more effective 
transcytosis per se, this process depends on binding/uptake and, consequently, too much 
of a reduction in valency can decrease the chance to traverse this barrier. Therefore, a 
balance must be achieved for optimal effects and will likely differ for each receptor-
targeted drug carrier given differences in expression and distribution of the targeted 
receptor, associated cell-signaling, mechanism(s) of transport, and mechanism(s) of carrier 
detachment. Therefore, this work is highly relevant for identifying parameters regulating 
carrier-cell communication and highlights the importance of empirically tuning these 
parameters for optimal efficacy. Ultimately, studies pertaining to these aspects will help 
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